var title_f43_1_44048="Pubertal events boys";
var content_f43_1_44048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Sequence of puberty in boys",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 506px; background-image: url(data:image/gif;base64,R0lGODlh0AH6AfcAAP///0QoRB8fHw8PDwYVCgAAAPLy8ubm5tnZ2czMzEBAQICAgMDAwL+/v39/f6CgoBAQEHCNxv/Q0P9wcNDZ7NDQ0P/lzPDw8ODg4CAgIP+ZM+PZ44KwkNbl26mNqTAwMP/MmWBgYP/Gjf/s2bCwsD8/P/8AAN/f3/+yZpCQkHBwcO/v71BQUM/Pz/8/PwAzmf+/vyBzOf9/f2YzZr/M5f/48v/y5bKZsoxmjC8vL9zj8f+fP//c3J+fnz9msurj6uDs5NbW1v/r2P/Ysv+lTFeWasfczf/x44+5nNjM2H+ZzP8PD4+Pj6+vr19fX/+fn/+sWf8fH//fv9LS0v/Pz5+y2P/f3/9vb5Sp1P/09P+4cr+pv/T2+/+UlKHErP/SpQ8/n/+/f29vb/X59u/y+P/Uqfj2+Onp6cWyxf9PT09PT//v79/l8v/FjM/Y6/+Pj//79v9fX+vl63lMeR9Mpf+vr19/v/8vL28/b4Gwjy9ZrC17RdXk2U9yuKiMqIJZgs+/z/Xy9WWedkmNXqvKtDuEUZ9/n4+l0uLY4q+/32+MxePt5pVylfH28nOng7nTwZ3BqLylvDMzM+Li4i8cCfz8/FlZWYyMjOXl5by8vJmZmfX19Xx8fCYmJpWVlXl5edjY2ENDQ6KiohJAILm5ufj4+M7V5IKCgmlpafP1+o9WHFxcXGxsbFNTU2ZmZsvDy+C8vK6ZrujExMDJ3Orx7DU1NURGS0BMROyBgdvPz7Oll5csLNnc4JCLhp2ryNOaYOOqcO/MzA4HDve9hDZFO+ru67WytfXhzv/ixYacx3akhP/b2/nr3OXg3KWlpYWFhfnAhuXXyTwpFtrl3dvi8JOTk//16+XZ2ba2tvXFxfLOzqOGo3JycvLm5vTv6xILEnF1ctPF09DM0MDXx9vf3MbSyVKAYGBEYIiIiHGUfKmpqWKQcNjO2PlqanyriuXCwpl8mUlJSdTR1J2dnTw8PCkpKV9MOWtAFc3S28vb0BkZGUxMTP/z8//69fj1+MLJ1yH5BAAAAAAALAAAAADQAfoBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNPWxMCAgdq3cONixJChwMAUBfJ+uCC3r9+/BRfktSvwwQMGHwqkAMy4sVq2eQ2qUOy4suWxkQlegACB7+XPoLNmFljhA4QKCAerXs26tevXsGPLnk27tu3buHPr3s27t+/fwIO/9jmaAecUDFAbJBxaInOEEyRAjEAhZAKR1x124BBRxAiJHjY0/8wOkrzH5zgFD14AQIFqBQfRN3cov2D06dXLY3+4vfv3iOGNtx9I9a3VVlsYAFDBgcnFN59zC933EHXWDdhQfxB5B554DJnnkYccFYiUiA+mFqF0E+b3EYgcsYgQhg9pCCCHC7mokY0YkWiUjiUWpKOEDlGoX4XacZfhfxAF2KGF50HFY48D/YhikCp+yORCMDokY5I0KoQjRl9a9ORQY2J1ggMNmKQjD1lApAMXRA7Z0BhARHQEHBL9YIaAcTb5VJkXNaCaEyqJUYJDLZTQQ0aJLpoQoDCFaZGkOFFKkaUQ/mmSoDk0IEABaQLQhAM9rADACQ2ccGqqALTggANNmP86UAMtNOBACyswwYRAK/TwahOn5gDqCSuwWiyxqa6AK6u1nqCrrLY2QWtBo5JqKhMFOBGqgz9hKpG3NIELkbj0OblpAZ0KMICpThRQwgA5KJstAO22gG0OJYBKUAED5AVvXg4A0MAAJXz66mBoFhCwoAkLWwLDAOTbr7sA9FCAAPkeum8JDgOg2qNAkeuQyJFeGaK5JQk6WAktnDCvxYuqCwC8ERfARLL7xitGAaVSrKyvFOcrEMQMC6oGrRDnS+ynM6/rscYDtTAq0xCD3K3JV/fZEaQ/cU2RoIdafLTCApONrRo8t/opvy1sDIAD+lJscQ5wHyp02QsrXHXShAn/TfHTBLUwgABiUE221Ql1wQNEWOigdUeWAuFFRGUcIdEWP/App59OeT0R2ACcvQLFcAPrcl7X4rpzwFEeCneaQRewgst2y14sug2svjfZdwut7ux/C1T6CsKWLYas3CYEZENCroj1i0bGiORDStb4fEae85R9RCrnJUDbFudFqEBoj492XvG6/Trg4ffrOsAACIuu3ofzLZDQ7Qff6sT9ArDCxIiDzpSYVyXIXc8gWWrIlqjXpYSQbEkEQhlJitWAChLkWARB27Zq1baCTAtVpppWqxpQrA7WClrISiGvmBWqWp2qVk2YF0FQdQIX+k+EyRMgfh7XIv5ET0vTc0j1/7x0wItsTydH9IjLBJATuHmvg2I60Q43Z6Ui+WdDmnNeBDV1kDO96otgDGMYMYLBnFQQikaUYop4uBFLJZAhCxRiAxHyQOttsXMI6d5tACOlKWqRigp540Li2JAhOrCIUeSiQbwoxkaO8SArQJOrVOUSWJ0JjQTxlZoWwiY3wQmQPXQIneyEp4joKYtV/EgScbLKhpSgBP9jHUsEZSunDaQEYhCIoTaZNVD6pI5EvGNTWskQi9HrUL361apURUP/MQFWAnEhrpz1qg7m6mYkFIivSvU2JpZgfNHEnbJChbRbXXMgXsQkRIhZEmAekijupGNI2EkTeirEASc4k8AIZv+wFsyrXoITgLBymS9h2Qpj/SKhwz6lUIKhq2JpwidB8pWXBtyNX/6SX8Dm9ilgTcSeiJxUUeJ5EJL6SIIp+VndACAzATCxXdKSWb6kNTt7tcsB2ArY6yyGJrSp0201Ewi6VrCznh3KpQ2IoRooAlI23mikIWUqSlEyt5Vi66o1e+UrgyqQdqnhput7Hdzw9cqftu5+hCFd3A7FL63m8qMLURzjHOfLpzpEcpSzXEQwh0oDCpMpTWVIvoB3qNMVQFU721WvuOqxHFRMYTylF6hi6ARTNYGSqXHsCi76PtgdKgcDSNMJPJop5Q2QIc1L5R8ZIkiFEJIhhpSnU3M01ZP/5E9j+Vqq/yjKL8a2C6MOIJ6/9LWzwZgVraDi7NvWqrbB6La0OlxjXTPixh8qMIiFnGNJowpXRarkhCJsJjotOEKCVBCDtWoA2ihJQeQlxII2/GA2ccjBivRRuqsli0kLst8o1XZHg3mr9tRIpdl6pb8DQbDH/lsUVGWTOAQmoIEnutWqKBgACg7sSzQcl/sWeLo+Gs1ULpxhnzyAPQQ5cQChpJA1tekhb5pwlEQsFRLPkycMCEFxdCwiDsPFx6FsyGCsYuO/3uQB7mEOkmm8LxYLOWQPGbKFuQtdJKKHyf518kKA3MYoY/kpRVYlca7cYy1v+QBoTrOa18zmNrv5/81wfnMC3lyKEHNZJAaIM5rnrOc+u5nPfg40mu9sRDI/SjiITrSigRNnXMhC0L7Ah6AnDWg213lfX34ICCHJKoVs2iBlVEie9VzpSfe51KaGM6EpwgD1LMAtrc7Lq3PoEQMgICS2BgkCDBCSXT9keagtYJAZImUAGOqVx3PI+gxStYQs24OHG4gmv0XliKx6IkhWgLYfAIBsb5vWHck1SMTtEV/rmtcOAfZCUutXIY8mX05AG9TIe8NOP9u8CisW8sRbkBZAkWH6RutEwsy5YeL51uNGeLnR/RFzN0TdCmH3sLf87rjZpQVrG0DbVJPL1wkufUObH78QOxhCre+3Ff/llL/OhLCIEHxrDNYIuWut8I44fOG/Pu26hd1l+lScVheLnwDkRahSNYFppQOte8HWgJvGcFfr3WkBlvo6pt/0BAbF7Miqvc6YZ2Tm4a45R25uc4YzBOIJkXjP3c0c3g4AWKuBZUH7N9ZohzxvB1ONrUAVVlARjXdee/nJvEtzXIt9I2Qfu9kjHGwZC7XiN5OVS2XFcmAJDW5iGMAAtP53UtmMV5EEFbYWVXWy2Y/aju8uHg3P+oYvXvEP6SSMP5nfFv88k23FWAwFGpnXxdCxszJ9voWFL74PS/MUraDwA9auHOxqXFyPstcxAnaOVF8jiUf863/pZeb4Suuneib/E1Q1qh5o0laqeiYUzyRaNAmkWsBC/6lwWi/2zz9NubqVy6NfLsKHvfU4d27w1H0zQTDEp1oIOHirl3AAWHa9tn09YSnFBhO+Ak0JOHEKaHAN+H+u94AD6HPXxhKCtxEhWBIadn0yd3jYB4EZkX0IIVcP0TipN4EX8WkLEWrtxH9P5n/Wp4IpKIBA+HA6F3E8Z1dstxH39l5kM20jMYIaUYIkcYI++HVTeBEu2IIsaBBohxBqZ4TElmkNIV7LhoMlVBB304Q6SGzTdxEoSIVBGIBC6EcXmBpgOBCj41gxlEvFNS/rEz4ytIdjk3cKIywrcIftVnskuIYW0YbUV4UW/3GFGAGJ9jGEaVeE1EWADbFeOyM1nxd1oDI67yMtU3d/CoN1wzJ6MHOIc4g9ilgRjMiGjlgRkviIWTiJcqiKtjcmTydQy6V3pYd3z3Z6oKgGtrR2iPiErUgRr7iIsUgRsyiLtUgQW3gQXXiJIPgQg/N5FvN8hfg6LlN0PLON73d6AHA+4GSMq0hbPLgRy+iKzTgRz+iM0TgQsucQMQZimFYmv2UqwlV8e5cm7fIu8SJcBfMwZNN8uxJD+oKLGJiI6/iDDNiBbwhl1+gQZ+Io76dM8icq1jIQ1ZJP7pd/bbNEx+iFMPeQbhiRcLiSFHmEMwE3z8eQ6JiBgHVwG6h9Hv84FBJYhynhK+41kw2JjCjZiDe5gjkpFDsJhSnhhKw4lLBYlFh4lAwBgw4hg/g4Y0qJEkypjgv4Ee2ojO8oEfEIj/MoENNoENUIJphIFVuZRk7JjFAZiWVJljl3i0EZHzypFG2ZSF1ZeCrpgBOpEGdZEGl5EThSQYg5GIh5XlCxl/aVjBPxlZEZlhExlmI5l4NJEIUpUgkBAbLhGbJ1IdYFR9gFW9plEI4pVW/pjnFphXN5mXWJX+nIArHxAXYkmlc0I311l1wZFBfQICbSmk8pkcR5dpTIhZaolgmBF7CBYu+Em0eCRRB0laq5E3ShZIOxF+DWg8IJjVLJSS9mj7T/l44VEBtuEUxzUicQcSd5sifTWZK9mR7F5pkXMBmLsRw2+ZewF5jcpxB1MRy3iZRpuGU8ARmEwQAFAB8ICh/42Z2sWZyAKaAKwWOtwQLvGRSpqXo7kRkLCgAduhypFmgnMAUh2mcjWqJxNgUngKIpuqIs+qIhimprdgmvsQCkBqM4amoymqM7CqNZ6WUC0aEf6iM52mYnWqRqdqRIegAquqRp1qROGqVq1qN79hqZcKNSmqUHQKUvyqUo+qM+NxD0aZ/byY6UGRGSWZmvqaYPQZUNYZXwKRCJwRoQsJsIgVcQUTmXkzkXKpNNqRPqIWvdlp2g2WQOCpb8aZTpdpzU/5ichskQk8EaIWCnB9FaCfFaCxFb25V6VXYTbHEgCQIAv6kcZQqRXnmmD2GZbLqodgmUBUECrcFtfZoQlooQmKoQmoqaA9pikCkRaYqmqOoQqgoRY5mZA7GZFREmF9AaoRqgWDKag1SamXqa/LWrK7YUUniosJmoB2GsAoGsl9IQSTYYGbB1VhSdujmrrvqnGqif3Amh+xmHsumnBBGoeaEC5gqd0iOdzkqvbtmXHHiq3CqXsflhcUoaq0EC+cpa0Opa0oqr1EoQGdqpSpGt7qqo8JoQ9dgQ93iwAuGZg1Go6MkQo7SepQQRp6SuJkmT2JqfApuxGIuhDkGbecGglP/KExNrbb0KrNq6qjCLsw7BnAXgnCoLtJyqs6uJqBcblQOrE5SCAYNxnje7EznbdUk7mT1LrGuqtR/YEHVRpw9xYWh4tFYLsO/6siwZr1O5ODFIVx4rEDpmoWH7EHj6EHq6V3zar7z5r+2Ktn6ZtjjJqvO6tylGGXN7rvuarnq7rvHZslkLEb+aqlsruQUrYdQpqgVAqlNLELV6ELeaELlarWQrfVfrq8HqEJErrJOrupXbeJcLAHJ7uPoKRPw6sunItzX5uA+Rug0xrJQruAZ7uwXRrAv7rLnJJZvLmWJWujy7tATbtNLIqGjpqMr7tgDQuQbxuQgRuhJrrcFptmb/qru9u7rj27o7N7qyy7DHy0DJm6w3xryQe7oNwbsM4bus6xAbyxAde7sYQKGDAQELILKbmp6k1J7tG65GVrEu+7cRCrgRmBAX4L90SrQDLKGvi7Tga6oMrLYN3JIGwWMKILVBmmQhIMAJBlXou4MZnJJ+y8Eu3J8fnBciXBAPoBcmjGEofMFl27cbfLYd/MIPHMMFIKsJUQGeaZsVLLMprIbwu7vyyxD0uxD2W74O4aYMAacJWMND3BBGPLRJrBB16xB3CxF8VbTKubwrTJTO65rfKZjSS5jU674EgaCG2xCwmrm6iri0q7i26698ycMB28Mx+8Om1aomWRexO7MJ/5rHs3tdtfuc1kuxSWGxLRy4P6uFb6yZcYzAAiEYnRERy1oAxIvDeuzIfAzJwvuYTYy6T7wQUawQU1y/mJnJx7rJAzcQ5VkACisR7kHEAlFd6ytHB3zLCTzJCxzIQMy08hq87ZYYiQwRgjGp3VvKpPnIoRnJGBwUJLAAD3DDlCzIyuzA3UrL32rLqOfJN8wQ5Qm2J0zN0WrNX0y4qhwUOpYYSNygazyc4vy8DZG/C7G/fuWZ90kRnkm8llKyD8GepuSei7uyDgkU5WmbOubLWZbPcHnJbKyTAAC1R9TL06zRS0ygQYGgtikYFCxUx+zDyczPMgurNksR0fzRFozNO//8E3XxAXVx0h5jADzd0z7900Ad1EB9BkEg1EZ91ENd1Ei91EIdBGfA1FAN1E4d1VRd1VbN0wlgAJ9QAKhw1T6NDQWQAT6d1V5d1mb902R91kad1moN1GAqERiQAilAmzMsVAhw13id13q913y910HQAn0d2ILt14A92Ibd1y0QBIe92Hud2Iz92JAd2XedAAgQCgWADpKt13mRCXhN2Zn92aCt154d2oE92qS9128dESQQa/d8UuI7v62cELEsxXNpxQuBxQZUF5pLEe6xy6TcEGHcEGP8EGXc0NaIxkDhHhBQwt9byeGL0bRovkRoHaGcEZOBr7/sQ8GcXcOMesj/nbsW/aD7nNHLbLkrQtIZAav3DMzoirxm/KjFPCIp/dzjHd3Aa94fEtMYEcqewd6J697GfcYFB97OrcErTd7GacjURZsDfRGJcZ7+vccA3sfyXJ2ArNIYPsgHHr0KDiZ1UdcUMRkoFuGmPOGo7MfzfOH0Dc4sTcjRxcwcoTIbUcMMSuLVfMrXnMoWTuAsrsb17Z34G54cO54doQkF0NoXwdHZLUrqmdAn+xApG+Dw/d2OG95K++PySBTcUADSrBEf/tszreMayuPInOHh7OI8sQ9evBE6xh5i6705zrIK/NpQHNsIMduwTL4v0QkFAOIVQeNgrsQ6TLpprM89bt/Q/81KBZDOE6Hkbx7SUp7iZG7mLIzmLa4Qtq0QuL0R5VmuHZEYJBA5k5OnekXGeUvhjIu7VV7glb7hQF7erusRNfzM1l0AKmDj74zj8ZzqfzzpK17mGm7JCT64GiHiHqHeuO6w8MzINE3oKm7glI7glm6LxJ4Rve0Robwt6tve7Pve1XuShX7RrC7trm6W5AwA4OocovwRiXEJ2s3twuztckzlc27lWJvoWX7fsc4RUDsAIDEZlvDu/93tkT7vA77qhy7u047oww7j6V0AkgASsBrx7qzsus7sYi7J8k3nrmznB4Hnsj2X/qwQAK0RghHwH1HdTF7AC93d+xffR/HNwP9+5uVOE+4hSx7x5SA96P0X7uKd8PmO7zRRF84QEjrW4B6c8dns69D+68K+8DURygqGF7QOw83e88/e6tHO8FBPEyStYJ3etVevwlnv40BPl9A7EJmeEJuOEdF8YXkxync66nZb6sR96ide4WOO8DOv9cH+9+Pc4RRx9BcmCbrcyDdu4nGu9xof8/Pd9DT/9G4s+BPx4RfmCraO+Lmu+Lvu0ELp81d+9tsq9N6K7ubcEI4uEjT60rTasJf6sKAbse3M82TP9H4P+Zcu+YVc7X++yBcm49s+8PFe8Jx88PU+7oZe86Pf8PidEW0e6JCj84Hk+rYK+9sr+0tO+0wcFKX/kRfMjc/Ir/DK77PMv+8Z8eUkdvTBL+EEj+qez64/4ZkkwOClevv2T+66jxAjnxAlDxAABA4kWNAgAAwFCghMcNDhQ4gJUhRgAVHgGCAWDR6Bo9HgDzMeG3okaXBkSZQLUa5kWRJCgRQqCpA4qLKlRwMIbuLUuRMiAgM+LQIVWhTlgwIKGBp9mIBBgQxMpYqcarIqQZtVFTy4OvCpQqU1DYwlW9bsWbRnzwRJ29atWrZv5aYNcmbu3bN18e7li3dVgU9jE/TdO1jhAcKJFZsdvPhtY8dps07NsKArgAsZMpD4UEBFTQShRY8mXdp06SAtTq9mjVp1a9inWwSJXbv0/2zbuXXb1ldAVOgEu3MHr+db+HHkpIMnb72c+enJUll8WFCdwdSnHwCQSFrzssCc38N3JXq5/HepCW2e7NpQpmX0V9nL/x6dqUL88KV2/vCSpkH7pBqvqwGrOu+qAy3qggeUsNBBKqTCAmC+qhqK0CIgvFipjCNY2uIHqr6jUKoAi2LgxBMxqOqCBxZIQUXvxOuJwBkNDMq8Gz2aQAKUIqBAqhAK0G9EqRqqoAAILOqAg5VEGIElDzYI8TIijSrRRBRhjK+gK4sqsKovpUpwqjEf2rHHH5nKoIDrlhJRIIW0PGjJJp9cKcop26vvss7y2xJA9MIUsEYyc0TQUIvOLP/JR6bUI6hKo0ZSYCaI6ETJSSil1AjSojj1qcubjlSgMkr/xCpQQqcS1KgymWr1IEVJYtQopCoayFOfRnqvUiYvtRMlPDdFD9ebQG3pKQa0UyAFU0+V8VnyEC20pFg9mrWoIJm9dViBuJNwzl5LwvROTS0i9qZzWTKWpacu8AwC/Zpd96ZVjapXqFeLyregajW6VqiXKniUW4QU4rXOTPOk77J5V1KABJkgELhZOFGF9tDv9iWIhyxQ0oELo45McuA3BQr4IYxW4oglkBSucE/0GJBTXosvu9cnjXfKmeKDJrJ125IBmJQrnndKl6WjU7rsgTUTmpjihlm62aepb9r/uaWrix6IBZgKShqlkxYoIASt0SW4q6hJcndNAKgrOm2UqqY3VVelFdPush86mWQqvSpAu7xX+rqkwT2CW6N2F1IgXlMPJ0nuliBfKevJ8Q68IJGtCtrdAi64nPCzr3IcoiNLL4BoqGumEceMLTdowQYfFMpnzfseqLP/DMpwww5X+tDlqQrXaHSIJlUIAs95Jt4iyVdqviTKUbq6X4v+vYlrbfnWc6BdwUWYXOCLhPmqC1RQIISnU7/4qudJih561/nlcdE0Py1g5glDv9B7XxMWNmjRXSZ3ZVseRNr3OLqxKn44W+BAqAcR67ELKgcR3v8E4ij+ietXJQmWuUJX/5UC1qQy+Guc6tiXQH010GoqBMADHxLBlcjkM7Xb3kDW1KaCWEqD/vMgAEF4GRWsKSmoo9n6wIRCfLGQJdObn6zqdxPcUfCD2MsgScYFrHJF5INTCaFDJnK8AW6piwc5IE9Yd0YdNdFaT2SJepLntQ/SziA6tOIGSdJBLfqQi0AU4gdCAC/12QyJQinjUJRYuZJwzGMg28n+aLiwgWTOIClDycpW0jIL1jCAaIOACiZ2ARKOb3WCRCPGPueQIDEOaLbDyv1O2UNWbvIqYXybCY9YShu98iB7e+TLCjI0XTZliyQK5h6NqKpB6uyQ0lumqSQpRT2KjWzF7GXwRGkUBv+wgJa1POagcDktagJAmsLUY3bCCUc9EnMqFVjTCPM2RoMUknnJXGHrSgK7kjhoJ8B0SAVhORDOvVEgu0MJhzwEokxCUpZTIQHXhqg1eBZEngakJ9aa6T4WutAhMPQI50KZv3RGkSB09MgVOZhFcsbyh5fBQArW1Enl2RKZ37wbtdToLzaWhDuA6+cwuzcQkmrEpHdEaU/TeZ8tMSBIMe0mUybqkPdh1KZoukmQZmhUlQoEKTwVSFAtMlSP4DGlmlzplgT6p4gS5KkOWatBouoRJlK1JTfMY1YxoxCBehUiYNWIWLFKVmNeBQPVsU5VUJSiGJFSsaaM1lTp1xIMjlX/oQTpDBH1+hC+WsSv0LQrUgWLH4WoUiigFVJiR3naXNLUIRo9CEctIkfJ+tIg4wRquOrIw7oCVp2GFVKWDHuilxBxIGkdSFvjWdElXhSuLFRkST7WEirmdrKRnOBAKFkSS6IEk/+c7m6r8gHhXgUpUTHtCZuaQnsW8yUfdVNnAcBLavpTuoGtSpD8dJU1hbdi5/USchGp2rw9hbzztaZDohtO+cbWu1IRsAIcrF+hjPchBXgOa1JT4dNcGMOkwc2GOUwbDz/HCRSBjXNCDJzVPKMAtTjxhk184hd7OK0JwSH5gjvhyLhlLTlOy455bBa9/BjIdhFyZARQAHXIBTJF/xZMW4KgkEkwmcdLZjKVhUzcDyyusFMRG1cBxV9C+peZ6fUIPkmiT5QcqXMJle1BRErQkhjUdwjlbpvLCkLQijY+xAWPmOPmZ6kC2CCsNYhrHSKTnxFYfA+RyTQv65DMQmSz1Vw02i5zWJlxc7Hmbayg5SfXkuQ3fEyBlIC7atuS2jGsReWsbj17lRRwhQELOCtaZerNTudaI4QuiKENouZat7q7BDnZow8S6YdMGp3uLcqM2YQZCGSviJu+pa5Tm0ZQewTRJEnwXw9CRWMbBNkOUbb2hm2lrjxlIIvTNGqrzVh4J+qm1cspREQ96ki9liIACHdBxn2Qcq/S1ej+LP+zKgABCKOHzwAwrkQBvVwy73reEKy3Q4DN7WESxFH9Jsi/DRLw9g682ZcxHpKCvedbO/XhGnkry5nbMecyUtv7xvhRCbImElyXJNktyXYVTeprSuUCCzhf+qbt7plaG5yfuze+O6URGcY34wQ/56dSbq+VGzLiebt4zZndrb9J3eYjr7rVwUy1rP9EuS4/5bZBN3aBeLSY3RY2fcuurqv319MMPGXTnS4UXPFTl3SnNNXvjvez76ThA2m51kliZo+g2SJd97rIBzKRW2iooL1Dye/YXGBLo4cE2xRj3sO8d2U61okzT/Tfc+WRIxEA1UJVdV9ZXfh8Myw+YstAwnX/n/i5ob6eJOE1QXwtEL+73mgkgQABlPE9LCrfbL//zgUg9oEalx74kUv7QxqvdtWvUSOUr/y5CxICAqwD+ieVfksI76xZXm7hiy9u96G6dsdj+7EWcTvYpl6QByAAczi8SlsoLnIniDI9tBM+iwo/nNKI5Gs/pCEJDCCAUTg5AhScoGOKIAIL36M+pMO1eFs6icu2gyC/8rMziCCGUSC9DPQ/EIQ1/IAAFww9aku6EawpkmguknguiOg/GPw6guAGApgmXUIEObA8s7uKDvybP9KzGHw3TsvBugmcCJRADSSJpxAAlPCDGZgBPDAEAEgCNDAKNEgCgcCBG1DCnSAu/yTxpLhjLwOUQjrUQaVrlq/AwJ/LPZKIE5KIhDlIQkD4AwC4ARxwiCRAw4EIhCRIQoFABEUEADVMwxuARBVcMKmoQVvbPqmxv4P4Pu/DP58IEiPMQiEkiAOziBuYg0AgiC+cgRtYxTmYgUD4A1v8A0YEwz/AgyRkBDz4A1hMgldMAhzAgznAAz8AvTm8jzb5AGkrIU50Hk90K1EMxbJRDzlUsALUCNiyCETAgxnAAT9IQkMUiFU8Q0MQw0CYg0hIAl4EADyIBECgRUlcw0mUxGSMBDxQxjtjilkbm+oAJKa6QRG8Nio8CMjTCMkzCJn4FlNkw4FKByQpiUAAhBvYxf9AKMdCPERJfMVgnAFK1MhJvMdJFEZ+tDujEBvSyr5NJEiVY8DkckB6c4gLeAmWfLtTPDW60ghHBAA5mIEk0EiRTMaBMMl6jARCrEelVEqjBLooLAoMeIoUQKx2m0KrJEGDlDcTHAgJWz64GykOsCqPMMQzZARCRAM8AISg5Mh5vIEkMAS3BMl6RAR2vAE8WENGwAFAkIOSlEuntMEX7EMFVLxpLAhQvD+ZpDiHuEKchEh+44Cd8gg58AMcUMMkzEi9RAOiBABAyEs/QARE4Eg/KMMkYARD+IM1RIS8nMwyDM2TxEShqAClcDDa/EDAvEoczEqshIjiGwgY4g7keb3/r6ytgKIYQwAENABKU3m/4eItACAtKNwJzlCIm5y/wnQ4mPwv/Vs9g5iU6MTCINQIOqksiqFMvWwW5tyvq6gAgYnKWfqb0SMh64xG+Nk63py4F8opbAS8/8shJqGtwHzIfmQKdzG40/mu01kA0ptPl0QvBuRBj/BBgiDFpxvOi8iIZwrQxhxQbLIJduOipLixL2tQvbvDKmwWzrlJAb1EjYAvU5GDNfyT9HzOrigdzMiAZ2y2hfAW0Gix0NCwFgPSEOuwFiNSHyUNMSgASaiwGPOwJoWNUCgATiCNTSgJSOxJRuzJh2hKj5gE5HjSCiOuNRkVV5qKzsAA7mg9OJEy/7LwMSlz0yILMimTUzY1iwEoAE3IMSsTsj2VC00oAHowi0ogCT/Ag2JMxBmYA2BEVEosxDmYRRz4Qo7UiE1QjD7NMeKSTaiwTZbgjgyAAIkprzosyN20wy2ZiAHjTwstCDdqiTlIRjmQA2FMQkNgBKOcxHNkVBndQAKsgOoIJQYNQQWyz4dISIuQPAwQ0QrNSQCAM5FaCbucA0PIRXPEgVtdQ43k0v5cwhUxH/RJQPosCfoDgMP8xIzCz42qn0lxSOFkVh1qtJtABDSYg7gUCMq81o0UCG1dVcS7ij5BkmxcRlLNzVI90e0UPwCYCAgI2BR8TYfQIVNjiTlAA0BgR/9hRAO0RAM5oFe0xFaOFEbk3JIZTStkQYjKqMpRfUkTHVbiQ9fW+pFk7ZptZNEqclGPQIO8vIFcNAQcKEPOxIF0LEPNHAhDjNFtbcN0W7O2+c7bTFmsy84xa1mqmhQvW1bHpKNUbIl9PaWRvQxQJVOja0lhfdqVddCDxSnuKICwVVV3ta1ubAnXFLumZYoK6IzeA1cSPb2yTaLEfKFZeAmmncBVpaPI0tA6g03DHdGxLdGDNFuNgFCN0AFbCDvzs1qL0DkAwLnEPdxXo1va/FxO5dCBHV2W3VufUMm1tVyanbmr2ty6Q9yd+AroRFmCrV2DbdxRVIgc/UvHPAhPLZv/atRGw3NdxcVN0nVc3TQK+wpd9ztaiPDDoplRkJrbkAkBBcCA66VdAeEEhu1EqK3PqbiAPmHe5uXXb5NZnpHeru2Kl1gIHNVepkjbrdBD7vveQCszBoEI8UUSBljI1VXdh4Czy6M5g5CzzqOzPQTgzmUwtVWcwBVdpiAFSQAtFngA+hXX62S84DXXvhUIdkISgTk+r2zbX5vIY6s9zbq9ZevdlSDZzumcaINfrGupf6UI8mWrDBaIcqXGDj64v5kYEZ4+EjaInfQ3FJY0FTa3/+VWyminMg2k06LhGQwBTaQo+4U4qT2IB3iJD3ijIC7fIT4/zzhh3BJePhTYoqjb/03FW6TDgCZEEir2XtNNvSwuCJVUAIH6YsENY4KITHE74mRLYoGrXCYWOvm7ugp4Ywj4VgS6Yrar44Gwr1IUCD1eUYetIoCC3o4DZHIT5JAjZKRFG216JwVMZCGCChWo4nHdYcM8V4LY3wMttIo7Y1A+NYcQvIHwuIIAuellYaXpij7ppO6FXbL1CBL4Iwp+ERx25Px7XJgDgA+GABWV0FoWYo3A3IEA0IHgOZLwOTNW4OGdCgxgmtIayMV1CIg5ZaigYoFa5Q3m4ZUYrJfIgNQVWee1iIhFz3vu16o45va94XC2XQpMARZoX7BIAYFxZ2J9CKXCjy7OG/W9jyfeVf/z/WXR+RtllmHG9QkGUIEazgBL8IQLbkDhe4CSe5jLiWijwGV7ruiSIC44JOVwfYhxLmjQWpZ6Jum9vQCXwo8QGGaX3tCd0OaWZlZ+Jl4uGcxjYYVOAK0MYIEFYICRBj8Ac+P2hYBdCIbYCeqGdQgBLoh8FggDLgnP41zehWDiDdYTqmmDVoinjmqdHsEKIGj8uNvepORZBmdaPpgJm2hdJgheVmnqRWq1lkIGSIEQqGGwSGWGZWWCKI9ZKzmFYAEcumsAqOTwrOZHw+W/HojA3ucWRmqHKGyBBoDDDgF1hgoWQGiqJh9PQAXFhoDVnhnLxmyhvuQ5mj2C0ObOFoj/z+bq4QGiPNNovT3nuCMBoiOtpFAAqFbQFDnMqEwBokvtDAiBB/io2s5rtr1a3fabVO1tAPhtow7t9USS2tQK0KpOpa7flThsFkht5XZo2mxuwqoOFvhc/JZs0OoEViCBkc5u4P68h+3u4Xpi8BZvX37pGi2VrpiUEPhVUS3tjWaJCziRFiE6B2vr+N5wDk8KqCaB64ir/Uvw2x5wi+Aa1DlwT+7laj7q/QDoknDwBQDW9ZZjUzqsC6/vBXgATMO0YLsayLUIal7idr3mjICIiTBCbvYIb/Y2Ii8W3lLuB45xBeiTtSXt4+VbZoZo0J48Ey5qEjecqpDN/IbxmROt/wI4ADVfczZvczd/czc/gSmAczqv8zifczvPczifghPQcz93cz7/c0EfdEJX8wQo9D8/dER/c0y400xYdEFXdEivc0mf9DcnLqkWiEyfCiqeTv1Kc0unczkPdTgfdVJv80A/dVTvc1VvdUp3dTav9FCPByGBdTeX9VbH9VN3wzb5UKkw6Eluzpk2ozkePg0VbKZ42/G25AWmFap1sHLGjkwb7RqXxi23xsfL3zOTnTCXvq8+QRMea5Io6wTebrS+CZWsa6AO6Cwv7uS9Xa0c8RbfY/EkcGJTWwBQcfAscXYvCgXIae3L2wUs9riOd+7sdgHHZAPrGn1P+L0mZp+w4P/AwXKVxV2+g+QHXPbM5mt9q4iGN+uHb3aJnm02Nt6Kf/fSLUF5f3JrVhJ7p66F+PhyL/Jz3wmCbt/dRblh1wiFZkAA13h+z22SwDmZ/2ZzR8n0IOcph3h3d1otJ/ifR3iQ90+SaLSid3LcHi0+gWOJN2eTL2aUR16ICHKIGPKsP3qUOfLxQ5Il14gmf92ZZfpike2u93qnb3pTDfuyQ/apsNmzp3mkj1/URt+j+/oJz/uCPTy+B5IxDvCpL2S6vfloL/y7H3iLp+Nj73KS+F3Hn3koR5vJrnvKl3C8h/fEv7vF/3V8B/qu7nehiGOZFnjCvHbEzPatZn1v1zySYIH/e9CFg9r31ie7rkBu0R/9drd8vb/4s51J3Hd4qi+JB1AFeyhjrI97kVdeh57qwD/5yjf2yxeIqJ93Zld4/VUFSgBqBBd/BS/vqN7inFe4av8z2udgjGd+qff8x1yJX6CE9wcIAAIHCvSwgSBCggkSMmzoUOHDiBILSKyYkAFFgQoWWOxYMaNHjwYQhBRJsmRFBAZQWlTZcYIEjxEosKy4sKbEmxU7cAgJjBKLkAZt4sxZ9CHIowQvFNgYogAJpSGTSiU4smrCq1gHutzKdaVFmDJpehWos+zZiDxDDqNU4ILHoUbLmqULgGrVBwX2hrCL1K/WsoG3di1bWKLYjjPt/6bd2tjhWo8ipBV4EPfgXLqPpeKteoEBBr9/7Q7eWrrqYcJgK/LI4lEHF8Z+NzMcAyTkkV4Fgnb8YYaobLqdlRbgKHo03dNVlStNjdX5cam0lU5XWqEABLSz7Q4/ujG6w+5KmY8/6RW6VPTgcVYv2v5oBqhe39ekj1I8zg8QFPC3vF4gfkWRd9SAOKl31IH/lWQfSgyypEIBfTm2nXDC7bWXcf8FiFOBHJqnml0JKuiRgyGVWBJG2U0YXFkbjkgcYB+aJiNqq51nY0Rd8OARFjqwqJ1FQHgRUhlHAABBARVYtMUPwGnGnVcMLPDZAlW+6CJLHdakJUoi1uSlQIlZtP/Ykz+q1ZNkIwDwlAoWyRXRiR3F+ZFXCgS1wIUMjIglSlz2SWN6OD4nqENiVkQmkGXuhGZHIqhJQgEZuIkZnBS26JV8C2SgaYbr8VmSn6AC2hyhgb4Uk2JkJbrqmSE5CmABoUn05kNzOokpplE90OYHnVYlpX8JfRpSqMSOimCppJ46lpkrLuqqmgCwUEAKFdHqkK2Z4bpVBh/ABQCkwVaFAZIKNDSsSaQdWxSYXSabkKESITqfpRJF1mi0en1gLaW11rsVuhHhud8H2H2LlQLlnhujunS1W1K78UY0r7OsPnSvRa8CwFSss/aL7b9YBRwRhHtloORWKUCgl7kMjVz/UbHpGvYuuzQT1NprsSlqsUO24QbHQNNWG5Fvt9JbYVmfobwVuSGkUMAHSxNUwAFVW3011llrnfUJU2z9Ndhcex022VtPcULZaWd9ttptu/121QnArbbcc799SaR2Z1233mDz3bfWL78IAEYXNuUy4GB3nfjWizOONduPQ4625JX7bfnVf2N+NQJIksK45pWH/rjggwuEUcvCMpzcugba/OXrpvvbrF9sShdyVaWbXoECbbq8umCtwx5i7LI3lG2l60Gq4lHIz36p8Uiz3vDMxEfPkvMgBzmkR0UiFF9UDjFpdMUAXw/99OnfaH1NNJDRERk0VJX98R1hXJHGA0HI/1tD19ZPO2fOty31eSVmLSkexJLlBh8wsAoNeYH8BqIIBzaEBi+IiA/cYBH6McQ+95NI/gSCgb0cLCH+6yDuAihAkQGvgMJjycNCoh4L0qAKdKAgQiBIAw0CoAoRdIP7CGLB+LFBIPELIgCUUETyYcWDjMpYtAhSMHEh5IQJ4eAVobTC3LVwRg5DoAyTZUGBMFAJPhAIBAHwAjr04QUO9IESAGAHMOgBDDwEgAXpqIcivkAPdLCjGmlgQTuk8X87a1WaEvK0ffXvY4bkmQq3CCPqBe+L7GPIGNkAhkOYEY3yc2MS6QAAOFYBDEV0wxLx+IIi0uEQAGBD/PQQRx2+QP8RSEQhABnywYiEUCAck5UJHYnLQ7JQkpMkoBerZ8kKvqCZdiBDJwMpzTHCMZoIGeMolUAGRdARDLMU5AWTR0zIPBF/USTItHwXTCbOT4vGLIruHGJAi8xTIjH0yAzDKZBopjGNibhgNfWAyXDC8RB0eB8cA4nN50GyNrfxyBGAlhBISYohRdPW0dD3zprEsyH1lMhHH3LPjuSTIAZNBCE/qYhE9MEO2WSDG1kaQVWSUQmlTIQNv7lQ7Y0zOkjSU31SeMyNsqSjDAnpQ5DakJEe0CELJAgZ7ADHDI6yDz54JgAmiEerKuJ9AnlqVh1oRjvY4Y1uACtDM6qgp0gIe0L/PYpRVxhXhCjVoy901yWJOsyGiuY6zGvQW+GpV452ESt1TQhTUwJGAWIRIY3tSHyoSKLA4mSu57PsQA6blbsmMK+DhUguEyIkIhmpIU/j30DGh9HyFfOzUynscjgbRs+6FgCPHYgToeWQEXaMIFZ0LGUJW1uPYFYgmqWrbPG5WJIud5+pZEki9LBGHG4wuALZ5UN6iRAFUKuKwsxiaAU73I4UFwDHtUpymUvbh7Bhh54USHtnisc7vpIGz+2hAw+hz+qGlyDYdYh2CaIv77LzdtIb70RgK5XzCiSx9ixeFV7gg00qoZkX7OMfyUCGPvjxBXE8BB3pIN+B7LTA1LFf/zlBeM6EcExqvwVtT4eKYORUEpk1Wm9DrgqA+EnzlWz4ZxVAjFAluOEFGlTEGRNiB1FOtr8D+W9DAkwQ2w3kxbi17n1mTCdKunCZyqwIiOlgBz7Kjw0TnrASoglHC1oYDAkxKH1N3DwU6/Yhy/Ptd4Hr5KJqOcFcTub6vFwRNlRBDy5NoxL0MGQ1K2GIDQFxnOXsno74DKISfUhkB3JRcfJVvH0Oj4LLI2gQWaSsNNBDH9RoUyWIWAnejHAiXK1NMPShhgIdiKsPIUiv8jfG68FT6uSE5ZKUV3blZbBx09vUUT+EpVd9XxV80IeowrGsSbwqGBzIBqn6wJUSZCADI/+dVtaOiLfA7HWnK/tpGnfZxqZitlJsGeH7tnPPokmniYb92nUv7M+GVbZicVwUq/YhEfYGbPRSlO+D75vfqvN3bOH9bgTfti7bI61FMq1aTqvVfA5/uLsXDPAHC1yvFbctnRNZkUUCwMoW97WnPz6QY48cpDUXaXMDPuOT51blEmmxy1HOcOJqGQMMkBpCaA5xZUmcIcvgh0eokYqhN/lZPpcIW4POc3cOd1p7YSTIayx2Un8ZMagak6o6Tu6GQJkhUmZIiuCRZxinW7jjXQAJSBAfoCY91AS6uUMcHJGInf1QaV+7ga2OL4/E5xxzvzLVLVJsu3wmAxAo4cz9LiD/wC815yQPS+HldfgmYrntCXk7Q54WgMe/vO58nnHh1Jn0zVXNcZizfeUihzndk+0d12jbP3hB+9E9jvhaI0c53BaNZrQtCAMQhjHKZvzETb9vk/cLhIY2e9rjvnLdfxzvc0852g+f/NUn/9YsUYBWSN/8tL++V0JAAgYUTPtT07yHmo4sLW99hdd5y2qR3oHVFpLshQJgHoDg35ZwHkMIHs7xn75FR/0FYL1p1HAxwNGB2tKJWtmR3Xj13wrpRUWNmwBaoMwpXcjtn/4hhI7wiI/A3KRdXPeUlkfEwjcUAN89ktpxkczd3wb+3Qq6zrKkSuShGyItXkj4QQlECMch/x5c9aAPpiAQduCgDCHaFWFFYEJH0MI4hAQyWENJhIM4OIADRIQWYmFEwN+eKGCWMCBied7gFY/EPATFlCAUmhzX9SAKjl0VBuFAzKFD1GEF3iFRVZwaKsgetlugUWGhhN7EjN4gEuI7GaIkJiKgeSAmPgQgNoQgJl5E2MAXgMAQ1EBRoIAQPEQNWMBRgAAKtIFHmCJ4UCIhWuK/+SEMFQ/OdARsONkQ7EAYgAARoEBRaIAqIoQFaIBAHGNRfMEOSMEQeAQxWgQrskceniAb/okt4tXOSYQN7MAXDIQUAIANhAEKPCMADMEXaIEWCAErgoA4imIrkmI0WoAWlCMAgP+ABoiiDbhjDbSjDQCABYQiCrgjQfTjQJIiChABCBQjQArkM1qAOYLAP+ajOv6jQYbBPw6BFHzBECSkKIIAKd7jKUqa3UEhLUYcI07cB0qEFCAjQdgAEYSBFOyAO6IAFAyBFuxAG8ykBRyjFkgBEbgiMVoAEXAkEQwBPoqiMoYBFEhBPd5jPn6BBoykQNikBUCBMHokQ4IATUolOwojAESjBqCAFGAlAISBFlgACmSlBkBBG3jkTD7jEGjAP5Lk693hSYpcNnbWNkYECEABQvSiQLwlAAzkObqkQirjPQojMbaBQgLjQrqkMmpAOHbjVwpENA7EPGqAQSLENAIAFID/wGeKpSoeoxDoJAiEATKiQBgIxGcyZWG2phG2lkleo6js5Wz15UO0ZEi6JmAuZmG6o2IOpGJOIzHapGgupGJOZjES42gyZFiqog1M5WcOxGcO5HNGJ0ASYz4mZ3C6JlhO51xSJQXKmDX+4ObhpnJ1RAt2RI/0Vw3QpEDUwBAc4z+i5XcOZ2QKBH4S4xcQASnWgBDY53YCQFECAG9m50DsgFzuAHASxDTWABFIwV+KI2kCwH/WgAZ8I0B+5z3+ZmGOJQD0I3nqIG3qoW0ai3qqF+gxCwwC5A4Eowa0ZhgQARQQwSkapn4eo43iaHTWAArsQEJ+Y4ymJTLOJArk44Nm/6ZA9GKQPmN1umZbBiOMQsEOiKWQNuNh3igReOgxhiaCasAztmRdkmAk1SZ65l9KMl1FbCJDdOKJWURPlumAhqQQWGQx3ql9WkBI8qlADGhdpqIQpOJ8WkBd2sBI+ulLGqpAIKpnokBPDoQN8KmfGiqjFmqelumkkiIwDqYW2GWWzWKKyswilmpEuGlCwOmc+YViGk+UVkV8cihZgiqxVeKodgSyOWDgyaEj0iEkemJZEGr0OKpXpGJvziYP4uWt0pMbIoSudp4VGh4aSuJxyKKypukCruiytWmvBuKvxulxwOJA3KlDCAFYOoSiRocFJCdBxqAJflxecqCp9iFruP+GLuqM6x0Fk3ooQ7RqQ+wrurokTkCmaILrAKGpFKbnmqogxSlFQJJjaUbkRL5lG5BifQJkPYLkQBxjOw7mWnKoRO7jutIpOYZBP+bjENhAPf5kk7KmRGKsPULouRqsx11rwqrpvN6Ybg4sg3LlPoKlWKalWwZnN4KAFEDqxmrATu6AKsrkEExodB6jkFIlFMhkWiblEAhBG1hAG+wAfTLoXFrAaX4BUJqjawopRtLsiZ7nzWbrwtYMBK4iWPYs0KpiNAomdoIoQSimQgLkW8rnUNIlQgipFJCiYtInUx6nK0YnwRLBp25sfSak2iYrwvJhLb6tEO5sTXxmUWbnZgb/56smo0sO5FxuLZgGbkLQ45X2pEt27Rcco1oSpHM+pij2q8BS4wCyreWiZM6qZI7siHu+YL4+xDRO52VOp902LWAOJDMabpnqZ4SeLusmRDiC5n5+J/JqQWsiLzNaZPUKROFi6O0GVe7C67LCTLMSxLM2IK+66PA6BD4mZGu2ZEJiqZWq4kFCgf5OZdJW5UIG4w4A7vQObo8O6g5AgRZwZZAG7gLzaUIm5OMKRE4+6eSeKYpiaxtqq85xq/vuYEmwothKamkabp3+aV2W8EAIK7luKrnyqbAao6Km4j8OKEDWgIBaAG/+aQgjBKAC69p+VgWEAH+ET9gpohHTa+8y/wSqIoSquuvAzqxrEWVCLu56WOtwaQp34eDvYDA2Yu7wtCgRvig3lqhr9bCCWHFtyQqE+EoCcvFtevEtRqvoTSu1RiB5fRp35WDmubGKwrE2cnAYv28d/wcaD5detFXSGYAiLzIjN7IjP7Ijn0EQQDIlV3IkT7IlZzIkB8EZaLInOzInf7I2dMMnG4ApdHIpl3ICGEAlDPIWGcAqp/InHyJWsFV4IAAu57Iu7zIv9zIvB0EL+LIwD/MvBzMxH7Mvt0AQIDMz87IyNzM0R7M043ICIMAkbA4ooB/5ZfMqlMApVA4CVPM0IzMtS8VT7EfvbHHbZnBZTEIr08UmvHPD0v/x4CwEpPRWJP7wYKkAf/CH7O3xOnexVxyAK7sVPb/ITXBXsFWweZovH5PqVhB0QS+IHZ/PTfAWETP0E4rqQ+Nq+g6ERE901eXraM1gSWzc8+BJBiAg+b6rw8XrFA70UcgATVvBizwBDAjySB8hFJWE1g3EBcQHG7f0wV5wQL+xTBeFDJhAHNj0iFzBE+i0sFmE6SEE6jXSrdzzueGuS/MbTCtsUheFCeQ0FbhAHCyBC6wBAMDAHZiAC1jBFbzBFVzBGlzBEkRBVD9BW99BVLO1W9v0G0TBElwBQkA1AJj1XTu1E3uwLqUYL60YvxiNQvsw5Rr17uplWYQ0Toz1Wpv/wBtQQRS8gRUsgQxYgQyUtQmkwRNcwR1YwROYABXAQB2YtgkAQBRcgWlTwRNEAQzAAF4ThAvIAAAwNQyYtUavquL1tFCwntANBEYft7px9FH3cVhvdk7DQG0ftgw8wRIAN2HbdhS4gAuMtRXEgQtEQW1HQRScNgCkQXi7AGkDt3Bztgy4AHRztb04dnZBtseQj0qz9MJ19bp9Nc5GtFJwNnYLRHBzt3wLxGD3NgyswR24AAy8NgCY9ng/gQukAYQrtnYPd07X930TNU+bk08zd2MENRMutj579fnaHF1odk0geHYHNxWYQB2sdVkLd3vfgVrXwY2/AQC8QW3TNQDc/wFNL4FNU0GOD0RwgzgAiDhy52uldURElcSmkWDhSFaAF7XuHvHlVjdLmACZ93aNC/cbLIEJLMGOC8QajPeaUwGRmwB6HzmZR4EV1DWZL0FUO/l8h7h9TzljD9ZmDAzSdXnNVi6Y866Bi/ROOyEeNgR3eQuJt/iAv3hEIJuMO3oT2uFKNsQFIAkiI7qlfxqBu62Yc7qZUrZrTceWG7SAmzqmJ9VHC8Smq7qJevpDlHRHeE9IoDRPNYShI1ys99mps3OqDwQVeLhDLLtA4LRESPmB5/SgC/rF6DeA8XdE/HRETDqAr/pG2+xly2ujM8STS8S5G3ZESPtRcHa1szg51f/ZZUhaqK/4o1f2l1+ivlfFrQMAFdy1C8R2W6eBTZ/1ev97eFOBYdfBwFtBwAPAake5fV8BeqcBFQDAFchAHHx3lH93Hdi3DKg3j491xB/2xbsAxUdBHaSBCXx3yC+BkAf7uz8ZtkeZtj8Et0fEq9+7Bed7mC+6UvS7hMcBDPy7aG/4a1tBHcjA0Ed4cGO3aJ82fYO8feO0FaRBGhz2EsRBn0O8Cah1GnD9EvQ2n4O4lHM2U1NBGixBHWC3nN8B2Tf5Xs38ddW82928Q+S8wGDHoYN7zFk20JM7VvT7h9eBW5+3C7x2HLyBWp97cMvAHRDE1Ev8WqcBfNs3yidEaFv/wVhL+ZN3fqCjPaALxFgjPnzz+NxDun/Z/enhPVaXZ0J4+1QXu5Ydu0CXe0I8+WtD+MU/QRwI9odrN7tPfn2PtgzAwBVgPuoPRMgHNsYH+ufDwNnn9OSDuFl3uMyrPs3Le0fofUTU+6j7fXSLe+DHNO4jBMqvQZADwBo8AbQb/mHHAfsHt+ED9o3XwRpYvsRj9xoAxJo4LgC4kAEAYUIrJpY8AfBmyZo1DQGYgCHjDgAYFivCACCDYEcZUaxorJMQJcIEKVm2dOly5cuUY4DIbHkEjs2WP8zoBBDTJwAGBQo8CAo0aFIABZQ2dfpUJlOoPg0gmKqz6lWZB16+MWHx/8mSr3HCfr0CoM5XGAYBXPkahUochncIggSQ5ivdggdZpomIEK+JNAgtUhHrgiNHux0FfqUIU6tNpJEpK52sc0EBCBV8Xq689HNoylJFJ8xaGuHp0lxRt3bd0vPn2K9lO1VQ4MMFnbMjk6b9m6Xv0qqHW0XNGnjy2q55K4favOUFCLh1y4Q+Vbhz2tlDExft/TNy7eOdXp9qnvzupxWm57bumnt60fErg/9sn7J4+ftfon+KHggvmirjCKe2+KEzqNijrj/4+HPQNfwok1Ar/R68UKXX0OuAg6ZEGMEpDzZIUMHpWGiwNfowxO41CrVycSoLV+TPv/KS4tBDEJsSkf/EEgsIAbIUZ2wqBAVeUjEyGKdS8ikEDHDNyaQmkECpCChgTsMbO1TqwxBHVO8qEogCkqUalUJyyIQeyICoI1s0DjUmnYqyNTp9mrLKK1sz0zItc/Syx6keGLNMCNO0iYHM6EPzKjmdclQpO0uT1CY8k7ISy0x9wpFLHZXiEUytBv0xJT6DYvTQpRY1gNVWXX0V1lhhPSMIWW29ddZacd1V1iDO4BVYWH0Ntp1sgjUgGVOOXTaBZZkNNh93loXmGGe3YYfXZp2NtRqi5nFV2213RfXQNl0qAIF01V2X3XbdbTeIFt6dl1545a0X33dbCCLfftvd119YcvGX4ILVTcD/YAROEPfWYqZZlhlvcMWk3VfkyRfhhN3lhKhTDtY4X3LTNLclkR+Fs7g6n1Q51VBbTs9Ul0IgyqifDH2ZpQduK0CBmlMyuSlIlRI6KEpDMxrnhGJOWqulW5q5KJuFZDqlRBe4moGS34wQ5aNXRg1ppp2m+r/SoH5gbDfJPnPr1oj2KWzK4sY5bZQagcSRPCBZpLRFkACu7pSgduDmtXUCeuiuu1O8srm1chylLnhQCgsdNK2siEGQQKKQv0Xjo4irDgw0NKgXmNpwnxBP6m2qGJf760ljr5TKS/VELXCEYjAiIb6LcGSQQfgAYBFB9ihi+DyQUJ4QRwQpRO/gh08I/3QAmn8+j0+/lMw1FQgtbfWkw3eda5bNv7P2oDDdU7RCOn+kEd0FMeJ5AAZxxIg8CgGgiBgEIQQJeyAEIfYwP0EIAiVGiAEAAjjAPUzPJ6Dinmsc8L3QjO9lGLRJ67DyushAbiogRIil1He70uSOeHno3x54tzsAKJAPMRhE5hZYhOwxMHQAcCEScogQBeJQd7wLigTfw5xRKaA6ldFgqpb4Eg5u0IOPm53XpJQ+n6wPd64RROhcqEAFPsIIYeSf53gYRCAm5Idl1KEQI7i9IrKPBO1JYm9Sd6q2xSmKVxFhk6b4EhJe0YSiQaEg+NaI3+nwEQzc3x5uCIkxIkSNO//s4QsXGEk26oSIKGIfABbkntHUUXV3TBnY+ti4UrbkjzrB4glF078YxKAI8YvBHmY5PCPQMgb7KwIZcyjJBFayl5e0SSaDtElOTicDnKEjKG3SRJc8USbQdMke53RKlvAgC0rRARcu1xoXYognpBMkSirwAc0o8yrOHJI6WSLNZ+YxhNaUIihR2JJvrq2eKJnMBcy5Ga2wc0UARYk7W0LQlFCzKQhdUT6Zqc8spYSfNEtnQ6Miyu/AEyoKTYpGL8RQikrNmCi5wNlY9FGtlc9tGOUjlOTZMo8qxW9DeulsSPoUgV7opqlR6VMMihKOwq2lCZEc5SwXUvlUDzijcxn/K18CNTI1Jaf8iWpPB7rThAY1o1gFQCptsspxJgd51sseIfQmiOpdD3oIIcQg0koZYsLmoS9JgQWTEtX9TNWqQcvrRrVazSrmqZuv8SUScomENArwETHgwy0f8YhCODIyby1UYHNGFBVA1aQnTSlKZcfSv9qOst7kXRmRMAgfAjOIASxCEQroVjdqMos6GVTW2JbZn1l0cefrbFC4KhOvhualKRlsDtMYzNKG0QgQvIpkSxVXm8zRjrZFCV45K5qf6mSPvX3Jb5cDnBjAb4tnLG4QCTi8mEb2tcWMLWrsKh/qbpaUnuWtFVUZSOAqJw+vnKF4UbtGAOT3lTfUCnMd/xraT0o3Ie/Fo26tq1VsapObRkXwTnqy1K+yd8IIUfAodxvfOgaXmTMtnG03fFEGU/HDGaaMiFGH4BLn1sMxNhyI6enc+aj4xffZa9H6etUaq7hpNr4gjnGr4xN/Zo9DTUrlDKxipU5Qwp9pb3pyXJ8dA1W+rUlFkyMT3H44xR9HEbKUiVxdE8u4wT6hQhqikAaP6IQGfaBDH9wQ5e7apLTQi59OLKAFImhBCEkJxA3+8IcbWPi+LZZulSd0Zez2OFItNcxXvnISmdDgBZl+ARjqzFQ7pwTA+uWzBkitgR0E2ic4mMGqZ2AIKK8XfGWG74LRjGKZBIbSUbCJHjSd6f8+wNrTL1nEK4kdA0LYBAqlJrUWfAIIVrMaEW8E9pAzTBRrXxvb2db2trndbW9/G9zhFve4yQ0AsVD6K6rSNgB6rWl1kxve8Za3ExRY7BggoYLbBoCyS/1ubTvgBs9e9Q3yLW+DHzzcQFZ4QxGD7iXYhA7t1kOGY2hvyL6ECPyGgk/QIPAZAGLhIRc509KC7jfYJBHtToSKXfnKPez5JV/gtxR8Eog5PPsPI9f5ztNUhygw5OQ6qQIYXkCHKgC5EY54ZVh18oUdaIAINA+KHFTd6kDwHOtZ1/rWud51r38d7GEX+9jJXnaznx3taVc7kFWATBKI5gIs0MxlP5MCBaD/s+24QedUipQSu+8dKhdQAN0BsIDpQMBnU2FAzxCCgZ19APBP6TtKFm8krQie8ArQvOYjs3ifjXQ6lr/K5AGggs0P/vKoR0g5xwRdss+VBWKCgGhukwK5J34qrC8AbQcV+wJk4CprIpnuaTuVvIueBSrwXgEwcJWdnU4oCljAbU4kKDb5Rjokg8rxE8wzzjufKNAHgDkXwIC3W59kplcAm0T/FO4jZDokkHsK0j5XyONmPkwZSvungoEFsIm25O7tzCnykiJRSMb/AFBUZob/AOA2iu8ppq8AxA8hxOSpnuIAfYMFzAmDHoABu48BCrApJBD6xIQFUmABXE8pMpAl/9gE95rCA3kmIaYjBbzn/NBuZ3ZPNNgkBeaqAafiAREiCIMwnYSDCK9i/1ICA34vMjKDAm8jA5rvn0hDTCpA+6AiCTXM2qrvKpwQITIjA8wJ+KYwJQZlDJFQBhFiKIjiB8durq5GM6SwMkiA/UilMohwCHWwCFPiCBUvDRvvA/xJK7wwISpATD6gN0gDAj5AUSgQA/+QMzBAAbtwAr+wEs0JAm1KOFyw89LwAjIgA0jAnAjP7G5jAPVQNG7vM4jQe+hvOlTwTIwQFf1Q9NgjmSiDEEOQk65QExNi89hQK7IQA95OEgtABJOCEC1w/IyRDBNirs4QDS1vKBBRTNow7P9kz5wQMTSmj00u8CoqQAHa47IwAAIWsQBI0Sl0hg2NAhzF8SpUoJ/uzt8csSnW7/eMRFEsK/h2hvG6TyvgUTPubg3p6insMQMsLxvtECrUkWeMIvte0CkAEgLkMRvjT+0q4Gpu8DOs5hidwv+uZgFqBgNQUCMxECTLDwA+8mogMike4CSb7yRRcipiEgAuwCVlUvFOEgKvRlReEgBIICOb8CQRwiZDMhh1kpMWgP4i4yavpvmKMgXkcO2mkiqr0iqvEiuzUiu3kiu70iu/EizDUizHkizL0izPEi3TUi3Xki3b0i3fEi7jUi7nki7r0i7vEi/zUi/3ki/70i//EjD/A1MwB5MwC9MwDxMxE1MxF5MxG9MxHxMyI1MyJ5MyK9MyLxMzM1MzN5MzO9MzPxM0Q1M0R5M0S/MrrbAAltI0V5Oilk8bEcIlGYABpNAlHwAWZVMNaStRorICV1I3KiBrKkA3gBInWdM4fWIRCRAhZuYDyI+fJhL/WkLuMGAJT4QBy7H5eMacjOQ2MFHuFMCcjlM8bUJMevAcd9FIhiIkJ5AB5K4AB8U8SaA6D5D+DPH/mMIUGeACfu8BZnM8/1M6f2RmZk89hWICM+MDNk8EISAMgW8oDlLzHsAWVYBNHJA0HmA6GARAN3QJIdQFl9BIBmUBLHA4qVMBVHM59XE/mj+g+YAzM0ggoiw0IRbARGdxQ8Vzrmqm9wAAaqbjdJaPKCpgUAAPNWkzQ1NzQTQDPxXR2rzxRo8TOKvjAnCzAlw0ampSNnWD9ArxD3NTCjFgNoGTkyBQNqXySc9UCK0NiVoiAzKRR68UTeOUMqbUP5VCTOUUT/NUT/eUT/vUT/8UUANVUAeVUAvVUA8VURNVUReVURvVUckjIAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequence of pubertal events in boys with average timing of pubertal development in the United States.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Biro FM et al, Pubertal staging in boys. J Pediatr 1995;127:100; Karpati AM et al, Stature and pubertal stage assessment in American boys: the 1988-1994 Third National Health and Nutrition Examination Survey. J Adolesc Health 2002;30:205-12; Dore E et al. Gender differences in peak muscle performance during growth. Int J Sports Med 2005; 26:274; Neu CM et al. Influence of puberty on muscle development at the forearm. Amer J Physiol Endocrin Metab 2002;283:E103; and Tanner et al. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44048=[""].join("\n");
var outline_f43_1_44048=null;
var title_f43_1_44049="Mini-case session #3: Metabolic alkalosis";
var content_f43_1_44049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mini-case session #3: Metabolic alkalosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44049/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44049/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44049/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44049/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44049/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/1/44049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 1997.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 43 year-old man with a history of a duodenal ulcer is admitted to the hospital after 3 days of anorexia and vomiting. The physical examination shows mild orthostatic hypotension, flat neck veins, and decreased skin turgor. The laboratory data on admission include:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Plasma sodium &nbsp;= &nbsp;138",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma potassium &nbsp;= &nbsp;2.4",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma chloride &nbsp;= &nbsp;88",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma bicarbonate &nbsp;= &nbsp;40",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Arterial pH &nbsp;= &nbsp;7.52",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;Arterial PCO2 &nbsp;= &nbsp;50 mmHg",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;Urine sodium &nbsp;= &nbsp;38",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine potassium &nbsp;= &nbsp;60",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;A. &nbsp;What is the acid-base disturbance and how was it caused? (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10692?source=see_link\">",
"     \"Pathogenesis of metabolic alkalosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;B. &nbsp;What would have been the acid-base change if the patient had made no gastric acid (achlorhydria)? (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;C. &nbsp;How do you account for the high urine sodium and potassium despite the presence of volume depletion and hypokalemia? (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39479?source=see_link\">",
"     \"Clinical manifestations and evaluation of metabolic alkalosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;D. &nbsp;What test would best confirm the presence of volume depletion in this setting?",
"   </p>",
"   <p>",
"    Overnight, the patient is treated with isotonic saline and KCl and with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    (an H2-blocker) to diminish gastric acid secretion. Repeat laboratory tests the next day reveal:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Plasma sodium &nbsp;= &nbsp;140",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma potassium &nbsp;= &nbsp;2.7",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma chloride &nbsp;= &nbsp;94",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma bicarbonate &nbsp;= &nbsp;34",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine sodium &nbsp;= &nbsp;60",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine potassium &nbsp;= &nbsp;20",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine chloride &nbsp;= &nbsp;20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;A. &nbsp;What three factors account for the fall in the plasma bicarbonate toward normal? (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;B. &nbsp;What will the urine pH be at this time?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppose a patient with the same history of vomiting and physical findings as the first patient also has a mass on chest x-ray that is later shown to be an oat cell carcinoma of the lung. The laboratory findings in this patient reveal:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Plasma sodium &nbsp;= &nbsp;114",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma potassium &nbsp;= &nbsp;2.9",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma chloride &nbsp;= &nbsp;75",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma bicarbonate &nbsp;= &nbsp;32",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Arterial pH &nbsp;= &nbsp;7.48",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;Urine osmolality &nbsp;= &nbsp;710",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine sodium &nbsp;= &nbsp;5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;A. &nbsp;What factors are responsible for persistence of the alkalosis? (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10692?source=see_link\">",
"     \"Pathogenesis of metabolic alkalosis\"",
"    </a>",
"    ). Are any of these factors related to persistence of the hyponatremia? (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;B. &nbsp;What is the likely urine pH at this time?",
"   </p>",
"   <p>",
"    The patient is initially treated with 2.5 liters of normal saline plus 40",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of KCl to correct the volume depletion and hypokalemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    .) The next day the plasma sodium concentration has risen to 122",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    At this time, there are three diagnostic possibilities to account for the hyponatremia, which was initially due to water retention induced by high ADH levels:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;1. &nbsp;Hypovolemia alone was responsible for the hyponatremia and the patient is still hypovolemic.",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;2. &nbsp;Hypovolemia alone was responsible and the patient is now euvolemic.",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;3. &nbsp;Hypovolemia, which is now corrected, was superimposed on underlying SIADH due to the lung tumor.",
"   </p>",
"   <p>",
"    &nbsp;A. &nbsp;What urine tests could distinguish between these possibilities &mdash; remember to consider osmoregulation and volume regulation separately? (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7246 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44049=[""].join("\n");
var outline_f43_1_44049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=related_link\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39479?source=related_link\">",
"      Clinical manifestations and evaluation of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_1_44050="CDC stature for age boys 2 to 20 years";
var content_f43_1_44050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Stature-for-age percentiles, boys, 2 to 20 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 669px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44050=[""].join("\n");
var outline_f43_1_44050=null;
var title_f43_1_44051="Pill splitter PI";
var content_f43_1_44051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Pill splitter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Always use a pill splitter when splitting a pill. Do not use a knife. To use a pill splitter correctly, it helps to have good vision and good use of your hands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44051=[""].join("\n");
var outline_f43_1_44051=null;
var title_f43_1_44052="Test lumbar nerve root comp";
var content_f43_1_44052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Testing for lumbar nerve root compromise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 549px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bigos S, Bowyer O, Braen G, et al. Acute Low Back Problems in Adults. Clinical Practice Guideline, Quick Reference Guide Number. 14. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR Pub. No. 95-0643. December 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44052=[""].join("\n");
var outline_f43_1_44052=null;
var title_f43_1_44053="Escitalopram: Patient drug information";
var content_f43_1_44053=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Escitalopram: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     see \"Escitalopram: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/21/36184?source=see_link\">",
"     see \"Escitalopram: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lexapro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F608961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cipralex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to escitalopram or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697339",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures or are on seizure drugs, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any natural products, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12430 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FC5DC09734-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44053=[""].join("\n");
var outline_f43_1_44053=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166813\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F608961\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021524\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021526\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021525\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021530\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021531\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021533\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021528\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021529\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021534\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021535\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=related_link\">",
"      Escitalopram: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/21/36184?source=related_link\">",
"      Escitalopram: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_1_44054="Pathobiology of mantle cell lymphoma";
var content_f43_1_44054=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathobiology of mantle cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44054/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44054/contributors\">",
"     Jennifer R Brown, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44054/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44054/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44054/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44054/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44054/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44054/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/1/44054/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mantle cell lymphoma (MCL) is a mature B cell non-Hodgkin lymphoma (NHL), which accounts for about 7 percent of adult NHLs in the United States and Europe. While it is often discussed together with the indolent forms of NHL, its behavior is more often that of an aggressive lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MCL has been previously referred to as intermediate lymphocytic lymphoma, mantle zone lymphoma, centrocytic lymphoma, and lymphocytic lymphoma of intermediate differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathobiology of MCL will be reviewed here. Information regarding the epidemiology, clinical presentation, diagnosis and treatment of MCL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/63/17402?source=see_link\">",
"     \"Initial treatment of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CELL OF ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most MCL cases are postulated to derive from na&iuml;ve pre-germinal center B cells of the mantle zone, while a subset of MCL may originate from marginal zone or peripheral blood memory B cells.",
"   </p>",
"   <p>",
"    The pre-germinal ancestry of most MCLs is principally supported by the absence of somatic mutations in the immunoglobulin heavy chain variable region (IgVH) genes, which serve as a marker of germinal center transit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/3\">",
"     3",
"    </a>",
"    ]. However, several studies have found somatic hypermutation in approximately 20 to 30 percent of MCL cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. IGHV3-21 and IGHV4-34 were significantly overrepresented in these MCLs. The V3-21 cases all lacked somatic hypermutation and were associated with the same light chain (IGLV3-19), suggesting possible prior exposure to antigen such as that seen in antigen-experienced mature B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of the overwhelming majority of MCL tumors is dependent upon the expression of the cyclin D1 gene (also called CCND1,BCL1, or PRAD1) located at 11q13, which encodes the cyclin D1 protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Cyclin D1 is not expressed in normal B lymphocytes. Expression of cyclin D1 promotes cell cycle transition from G1 to S phase and proliferation. Cyclin D1 expression alone is not sufficient for the transformation of a normal B lymphocyte into MCL, as transgenic mice that overexpress cyclin D1 alone do not develop lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition to cyclin D1 expression, MCL tumors demonstrate a decreased response to DNA damage and enhanced cell survival (impaired apoptosis). Alterations in these three pathways (ie, cell cycle, DNA repair, and apoptosis) are described in the following sections (",
"    <a class=\"graphic graphic_figure graphicRef73115 \" href=\"mobipreview.htm?27/17/27927\">",
"     figure 1",
"    </a>",
"    ). Abnormalities in other pathways are likely, but remain to be further characterized. As an example, a subset of cases of MCL has gain-of-function mutations in or hypomethylation of the gene that encodes the Notch1 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cell cycle progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;All cases of MCL demonstrate increased cell division and replication. In the vast majority of cases, cyclin D1 expression drives cell cycle progression from G1 to S phase. A small number of cases that resemble MCL but do not express cyclin D1 appear to stem from the deregulation of other cell cycle mediators, such as cyclin D2 and cyclin D3. Preliminary data suggest that Notch1 signaling in MCLs with Notch1 mutations directly upregulates the MYC gene, another factor that stimulates cell growth and proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cyclin D1 expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclin D1 is not expressed in normal B lymphocytes and its expression appears to be necessary, but not sufficient for the development of the overwhelming majority of MCL cases. Cyclin D1 is an activating regulatory subunit for cyclin dependent kinases (CDKs) 4 and 6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/11\">",
"     11",
"    </a>",
"    ]. Activated cyclin-CDK complexes are involved in the phosphorylation and inactivation of the retinoblastoma protein that normally impairs cell cycle progression. This complex also binds the cyclin dependent kinase inhibitor 1B (CDKI1B,Kip1,p27) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/12\">",
"     12",
"    </a>",
"    ]. This binding both stabilizes the activity of the cyclin D1-CDK4 complex and sequesters CDKI1B so it cannot inhibit the subsequent activation of other CDK complexes required for cell cycle progression.",
"   </p>",
"   <p>",
"    Aberrant expression of cyclin D1 may occur through at least one of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The (11;14)(q13;q32) translocation juxtaposes the DNA coding sequence for cyclin D1 at 11q13 with the immunoglobulin heavy-chain joining region at 14q32 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. This translocation appears to be mediated by recombinase-activating genes (RAG) and activation-induced cytidine deaminase (AID) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/15\">",
"       15",
"      </a>",
"      ]. While found in the majority of MCL cases, t(11;14) is not specific for MCL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Genetic features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Point mutations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      genomic deletions that affect the 3' untranslated region of cyclin D1 result in the expression of truncated mRNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/16\">",
"       16",
"      </a>",
"      ]. These truncated RNAs result in increased cyclin D1 mRNA and protein levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. An increase in truncated relative to full-length cyclin D1 mRNAs is associated with poor clinical outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Genetic features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Up to 50 percent of patients with MCL demonstrate activation of the Wnt signaling pathway, which results in the incorporation of beta-catenin into a transcriptionally active complex in the nucleus and the activation of multiple target genes, including cyclin D1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenetic role of cyclin D1 activation in MCL is suggested by the ability of cyclin D1 overexpression to transform cells in vitro and contribute to B cell lymphomagenesis in transgenic mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, gene expression profile analyses have confirmed the central role of cyclin D1 in MCL pathogenesis. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Heterogeneity of MCL'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cyclin D1 negative cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression studies have noted a small number of lymphomas that morphologically resembled MCL and express the characteristic gene expression signature, but are negative for cyclin D1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/20\">",
"     20",
"    </a>",
"    ]. Of six cases identified in one study, two overexpressed cyclin D2 and four overexpressed cyclin D3, typically without chromosomal rearrangements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/21\">",
"     21",
"    </a>",
"    ]. In another study, 22 of 40 cases of cyclin D1 negative MCL displayed a cyclin D2 gene rearrangement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/22\">",
"     22",
"    </a>",
"    ]. These tumors expressed the transcription factor SOX11 and had an otherwise typical morphology and immunophenotype (CD5+, CD10-, CD23-) for MCL. Cyclins D1, D2, and D3 are highly homologous and appear to be functionally interchangeable, and MCLs with cyclin D1 or cyclin D2 dysregulation appear to be very similar in terms of their presentation and clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/22\">",
"     22",
"    </a>",
"    ]. Although the current WHO classification advises that the diagnosis of cyclin D1 negative MCL must be made only with great caution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/23\">",
"     23",
"    </a>",
"    ], these new data suggest that tumors fitting the criteria described above are best classified as MCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the overexpression of cyclin D1, MCLs often have other acquired alterations that contribute to increased proliferation, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased CDKI1B &mdash; The cyclin",
"      <span class=\"nowrap\">",
"       E/CDK2",
"      </span>",
"      complex is similar to the cyclin D1-CDK complexes in that it phosphorylates and inactivates the retinoblastoma protein that normally impairs cell cycle progression. The cyclin",
"      <span class=\"nowrap\">",
"       E/CDK2",
"      </span>",
"      complex is normally inhibited by the cyclin dependent kinase inhibitor cyclin-dependent kinase inhibitor 1B (CDKI1B, also known as Kip1 and p27), levels of which are decreased in MCL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/23\">",
"       23",
"      </a>",
"      ]. CDKI1B is typically expressed at lower levels in highly proliferative subtypes of non-Hodgkin lymphoma. In MCL, there is a gradient of CDKI1B expression with greater expression in more highly proliferative tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/12\">",
"       12",
"      </a>",
"      ]. This is likely because the CDKI1B is sequestered in complexes containing cyclin D1, thereby blocking its cell cycle inhibitory function.",
"     </li>",
"     <li>",
"      Deletions of",
"      <span class=\"nowrap\">",
"       INK4a/ARF",
"      </span>",
"      - The INK",
"      <span class=\"nowrap\">",
"       4a/ARF",
"      </span>",
"      locus on 9p21 encodes the tumor suppressor genes p14 and p16 that, like p27, inhibit cell cycle progression by binding to",
"      <span class=\"nowrap\">",
"       cyclin/CDK",
"      </span>",
"      complexes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/20,24\">",
"       20,24",
"      </a>",
"      ]. Deletion of this locus occurs in 14 to 20 percent of cases and has been associated with more aggressive (blastic) histology.",
"     </li>",
"     <li>",
"      Abnormalities in p53 &mdash; p53 is involved in the regulation of the cell cycle primarily at the G1-S transition. A minority of MCLs have mutations or deletions involving the p53 gene, which have been associated with a poor prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'p53 gene'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Expression of SOX11 &mdash; SOX11 is a neural transcription factor involved in central nervous system development. While studies of SOX11 expression in MCL have had conflicting results, overexpression of SOX11 in the nuclei of MCL appears to confer a worse prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/22,27,28\">",
"       22,27,28",
"      </a>",
"      ]. In addition, cases of cyclin D1 negative, cyclin D2 negative, SOX11 positive MCL with an aggressive clinical course have been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/22\">",
"       22",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Impaired DNA damage response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of MCL appear to have an impaired response to DNA damage, which results in increased chromosomal instability. This impaired response is largely due to defects in the p53 and ataxia-telangiectasia mutated (ATM) genes. ATM mutations and p53 mutations are seen together in only 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, the cell cycle checkpoint kinases (CHK) 1 and 2 are downregulated in some MCL cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     p53 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of p53 are seen in 10 to 25 percent of MCL cases and are associated with more aggressive histology and shorter survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/24,29,30\">",
"     24,29,30",
"    </a>",
"    ]. The normal \"wild type\" p53 tumor suppressor gene, located at 17p13.1, produces a DNA-binding protein that acts as a transcriptional activator of growth inhibitory genes. Normally, activated p53 induces a variety of growth-limiting responses, including cell cycle arrest (in order to facilitate DNA repair), apoptosis, senescence, and differentiation. Downregulation of p53 expression or expression of mutant p53 products results in a loss of the normal growth-limiting activities of this gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     ATM gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletion of or point mutations in the ataxia telangiectasia mutated (ATM) tumor suppressor gene (11q22-q23) are seen in approximately one-third to one-half of MCL cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/20,29,31\">",
"     20,29,31",
"    </a>",
"    ]. ATM is involved in the detection of DNA damage, and plays an important role in the regulation of cell cycle progression. In one study, ATM deletions were not correlated with tumor proliferation, cyclin D1 levels, or INK4a mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=see_link&amp;anchor=H2#H2\">",
"     \"Ataxia-telangiectasia\", section on 'Genetics and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Enhanced cell survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microarray studies have suggested that MCL cases display disturbances of pathways associated with apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/32\">",
"     32",
"    </a>",
"    ]. Specifically, MCL cells appear to avoid programmed cell death (apoptosis) by the expression of B cell lymphoma 2 (BCL-2), upregulation of the PI-3",
"    <span class=\"nowrap\">",
"     kinase/AKT",
"    </span>",
"    prosurvival signaling pathway, activation of nuclear factor-KB (NFkB), and mutations in p53.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      2 (BCL-2) is an oncogene that blocks programmed cell death, leading to prolonged cell survival. BCL-2 overexpression is common in follicular lymphoma, but is also seen in other non-Hodgkin lymphomas, including more than half of MCL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24215?source=see_link&amp;anchor=H26243875#H26243875\">",
"       \"Pathobiology of follicular lymphoma\", section on 'Translocations involving BCL-2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The PI-3 kinase",
"      <span class=\"nowrap\">",
"       (PI3K)/AKT",
"      </span>",
"      signaling pathway promotes cell growth, cell survival and tumorigenesis by inactivating several proteins including CDKI1B (p27) BAD (a member of the BCL-2 family) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/34\">",
"       34",
"      </a>",
"      ], and FOXO1, a transcription factor that regulates the expression of pro-apoptotic genes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/35\">",
"       35",
"      </a>",
"      ]. The",
"      <span class=\"nowrap\">",
"       PI3K/AKT",
"      </span>",
"      pathway also increases the levels of nuclear factor-kappa B and mammalian target of rapamycin (mTOR), resulting in a decrease in functional p53 and subsequent cell survival. MCLs, especially those with blastoid morphology, have active",
"      <span class=\"nowrap\">",
"       PI3K/AKT",
"      </span>",
"      signaling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nuclear factor-kappa B is a protein complex integral in the control of DNA transcription. NFkB is constitutively activated in MCL and inhibition of its activity has been shown to result in cell cycle arrest and apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      p53 can induce apoptotic cell death. As mentioned earlier, a minority of patients with MCL will demonstrate mutations or deletions involving the p53 gene. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'p53 gene'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HETEROGENEITY OF MCL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic category of \"MCL\" is heterogeneous in terms of morphology, genetics, and biologic behavior. MCL heterogeneity may not depend upon cytologic features, but rather upon the tumor genotype. As an example, indolent MCL often presents as non-nodal leukemic disease with hypermutated IgVH and a noncomplex karyotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/38\">",
"     38",
"    </a>",
"    ]. The role that gene expression profiling plays in the diagnosis and treatment of MCL is a matter of ongoing research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/9,20,38,39\">",
"     9,20,38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\", section on 'Lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gene expression has been studied in MCL using microarray technology. As an example, a gene expression profile primarily composed of genes required for cell proliferation was predictive of aggressive disease and worse survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/20\">",
"     20",
"    </a>",
"    ]. Higher expression of cyclin D1 is also associated with worse survival and correlated with a proliferation signature. Two large subsequent studies confirmed the clinical prognostic importance of these cell proliferation rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Another study compared the gene expression profiles of indolent MCL with conventional MCL, and identified a 13-gene signature that was highly expressed in conventional MCL, but underexpressed in indolent MCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/38\">",
"     38",
"    </a>",
"    ]. In both the test and validation cohorts, lack of expression of SOX11 was associated with an indolent course. MCLs with activating Notch1 mutations have also been reported to pursue a more aggressive course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44054/abstract/10\">",
"     10",
"    </a>",
"    ], but this observation needs to be confirmed in other series. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mantle cell lymphoma (MCL) is a mature B cell non-Hodgkin lymphoma (NHL), which accounts for about 7 percent of adult NHLs in the United States and Europe. While it is often discussed together with the indolent forms of NHL, its behavior is more often that of an aggressive lymphoma.",
"     </li>",
"     <li>",
"      Most MCL cases are postulated to derive from na&iuml;ve pre-germinal center B cells of the mantle zone, while a subset of MCL may originate from marginal zone or peripheral blood memory B cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cell of origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All cases of MCL demonstrate increased cell division and replication. In the vast majority of cases, expression of the cyclin D1 gene, located at 11q13, drives cell cycle progression from G1 to S phase. A minority of cases does not demonstrate cyclin D1, but often overexpresses other cell cycle mediators, particularly cyclin D2 and cyclin D3 (",
"      <a class=\"graphic graphic_figure graphicRef73115 \" href=\"mobipreview.htm?27/17/27927\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cell cycle progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to cyclin D1 expression, MCL tumors demonstrate a decreased response to DNA damage and enhanced cell survival (impaired apoptosis). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Impaired DNA damage response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Enhanced cell survival'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/1\">",
"      Jiang W, Kahn SM, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993; 8:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/2\">",
"      Bodrug SE, Warner BJ, Bath ML, et al. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994; 13:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/3\">",
"      Walsh SH, Thors&eacute;lius M, Johnson A, et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 2003; 101:4047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/4\">",
"      Camacho FI, Algara P, Rodr&iacute;guez A, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003; 101:4042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/5\">",
"      Kienle D, Kr&ouml;ber A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003; 102:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/6\">",
"      Rimokh R, Berger F, Delsol G, et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 1994; 83:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/7\">",
"      Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101:4975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/8\">",
"      Lovec H, Grzeschiczek A, Kowalski MB, M&ouml;r&ouml;y T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 1994; 13:3487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/9\">",
"      Leshchenko VV, Kuo PY, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010; 116:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/10\">",
"      Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012; 119:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/11\">",
"      Seto M, Yamamoto K, Iida S, et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene 1992; 7:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/12\">",
"      Quintanilla-Martinez L, Davies-Hill T, Fend F, et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 2003; 101:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/13\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/14\">",
"      Raffeld M, Jaffe ES. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 1991; 78:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/15\">",
"      Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/16\">",
"      Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007; 109:4599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/17\">",
"      Chen RW, Bemis LT, Amato CM, et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 2008; 112:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/18\">",
"      Shakir R, Ngo N, Naresh KN. Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma. J Clin Pathol 2008; 61:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/19\">",
"      Gelebart P, Anand M, Armanious H, et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 2008; 112:5171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/20\">",
"      Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/21\">",
"      Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106:4315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/22\">",
"      Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 2013; 121:1394.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/24\">",
"      Pinyol M, Hernandez L, Cazorla M, et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997; 89:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/25\">",
"      Stefancikova L, Moulis M, Fabian P, et al. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. Int J Oncol 2010; 36:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/26\">",
"      Espinet B, Salaverria I, Be&agrave; S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer 2010; 49:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/27\">",
"      Ek S, Dictor M, Jerkeman M, et al. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008; 111:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/28\">",
"      Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012; 119:4215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/29\">",
"      Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A 2006; 103:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/30\">",
"      Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87:4302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/31\">",
"      Stilgenbauer S, Schaffner C, Winkler D, et al. The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol 2000; 11 Suppl 1:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/32\">",
"      Hofmann WK, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001; 98:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/33\">",
"      Menendez P, Vargas A, Bueno C, et al. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia 2004; 18:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/34\">",
"      Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/35\">",
"      Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009; 139:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/36\">",
"      Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006; 108:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/37\">",
"      Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/38\">",
"      Fern&agrave;ndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/39\">",
"      Iqbal J, Shen Y, Liu Y, et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 2012; 119:4939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/40\">",
"      Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44054/abstract/41\">",
"      Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111:2385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4725 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-1745D172DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44054=[""].join("\n");
var outline_f43_1_44054=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CELL OF ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cell cycle progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cyclin D1 expression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cyclin D1 negative cases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Impaired DNA damage response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - p53 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - ATM gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Enhanced cell survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HETEROGENEITY OF MCL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4725\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4725|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/17/27927\" title=\"figure 1\">",
"      MCL pathogenesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/63/17402?source=related_link\">",
"      Initial treatment of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24215?source=related_link\">",
"      Pathobiology of follicular lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_1_44055="Lovastatin and niacin: Drug information";
var content_f43_1_44055=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lovastatin and niacin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/16/10501?source=see_link\">",
"    see \"Lovastatin and niacin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advicor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advicor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor;",
"     </li>",
"     <li>",
"      Antilipemic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F201054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage forms are a fixed combination of niacin and lovastatin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dyslipidemia:",
"     </b>",
"     Oral: Lowest dose: Niacin 500 mg/lovastatin 20 mg; may increase by not more than 500 mg (niacin) at 4-week intervals (maximum dose: niacin 2000 mg/lovastatin 40 mg daily); should be taken at bedtime with a low-fat snack.",
"     <b>",
"      Note:",
"     </b>",
"     If therapy is interrupted for &gt;7 days, reinstitution of therapy should begin with the lowest dose followed by retitration as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not for use as initial therapy of dyslipidemias. May be substituted for equivalent dose of Niaspan&reg;; however, manufacturer does not recommend direct substitution with other niacin products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for lovastatin component with concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Amiodarone:",
"     </i>",
"     Maximum recommended lovastatin dose: 40 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Danazol, diltiazem, dronedarone, or verapamil:",
"     </i>",
"     Initial lovastatin dose: 10 mg daily (dosage unavailable with combination product; use separate components); Maximum recommended lovastatin dose: 20 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F201055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5354644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use doses of lovastatin &gt;20 mg daily with caution",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5354645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Do not use in active liver disease or unexplained persistent elevations of serum transaminases.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, variable release, oral (Advicor&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500/20: Niacin 500 mg [extended release] and lovastatin 20 mg [immediate release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750/20: Niacin 750 mg [extended release] and lovastatin 20 mg [immediate release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000/20: Niacin 1000 mg [extended release] and lovastatin 20 mg [immediate release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000/40: Niacin 1000 mg [extended release] and lovastatin 40 mg [immediate release]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F201036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablet must be swallowed whole; do not crush or chew. Administer with a low-fat snack at bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For use when treatment with both extended-release niacin and lovastatin is appropriate in combination with a standard cholesterol-lowering diet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Extended-release niacin:",
"     </i>",
"     Adjunctive treatment of dyslipidemias (types IIa and IIb or primary hypercholesterolemia) to lower the risk of recurrent MI and/or slow progression of coronary artery disease, including combination therapy with other antidyslipidemic agents when additional triglyceride-lowering or HDL-increasing effects are desired; treatment of hypertriglyceridemia in patients at risk of pancreatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Lovastatin:",
"     </i>",
"     Treatment of primary hypercholesterolemia (Frederickson types IIa and IIb); primary and secondary prevention of cardiovascular disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Advicor&reg; may be confused with  Adcirca&reg;, Advair&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lovastatin, niacin, or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; active peptic ulcer disease; arterial bleeding; pregnancy; breast-feeding; concomitant  use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole, protease inhibitors including boceprevir and telaprevir, telithromycin).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia. Use niacin with caution in patients with diabetes mellitus; niacin may increase fasting blood glucose, although clinical data suggest increases are generally modest (&lt;5%). Monitor glucose; adjustment of hypoglycemic therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flushing/pruritus: Flushing and pruritus, common adverse effects of niacin, may be attenuated with a gradual increase in dose, and/or by taking aspirin or another NSAID (eg, ibuprofen) 30-60 minutes before dosing; avoid concurrent ingestion of ethanol or hot liquids to minimize flushing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure with lovastatin are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart lovastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of other lipid-lowering medications, including niacin at doses &ge;1 g/day. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use niacin with caution in patients with unstable angina or MI; risk of arrhythmias at high doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use niacin with caution in patients with diabetes mellitus; interferes with glucose control. Monitor glucose closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use niacin with caution in patients with active gallbladder disease; can exacerbate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: Use niacin with caution in patients with gout.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease; use is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use of lovastatin is contraindicated in patients taking strong CYP3A4 inhibitors (see Drug Interactions); consider alternative agents that avoid or lessen potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients with advanced age, these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability: Bioavailability of niacin formulations vary (regular release versus extended release) and are not interchangeable; cases of severe hepatotoxicity, including fulminant hepatic necrosis, have occurred in patients who have substituted niacin products at equivalent doses. Tablet strengths of Advicor&reg; are not interchangeable; bioavailability varies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Prior to initiation, secondary causes for hypercholesterolemia (eg, poorly controlled diabetes mellitus, hypothyroidism) should be excluded.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F201062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Niacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Lovastatin. Lovastatin may increase the serum concentration of Diltiazem. Management: Initiate lovastatin at a maximum adult dose of 10 mg/day, and do not exceed 20 mg/day, in patients receiving diltiazem. Monitor closely for signs of HMG-CoA reductase inhibitor toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Lovastatin. Management: Limit lovastatin to a maximum of 20 mg/day (in adults).  Increase monitoring for signs of lovastatin toxicity (e.g., myopathy, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Lovastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Lovastatin. Gemfibrozil may increase the serum concentration of Lovastatin. More specifically, gemfibrozil may increase the serum concentrations of lovastatin acid (active form of parent drug).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Niacin may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.  Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Lovastatin. Management: Consider reducing lovastatin doses during concomitant treatment with lomitapide, and monitor for signs and symptoms of muscle toxicity.  Specific dosing recommendations are not presently available.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Lovastatin. Management: Avoid lovastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May enhance the myopathic (rhabdomyolysis) effect of Lovastatin. Ranolazine may increase the serum concentration of Lovastatin. Ranolazine may also enhance the distribution of lovastatin to specific cells/tissues/organs where P-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Lovastatin. Management: Avoid using doses of lovastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Lovastatin. Management: Initiate lovastatin at a maximum adult dose of 10 mg/day, and do not exceed 20 mg/day, in patients receiving verapamil. Monitor closely for signs of HMG-CoA reductase inhibitor toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F201047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Consumption of large amounts of ethanol may increase the risk of liver damage with HMG-CoA reductase inhibitors. Concurrent ingestion of ethanol may increase the risk of flushing associated with niacin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Lovastatin absorption may be decreased with food, however, the combination product is recommended to be taken with a low-fat snack at bedtime. Lovastatin serum concentrations may be increased if taken with grapefruit juice; avoid concurrent use. Concurrent ingestion of hot liquids may increase the risk of flushing associated with niacin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease lovastatin levels. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F201057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F201043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Niacin is excreted in breast milk. The excretion of lovastatin is unknown, although similar agents are known to be excreted in breast milk. Use during breast-feeding is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F201044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continue standard cholesterol-lowering diet during therapy. Should be taken with a low-fat snack.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F201041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Advicor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-20 mg (90): $501.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750-20 mg (90): $537.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000-20 mg (90): $576.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000-40 mg (90): $667.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F201032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose (in patients with diabetes), CBC, prothrombin time (surgical patients), and serum phosphorus (if predisposed to hypophosphatemia). Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Analyze lipid panel at intervals of 4 weeks or more.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Advicor (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lovastatin acts by competitively inhibiting 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis. Niacin is a component of two coenzymes which is necessary for tissue respiration, lipid metabolism, and glycogenolysis; inhibits the synthesis of very low density lipoproteins.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablet strengths (ie, two tablets of 500 mg/20 mg and one tablet of 1000 mg/40 mg) are not interchangeable; bioavailability varies.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, \"2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-e118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fonarow GC, French WJ, Parsons LS, et al, &ldquo;Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2001, 103(1):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/11136683/pubmed\" id=\"11136683\" target=\"_blank\">",
"        11136683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahley RW and Bersot TP, &ldquo;Drug Therapy for Hypercholesterolemia and Dyslipidemia,&rdquo;",
"      <i>",
"       Goodman and Gilman's The Pharmacological Basis of Therapeutics",
"      </i>",
"      , 10th ed, Hardman JE and Limbird LE, eds, New York, NY: McGraw-Hill, 2001, 993-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9326):7-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/12114036/pubmed\" id=\"12114036\" target=\"_blank\">",
"        12114036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), &ldquo;Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 106(25):3143-421. Available at file://circ.ahajournals.org/cgi/content/full/106/25/3143",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/12485966/pubmed\" id=\"12485966\" target=\"_blank\">",
"        12485966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2002, 33(9):2337-41. Available at file://stroke.ahajournals.org/cgi/content/short/33/9/2337",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/12215610/pubmed\" id=\"12215610\" target=\"_blank\">",
"        12215610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearson TA, Mensah GA, Alexander RW, et al, &ldquo;Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(3):499-511.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/12551878/pubmed\" id=\"12551878\" target=\"_blank\">",
"        12551878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(20):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/1/44055/abstract-text/7566020/pubmed\" id=\"7566020\" target=\"_blank\">",
"        7566020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10145 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44055=[""].join("\n");
var outline_f43_1_44055=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201051\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935232\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201067\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201054\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201055\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5354644\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5354645\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201034\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201021\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201036\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201035\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201073\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201065\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201039\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201025\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201062\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201028\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201047\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201031\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201042\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201057\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201043\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201044\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201041\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201032\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301438\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201024\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201038\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10145\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10145|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/16/10501?source=related_link\">",
"      Lovastatin and niacin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_1_44056="Acquired melanocytic nevi (moles)";
var content_f43_1_44056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired melanocytic nevi (moles)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44056/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44056/contributors\">",
"     Julie V Schaffer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44056/contributors\">",
"     Jean L Bolognia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44056/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44056/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44056/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44056/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44056/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44056/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/1/44056/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired melanocytic nevi will be discussed here. Congenital melanocytic nevi and other benign pigmented lesions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7447?source=see_link\">",
"     \"Congenital melanocytic nevi and speckled lentiginous nevi\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/17/43287?source=see_link\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanocytic nevi are benign proliferations of a type of melanocyte known as a \"nevus cell.\" The two major differences between ordinary melanocytes that reside in the basal layer of the epidermis and nevus cells are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nevus cells cluster as nests within the lower epidermis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dermis, whereas epidermal melanocytes are evenly dispersed as single units.",
"     </li>",
"     <li>",
"      Nevus cells do not have dendritic processes (with the exception of those within blue nevi).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both melanocytes and nevus cells are capable of producing the pigment melanin. Melanocytic nevi may be congenital or acquired. Acquired nevi can be classified as common (banal) or atypical, and there are several additional variants, including halo nevi, blue nevi, and Spitz nevi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The names applied to acquired nevi reflect the location of the nests of melanocytes (",
"    <a class=\"graphic graphic_figure graphicRef65457 \" href=\"mobipreview.htm?0/38/609\">",
"     figure 1",
"    </a>",
"    ). In junctional nevi, the nests of melanocytes are at the dermal-epidermal junction. In compound nevi, the nests of melanocytes are at the dermal-epidermal junction and in the dermis. In intradermal nevi, the nests of melanocytes are in the dermis. With progressive migration of melanocytes from the dermal-epidermal junction into the dermis, nevi become more elevated and less pigmented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors related to the development of nevi (with the exception of blue and perhaps Spitz nevi) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heredity (having parents with a large number of moles).",
"     </li>",
"     <li>",
"      Degree of sun exposure during childhood, especially when intense and intermittent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/1-5\">",
"       1-5",
"      </a>",
"      ]. Although the results of studies evaluating the effects of sunscreen use on the development of nevi are inconsistent, in one randomized controlled study, school-aged children who were supplied with and instructed to use a broad-spectrum sunscreen developed significantly fewer new nevi over a three-year period than controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phenotypic characteristics such as skin type, with higher nevus counts seen in individuals with lightly pigmented skin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/2,8-10\">",
"       2,8-10",
"      </a>",
"      ]. The mean number of nevi in white adolescents is approximately 15 to 25, compared to five or fewer in adolescents of African, Asian, or Native American heritage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]. However, individuals with the fairest skin, especially when accompanied by red hair, also tend to have fewer nevi than children with dark hair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a nevus is based upon the clinical appearance, as described below.",
"   </p>",
"   <p>",
"    Melanocytic nevi with atypical features must be differentiated from melanoma. Clinical characteristics suggestive of melanoma include diameter &gt;6 mm, irregular borders, asymmetry, variable pigmentation, and change in appearance of a longstanding pigmented lesion. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Atypical nevi'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H29\">",
"     'Biopsy considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMMON ACQUIRED MELANOCYTIC NEVI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2160246000\">",
"    <span class=\"h3\">",
"     General features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common (banal) nevi have a wide variety of clinical appearances. However, they tend to be &le;6 mm in diameter and symmetric with a homogeneous surface, even pigmentation, round or oval shape, regular outline, and sharply demarcated border (",
"    <a class=\"graphic graphic_picture graphicRef73384 \" href=\"mobipreview.htm?8/54/9062\">",
"     picture 1",
"    </a>",
"    ). Close inspection sometimes reveals pigmentary stippling or perifollicular hypopigmentation. Nevi are often concentrated in sun-exposed areas of the trunk or, particularly in girls, on the lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/13\">",
"     13",
"    </a>",
"    ]. Less commonly, they occur in acral sites such as the palms, soles, and nail matrix. As many as one-third of children and adolescents have acquired nevi on the scalp, and nevi in this location may be a marker for the development of a greater total number of nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2160246105\">",
"    <span class=\"h3\">",
"     Nevi on palms/soles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nevi on the palms and soles (acral melanocytic nevi) occur in individuals of all ethnic backgrounds, but are more common in those with dark skin pigmentation or numerous melanocytic nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Nevi located on the palms and soles are usually of the junctional or compound type, and are typically brown to dark brown in color. They often have linear streaks of darker pigmentation that reflect the prominent skin markings in these sites. Referral to a dermatologist is generally warranted when acquired acral nevi have marked asymmetry, mottled pigmentation, or a large size (&ge;6 mm). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathologic characteristics of melanoma\", section on 'Acral lentiginous melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2160246112\">",
"    <span class=\"h3\">",
"     Nevi originating from the nail matrix",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acral nevi or lentigines that involve the nail matrix can present as longitudinal melanonychia, a tan, brown, or black streak caused by increased melanin deposition in the nail plate (",
"    <a class=\"graphic graphic_picture graphicRef54197 \" href=\"mobipreview.htm?3/29/3540\">",
"     picture 2",
"    </a>",
"    ). In darkly pigmented individuals, longitudinal melanonychia is commonly seen on multiple nails due to increased melanin production by normal nail matrix melanocytes (",
"    <a class=\"graphic graphic_picture graphicRef64603 \" href=\"mobipreview.htm?27/6/27745\">",
"     picture 3",
"    </a>",
"    ). Streaks that develop in childhood are usually benign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/19\">",
"     19",
"    </a>",
"    ]. However, single bands that are",
"    <span class=\"nowrap\">",
"     dark/irregular",
"    </span>",
"    in color or wide (&ge;4 mm), become darker or wider with time, are associated with nail dystrophy, or have extension of pigmentation beyond the nail fold may warrant biopsy of the nail matrix to exclude melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Biopsy considerations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathologic characteristics of melanoma\", section on 'Acral lentiginous melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2160245993\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common acquired melanocytic nevi begin to appear after the first six months of life, increase in number during childhood and adolescence, reach a peak count in the third decade, and then slowly regress with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/8,21\">",
"     8,21",
"    </a>",
"    ]. Substantial nevus turnover also occurs during the first two decades of life. For example, over a three- to four-year period in early adolescence, the net number of nevi increases by a mean of 40 to 60 percent and approximately 15 percent of nevi disappear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical and histologic evolution of individual lesions from junctional to compound to dermal nevi (",
"    <a class=\"graphic graphic_figure graphicRef65457 \" href=\"mobipreview.htm?0/38/609\">",
"     figure 1",
"    </a>",
"    ) can correspond to this cycle.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Junctional nevi &mdash; Junctional nevi are macular or minimally raised, have preserved skin markings, and range from brown to black in color, sometimes with darker pigmentation in the center than at the edge (",
"      <a class=\"graphic graphic_picture graphicRef57022 \" href=\"mobipreview.htm?18/55/19313\">",
"       picture 4",
"      </a>",
"      ). They can be similar in appearance to simple lentigines. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/17/43287?source=see_link&amp;anchor=H3#H3\">",
"       \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Simple lentigo'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compound nevi &mdash; Compound nevi are classically pigmented papules, but in some lesions the degree of elevation is subtle. Their surface can be smooth and dome-shaped or papillomatous, and they vary in color from tan to dark brown (",
"      <a class=\"graphic graphic_picture graphicRef81931 \" href=\"mobipreview.htm?41/52/42817\">",
"       picture 5",
"      </a>",
"      ). The more symmetric and uniform in color a compound nevus is, especially when tan to medium brown in color, the less one needs to worry about the lesion",
"     </li>",
"     <li>",
"      Intradermal nevi &mdash; Nevus cells residing in the dermis often lose their capacity to produce melanin. As a result, intradermal nevi are usually skin-colored to tan papules that are dome-shaped, papillomatous, or pedunculated with a soft, rubbery texture (",
"      <a class=\"graphic graphic_picture graphicRef76961 \" href=\"mobipreview.htm?5/26/5540\">",
"       picture 6",
"      </a>",
"      ). Occasionally, they have speckles of brown pigmentation, terminal hairs, or pseudo-horn cysts (ie, accumulations of keratin within invaginations of hyperplastic epidermis). Pseudo-horn cysts occur more frequently in seborrheic keratoses, which typically develop in adults, than in intradermal nevi. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=see_link&amp;anchor=H1101421989#H1101421989\">",
"       \"Overview of benign lesions of the skin\", section on 'Seborrheic keratosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most acquired nevi remain benign throughout the lifetime of a person and require no treatment other than longitudinal observation. However, having a large number of acquired nevi increases the risk of melanoma, and patients with multiple acquired nevi should be followed with periodic total body skin examinations and counseled regarding sun protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H12#H12\">",
"     \"Risk factors for the development of melanoma\", section on 'Typical nevi'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=see_link\">",
"     \"Primary prevention of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=see_link&amp;anchor=H6082563#H6082563\">",
"     \"Skin examination and clinical features of melanoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because more than half of cutaneous melanomas arise de novo (ie, not in association with a nevus), there is no benefit to \"prophylactic\" removal of nevi. Nevertheless, when melanocytic nevi are removed, no matter what the reason, the specimens should always be sent for histologic examination. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Biopsy considerations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link\">",
"     \"Pathologic characteristics of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ATYPICAL NEVI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical nevi are benign acquired melanocytic nevi that share, usually to a lesser degree, some of the clinical features of melanoma (ie, asymmetry, border irregularities, color variability, and diameter &gt;6 mm) (",
"    <a class=\"graphic graphic_picture graphicRef68734 \" href=\"mobipreview.htm?22/39/23153\">",
"     picture 7",
"    </a>",
"    ). Considerable controversy has surrounded terms such as dysplastic nevus, and the 1992 NIH Consensus Conference recommended the use of the more clinically descriptive term \"atypical nevus\". They also recommended that the lesions be described histologically as \"nevi with architectural disorder,\" with specification of the degree of melanocytic atypia present (ie, none, mild, moderate, or severe) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most studies, the prevalence of clinically atypical nevi in white populations is 2 to 10 percent. However, the prevalence of at least one nevus with architectural disorder confirmed histologically can be as high as 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tendency to develop atypical nevi has a genetic basis, and the diagnosis of \"atypical mole syndrome\" has been applied to a spectrum of phenotypic expressions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/26\">",
"     26",
"    </a>",
"    ], ranging from individuals with multiple atypical nevi and no personal or family history of melanoma to the familial atypical multiple mole and melanoma syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H19#H19\">",
"     \"Risk factors for the development of melanoma\", section on 'FAMMM syndrome and atypical mole syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical nevi often do not appear until puberty and are believed to develop throughout life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/26\">",
"     26",
"    </a>",
"    ]. Nevi arising on the scalp during childhood may be an early clue to the diagnosis of atypical mole syndrome in patients with a positive family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The density of atypical nevi is generally greater on areas of the body that receive intermittent sun exposure (eg, the trunk and lower extremities) than sites that are not exposed to sun (eg, breast and buttocks). Individuals with numerous nevi usually have some nevi that are atypical (",
"    <a class=\"graphic graphic_picture graphicRef78891 \" href=\"mobipreview.htm?29/62/30693\">",
"     picture 8",
"    </a>",
"    ), but occasionally all the nevi are uniform in color and outline. Many patients with multiple nevi exhibit a predominant morphologic type of nevus, or a \"signature nevus\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/29\">",
"     29",
"    </a>",
"    ]. The &ldquo;eclipse&rdquo; nevus is a type of compound nevus that often develops on the scalp of children and is characterized by a tan center and brown, oftentimes stellate rim (",
"    <a class=\"graphic graphic_picture graphicRef73770 graphicRef53622 \" href=\"mobipreview.htm?13/5/13402\">",
"     picture 9A-B",
"    </a>",
"    ). Despite their two colors and irregular borders, eclipse nevi have benign behavior and (in the absence of a superimposed concerning feature) do not need to be biopsied or excised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several clinical features characterize a nevus as atypical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The color is often variegated, with areas of pink, tan, brown, and dark brown.",
"     </li>",
"     <li>",
"      Lesions frequently have macular and papular components, eg, flat lesions with a slightly elevated center (\"fried egg\" appearance) or those with a \"pebbly\" surface.",
"     </li>",
"     <li>",
"      The borders are characteristically ill defined or \"fuzzy\", fading imperceptibly into surrounding skin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/32\">",
"       32",
"      </a>",
"      ]. They may be notched or more irregular (",
"      <a class=\"graphic graphic_picture graphicRef70320 \" href=\"mobipreview.htm?13/49/14099\">",
"       picture 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Atypical nevi may be somewhat larger than common nevi (usually 4 to 12 mm in diameter, (",
"      <a class=\"graphic graphic_picture graphicRef80725 \" href=\"mobipreview.htm?7/52/8006\">",
"       picture 11",
"      </a>",
"      )) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/31,33\">",
"       31,33",
"      </a>",
"      ], but vary considerably in size. Size is the least reliable criterion for atypical nevi with moderate or severe cellular atypia histologically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although atypical nevi share some of the clinical characteristics of melanoma, they are generally stable and asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Progression to melanoma most often manifests as a new focal area of deep pigmentation or firm elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Risk of melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple atypical nevi are a phenotypic marker of increased risk of melanoma. The risk of melanoma in patients with atypical nevi depends upon their total nevus burden, family history, personal history, and sun exposure history. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H18#H18\">",
"     \"Risk factors for the development of melanoma\", section on 'Atypical nevi'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6569?source=see_link\">",
"     \"Inherited susceptibility to melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance by total body skin examination beginning around puberty is recommended for patients with multiple atypical nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients suspected of having the atypical nevus syndrome should be referred to a dermatologist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H18#H18\">",
"     \"Risk factors for the development of melanoma\", section on 'Atypical nevi'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6569?source=see_link\">",
"     \"Inherited susceptibility to melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Biopsy indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest removal of nevi simply to confirm the presence of architectural disorder histologically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/38\">",
"     38",
"    </a>",
"    ]. However, a biopsy is indicated when the differential diagnosis for a lesion includes early melanoma (eg, marked asymmetry, areas of pink or red color).",
"   </p>",
"   <p>",
"    A nevus that has different characteristics from other nevi in a given patient (the \"ugly duckling\") should be regarded with particular suspicion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/39\">",
"     39",
"    </a>",
"    ]. As an example, the most worrisome lesion in a patient with 10 large nevi on the back could be a 4 mm black nevus with irregular borders on the thigh. Baseline close-up photographs of larger nevi on the trunk can prove particularly helpful in avoiding unnecessary surgery.",
"   </p>",
"   <p>",
"    When a biopsy is performed, partial sampling should be avoided unless the patient has a large pigmented lesion in a cosmetically sensitive area. The entire pigmented lesion must be included for complete architectural evaluation. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Biopsy considerations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Initial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple atypical nevi should be educated regarding the signs of melanoma and counseled regarding sun protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/24,40\">",
"     24,40",
"    </a>",
"    ]. The Skin Cancer Foundation Web site provides information about and pictures of typical and atypical moles (",
"    <a class=\"external\" href=\"file://www.skincancer.org/\">",
"     www.skincancer.org",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=see_link\">",
"     \"Primary prevention of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HALO NEVI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The halo nevus (Sutton's nevus) is a melanocytic nevus surrounded by a round or oval, usually symmetric, halo of depigmentation. This pigment loss often heralds the spontaneous regression of the central nevus via a process thought to involve a T-cell mediated immune response to nevus antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/41\">",
"     41",
"    </a>",
"    ]. The halo phenomenon typically involves common acquired melanocytic nevi, but may also be seen with congenital nevi, blue nevi, Spitz nevi, and melanoma.",
"   </p>",
"   <p>",
"    Halo nevi occur in up to 5 percent of white children 6 to 15 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], and have a higher incidence in patients with an increased number of nevi and a personal or family history of vitiligo. The back is the most common location for halo nevi, and multiple lesions are present in approximately half of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/42,44\">",
"     42,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any one of four clinical stages can be seen, with the duration of the process ranging from weeks to several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &mdash; Pigmented nevus surrounded by a halo of depigmentation (",
"      <a class=\"graphic graphic_picture graphicRef65988 \" href=\"mobipreview.htm?19/14/19682\">",
"       picture 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stage II &mdash; Pink nevus surrounded by a halo of depigmentation (",
"      <a class=\"graphic graphic_picture graphicRef57744 \" href=\"mobipreview.htm?33/28/34240\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stage III &mdash; Circular area of depigmentation, with disappearance of the nevus",
"     </li>",
"     <li>",
"      Stage IV &mdash; Normal-appearing skin after repigmentation of the halo",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, the central nevus may darken rather than lighten, developing hyperpigmentation in a reticular pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to assess the clinical features of the central nevus. A biopsy is not indicated if the central nevus is banal in appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/47\">",
"     47",
"    </a>",
"    ]. Because children with halo nevi often have an increased number of nevi in general, a total body skin examination should be performed. Referral to a dermatologist may be warranted. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Common acquired melanocytic nevi'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If there are atypical or worrisome features, then a biopsy of the central nevus can be performed. However, there is no reason to excise the halo. Although development of multiple halo nevi is not unusual in adolescents and young adults, it is rare in middle-aged and older adults; in the latter population, the possibility of the halo nevi representing an immune reaction to a cutaneous or ocular melanoma must be considered. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Atypical nevi'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H29\">",
"     'Biopsy considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     BLUE NEVI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blue nevi are benign proliferations of dendritic dermal melanocytes that actively produce melanin. The blue color (ceruloderma) is due to the preferential scattering of shorter wavelengths of light by the dermal melanin, a phenomenon known as the Tyndall effect. The sites of predilection of blue nevi (eg, the head and neck, dorsal aspect of the distal extremities, and sacral area) represent locations where active dermal melanocytes are normally still present at the time of birth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/17/43287?source=see_link&amp;anchor=H14#H14\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Dermal melanocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several variants of blue nevi have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The common blue nevus typically presents as a solitary, uniformly blue to blue-black, dome-shaped papule with preserved skin markings that measures &lt;1 cm in diameter. These nevi often arise in adolescence, and are most often found on the dorsal surface of the hands and feet.",
"     </li>",
"     <li>",
"      The cellular blue nevus tends to be a larger and more elevated nodule or plaque, measuring at least 1 cm in diameter, with a smooth or slightly irregular surface. Cellular blue nevi may be congenital or acquired, and are most often located on the scalp, buttocks, sacrum, or face.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most blue nevi have a somatic activating mutation in the",
"    <em>",
"     GNAQ",
"    </em>",
"    gene that encodes the Q-class of G-protein &alpha;-subunits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/49\">",
"     49",
"    </a>",
"    ]. Occasionally, mutations in",
"    <em>",
"     KRAS",
"    </em>",
"    are also seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If multiple blue nevi are present, syndromes such as the Carney complex should be considered (",
"    <a class=\"graphic graphic_table graphicRef66428 \" href=\"mobipreview.htm?27/19/27966\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=see_link&amp;anchor=H5#H5\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\", section on 'Carney complex (CNC)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common entity in the clinical differential diagnosis of a blue nevus is a traumatic tattoo (eg, from implantation of carbon from a pencil). This is easily distinguished by history. In addition, blue nevi can resemble nodular melanoma or dermal metastases of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/52\">",
"     52",
"    </a>",
"    ]. However, there is typically no history of recent change or growth in blue nevi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although small, stable blue nevi require no intervention, lesions appearing suddenly or undergoing clinical change should be biopsied. Because there have been reports of melanoma arising within cellular blue nevi, particularly those located on the scalp, patients with congenital cellular blue nevi that are difficult to follow due to color or location should be referred to a dermatologist for discussion of possible surgical excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Biopsy considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SPITZ NEVI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spitz nevi (spindle- and epithelioid-cell nevi) are benign, usually acquired proliferations of melanocytes with histopathologic features that sometimes overlap with those of melanoma. Most Spitz nevi appear during childhood, and they are commonly located on the face and lower extremities. Lesions tend to present with a rapid initial growth phase that can be alarming to patients and their parents.",
"   </p>",
"   <p>",
"    Spitz nevi classically appear as uniformly pink, tan, red or red-brown, dome-shaped, hairless papules or nodules (",
"    <a class=\"graphic graphic_picture graphicRef56097 \" href=\"mobipreview.htm?12/34/12834\">",
"     picture 14",
"    </a>",
"    ). They are usually symmetric, well-circumscribed, and &lt;1 cm in diameter. The surface may be smooth or, in some cases, verrucous. Darkly pigmented lesions are occasionally seen. The pigmented spindle cell nevus of Reed, a variant of the Spitz nevus, typically presents in an adolescent girl or young woman as a dark brown to black thin papule on the thigh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/54\">",
"     54",
"    </a>",
"    ]. Pigmented Spitz nevi can be identified with dermatoscopic examination (using a handheld magnifying device and special lighting to better visualize skin lesions) by their characteristic &lsquo;starburst&rsquo; pattern, and studies using this technique have documented a tendency for spontaneous involution of Spitz nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subset of Spitz nevi have increased copy numbers of chromosome 11p, a pattern of aberration not observed in melanoma; these nevi frequently harbor mutations in the HRAS gene located on chromosome 11p [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a Spitz nevus includes common intradermal nevus, juvenile xanthogranuloma, molluscum contagiosum, pyogenic granuloma (",
"    <a class=\"graphic graphic_picture graphicRef60189 \" href=\"mobipreview.htm?36/49/37651\">",
"     picture 15",
"    </a>",
"    ), verruca vulgaris, and dermatofibroma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=see_link\">",
"     \"Overview of benign lesions of the skin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any presumed Spitz nevus with atypical clinical features (eg, diameter &gt;1 cm, asymmetry, or ulceration) should be biopsied, and lesions with unusual histologic features should be excised in their entirety. When a biopsy has been done to confirm the diagnosis of a classic Spitz nevus but no further reexcision is performed, a dermatologist can provide longitudinal follow-up. Occasionally, unequivocal histologic distinction of Spitz nevus from cutaneous melanoma is not possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     BIOPSY CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Possible indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest removal of nevi simply to confirm the presence of architectural disorder histologically. Potential indications for biopsy of melanocytic nevi include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nevi on the palms or soles with mottled pigmentation or that are &gt;5 mm in diameter. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathologic characteristics of melanoma\", section on 'Acral lentiginous melanoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nevi originating in the nail matrix that present as single bands of dark color or are &ge;4 mm wide. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathologic characteristics of melanoma\", section on 'Acral lentiginous melanoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nevi with marked asymmetry (based on irregular outline",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      color variation), areas of regression (oftentimes gray-blue or white in color), development of areas of pink or red color, or a history of rapid change or symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=see_link&amp;anchor=H6082563#H6082563\">",
"       \"Skin examination and clinical features of melanoma\", section on 'Introduction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=see_link&amp;anchor=H81531898#H81531898\">",
"       \"Skin examination and clinical features of melanoma\", section on 'Management of patients with suspicious skin lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An atypical nevus that has different clinical characteristics as compared to the remainder of the nevi in a given patient (ie, the \"ugly duckling\"). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Biopsy indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A halo nevus in which the central nevus has atypical or worrisome features. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Halo nevi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A cellular blue nevus that has developed a superimposed change (eg, a papulonodule). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Blue nevi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A Spitz nevus with atypical clinical features (eg, diameter &gt;1 cm, asymmetry, or ulceration). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Spitz nevi'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An occasional misconception is that the presence of hairs within a melanocytic nevus is a sign of benignity. However, melanoma can develop within congenital nevi (which often contain terminal hairs) and \"de novo\" cutaneous melanomas can have the same density of terminal hairs as the surrounding skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44056/abstract/59\">",
"     59",
"    </a>",
"    ]. Pigmented lesions with features suspicious for melanoma should be biopsied regardless of the presence or absence of hair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred biopsy technique for lesions suspicious for melanoma is one that allows histologic examination of the entire lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to give the dermatopathologist information (eg, foci of eccentric hyperpigmentation) about any pigmented lesion that has been biopsied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common (banal) acquired melanocytic nevi tend to be &le;6 mm in diameter and symmetric with a homogeneous surface, even pigmentation, round or oval shape, regular outline, and sharply demarcated border (",
"      <a class=\"graphic graphic_picture graphicRef73384 \" href=\"mobipreview.htm?8/54/9062\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Common acquired melanocytic nevi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atypical nevi are benign acquired melanocytic nevi that share some of the clinical features of melanoma (ie, asymmetry, border irregularities (",
"      <a class=\"graphic graphic_picture graphicRef68734 \" href=\"mobipreview.htm?22/39/23153\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef70320 \" href=\"mobipreview.htm?13/49/14099\">",
"       picture 10",
"      </a>",
"      )), color variability, and diameter &gt;6 mm (",
"      <a class=\"graphic graphic_picture graphicRef80725 \" href=\"mobipreview.htm?7/52/8006\">",
"       picture 11",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Atypical nevi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple atypical nevi are a phenotypic marker of increased risk of melanoma. The risk of melanoma depends also upon the total number of nevi, family",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      personal history of melanoma, and sun exposure history. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H18#H18\">",
"       \"Risk factors for the development of melanoma\", section on 'Atypical nevi'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6569?source=see_link\">",
"       \"Inherited susceptibility to melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The halo nevus is a melanocytic nevus surrounded by a round or oval halo of depigmentation (",
"      <a class=\"graphic graphic_picture graphicRef65988 \" href=\"mobipreview.htm?19/14/19682\">",
"       picture 12",
"      </a>",
"      ). The halo phenomenon usually involves common acquired melanocytic nevi, but may also be seen with congenital nevi, blue nevi, Spitz nevi, and melanoma. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Halo nevi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blue nevi are benign proliferations of dendritic dermal melanocytes that actively produce melanin; they typically occur on the head and neck, dorsal aspect of the distal extremities, and sacral area. Multiple blue nevi may indicate a syndrome such as the Carney complex (",
"      <a class=\"graphic graphic_table graphicRef66428 \" href=\"mobipreview.htm?27/19/27966\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Blue nevi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spitz nevi are uniformly pink, tan, red or red-brown, dome-shaped, hairless papules or nodules; they are usually symmetric, well-circumscribed, and &lt;1 cm in diameter (",
"      <a class=\"graphic graphic_picture graphicRef56097 \" href=\"mobipreview.htm?12/34/12834\">",
"       picture 14",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Spitz nevi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest removal of nevi simply to confirm the presence of architectural disorder histologically (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, a biopsy is indicated when the differential diagnosis for a lesion includes early melanoma. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Biopsy considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/1\">",
"      Dulon M, Weichenthal M, Blettner M, et al. Sun exposure and number of nevi in 5- to 6-year-old European children. J Clin Epidemiol 2002; 55:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/2\">",
"      Wiecker TS, Luther H, Buettner P, et al. Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood: a risk factor study in 1,812 kindergarten children. Cancer 2003; 97:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/3\">",
"      Harrison SL, MacLennan R, Buettner PG. Sun exposure and the incidence of melanocytic nevi in young Australian children. Cancer Epidemiol Biomarkers Prev 2008; 17:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/4\">",
"      Oliveria SA, Satagopan JM, Geller AC, et al. Study of Nevi in Children (SONIC): baseline findings and predictors of nevus count. Am J Epidemiol 2009; 169:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/5\">",
"      Aalborg J, Morelli JG, Mokrohisky ST, et al. Tanning and increased nevus development in very-light-skinned children without red hair. Arch Dermatol 2009; 145:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/6\">",
"      Gallagher RP, Rivers JK, Lee TK, et al. Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial. JAMA 2000; 283:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/7\">",
"      Autier P, Dor&eacute; JF, Cattaruzza MS, et al. Sunscreen use, wearing clothes, and number of nevi in 6- to 7-year-old European children. European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Natl Cancer Inst 1998; 90:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/8\">",
"      Luther H, Altmeyer P, Garbe C, et al. Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. Arch Dermatol 1996; 132:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/9\">",
"      Garbe C, B&uuml;ttner P, Weiss J, et al. Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994; 102:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/10\">",
"      Schaffer JV. Pigmented lesions in children: when to worry. Curr Opin Pediatr 2007; 19:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/11\">",
"      Dellavalle RP, Johnson KR, Hester EJ, et al. Children with red hair have more freckles but fewer melanocytic nevi: results from a cohort study of 280 three-year-olds. Arch Dermatol 2005; 141:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/12\">",
"      Aalborg J, Morelli JG, Byers TE, et al. Effect of hair color and sun sensitivity on nevus counts in white children in Colorado. J Am Acad Dermatol 2010; 63:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/13\">",
"      Harrison SL, Buettner PG, MacLennan R. Body-site distribution of melanocytic nevi in young Australian children. Arch Dermatol 1999; 135:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/14\">",
"      De Giorgi V, Sestini S, Grazzini M, et al. Prevalence and distribution of melanocytic naevi on the scalp: a prospective study. Br J Dermatol 2010; 162:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/15\">",
"      Coleman WP 3rd, Gately LE 3rd, Krementz AB, et al. Nevi, lentigines, and melanomas in blacks. Arch Dermatol 1980; 116:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/16\">",
"      Mart&iacute;n RF, S&aacute;nchez JL, V&aacute;zquez-Botet M, Lugo A. Pigmented macules on palms and soles in Puerto Ricans. Int J Dermatol 1994; 33:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/17\">",
"      Kogushi-Nishi H, Kawasaki J, Kageshita T, et al. The prevalence of melanocytic nevi on the soles in the Japanese population. J Am Acad Dermatol 2009; 60:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/18\">",
"      Palicka GA, Rhodes AR. Acral melanocytic nevi: prevalence and distribution of gross morphologic features in white and black adults. Arch Dermatol 2010; 146:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/19\">",
"      Goettmann-Bonvallot S, Andr&eacute; J, Belaich S. Longitudinal melanonychia in children: a clinical and histopathologic study of 40 cases. J Am Acad Dermatol 1999; 41:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/20\">",
"      Buka R, Friedman KA, Phelps RG, et al. Childhood longitudinal melanonychia: case reports and review of the literature. Mt Sinai J Med 2001; 68:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/21\">",
"      Siskind V, Darlington S, Green L, Green A. Evolution of melanocytic nevi on the faces and necks of adolescents: a 4 y longitudinal study. J Invest Dermatol 2002; 118:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/22\">",
"      Scope A, Dusza SW, Marghoob AA, et al. Clinical and dermoscopic stability and volatility of melanocytic nevi in a population-based cohort of children in Framingham school system. J Invest Dermatol 2011; 131:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/23\">",
"      Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res 2003; 16:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/24\">",
"      NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA 1992; 268:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/25\">",
"      Piepkorn M, Meyer LJ, Goldgar D, et al. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol 1989; 20:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/26\">",
"      Slade J, Marghoob AA, Salopek TG, et al. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 1995; 32:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/27\">",
"      Precursors to malignant melanoma. National Institutes of Health Consensus Development Conference Statement, Oct. 24-26, 1983. J Am Acad Dermatol 1984; 10:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/28\">",
"      Tucker MA, Greene MH, Clark WH Jr, et al. Dysplastic nevi on the scalp of prepubertal children from melanoma-prone families. J Pediatr 1983; 103:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/29\">",
"      Suh KY, Bolognia JL. Signature nevi. J Am Acad Dermatol 2009; 60:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/30\">",
"      Kessides MC, Puttgen KB, Cohen BA. No biopsy needed for eclipse and cockade nevi found on the scalps of children. Arch Dermatol 2009; 145:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/31\">",
"      Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003; 349:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/32\">",
"      Seykora J, Elder D. Dysplastic nevi and other risk markers for melanoma. Semin Oncol 1996; 23:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/33\">",
"      Grob JJ, Andrac L, Romano MH, et al. Dysplastic naevus in non-familial melanoma. A clinicopathological study of 101 cases. Br J Dermatol 1988; 118:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/34\">",
"      Halpern AC, Guerry D 4th, Elder DE, et al. Natural history of dysplastic nevi. J Am Acad Dermatol 1993; 29:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/35\">",
"      Tucker MA, Fraser MC, Goldstein AM, et al. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993; 100:350S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/36\">",
"      Bolognia JL, Lin A, Shapiro PE. The significance of eccentric foci of hyperpigmentation ('small dark dots') within melanocytic nevi. Analysis of 59 cases. Arch Dermatol 1994; 130:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/37\">",
"      Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/38\">",
"      Salopek TG. The dilemma of the dysplastic nevus. Dermatol Clin 2002; 20:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/39\">",
"      Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998; 134:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/40\">",
"      Bergman W, van Voorst Vader PC, Ruiter DJ. [Dysplastic nevi and the risk of melanoma: a guideline for patient care. Nederlandse Melanoom Werkgroep van de Vereniging voor Integrale Kankercentra]. Ned Tijdschr Geneeskd 1997; 141:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/41\">",
"      Zeff RA, Freitag A, Grin CM, Grant-Kels JM. The immune response in halo nevi. J Am Acad Dermatol 1997; 37:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/42\">",
"      Kopf AW, Morrill SD, Silberberg I. Broad spectrum of leukoderma acquisitum centrifugum. Arch Dermatol 1965; 92:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/43\">",
"      Rivers JK, MacLennan R, Kelly JW, et al. The eastern Australian childhood nevus study: prevalence of atypical nevi, congenital nevus-like nevi, and other pigmented lesions. J Am Acad Dermatol 1995; 32:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/44\">",
"      Mooney MA, Barr RJ, Buxton MG. Halo nevus or halo phenomenon? A study of 142 cases. J Cutan Pathol 1995; 22:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/45\">",
"      FRANK SB, COHEN HJ. THE HALO NEVUS. Arch Dermatol 1964; 89:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/46\">",
"      Huynh PM, Lazova R, Bolognia JL. Unusual halo nevi--darkening rather than lightening of the central nevus. Dermatology 2001; 202:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/47\">",
"      Lai C, Lockhart S, Mallory SB. Typical halo nevi in childhood: is a biopsy necessary? J Pediatr 2001; 138:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/48\">",
"      Gonz&aacute;lez-C&aacute;mpora R, Galera-Davidson H, V&aacute;zquez-Ram&iacute;rez FJ, D&iacute;az-Cano S. Blue nevus: classical types and new related entities. A differential diagnostic review. Pathol Res Pract 1994; 190:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/49\">",
"      Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/50\">",
"      Emley A, Nguyen LP, Yang S, Mahalingam M. Somatic mutations in GNAQ in amelanotic/hypomelanotic blue nevi. Hum Pathol 2011; 42:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/51\">",
"      Carney JA, Gordon H, Carpenter PC, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985; 64:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/52\">",
"      Granter SR, McKee PH, Calonje E, et al. Melanoma associated with blue nevus and melanoma mimicking cellular blue nevus: a clinicopathologic study of 10 cases on the spectrum of so-called 'malignant blue nevus'. Am J Surg Pathol 2001; 25:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/53\">",
"      Aloi F, Pich A, Pippione M. Malignant cellular blue nevus: a clinicopathological study of 6 cases. Dermatology 1996; 192:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/54\">",
"      Sau P, Graham JH, Helwig EB. Pigmented spindle cell nevus: a clinicopathologic analysis of ninety-five cases. J Am Acad Dermatol 1993; 28:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/55\">",
"      Nino M, Brunetti B, Delfino S, et al. Spitz nevus: follow-up study of 8 cases of childhood starburst type and proposal for management. Dermatology 2009; 218:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/56\">",
"      Argenziano G, Agozzino M, Bonifazi E, et al. Natural evolution of Spitz nevi. Dermatology 2011; 222:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/57\">",
"      LeBoit P. Spitz nevus: a look back and a look ahead. Adv Dermatol 2000; 16:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/58\">",
"      Spatz A, Calonje E, Handfield-Jones S, Barnhill RL. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol 1999; 135:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44056/abstract/59\">",
"      Scope A, Tabanelli M, Busam KJ, et al. Dispelling the myth of the \"benign hair sign\" for melanoma. J Am Acad Dermatol 2007; 56:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4846 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44056=[""].join("\n");
var outline_f43_1_44056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMMON ACQUIRED MELANOCYTIC NEVI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2160246000\">",
"      - General features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2160246105\">",
"      - Nevi on palms/soles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2160246112\">",
"      - Nevi originating from the nail matrix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2160245993\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ATYPICAL NEVI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Risk of melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Biopsy indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HALO NEVI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      BLUE NEVI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SPITZ NEVI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      BIOPSY CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Possible indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4846\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4846|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/38/609\" title=\"figure 1\">",
"      Nomenclature nevi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4846|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/54/9062\" title=\"picture 1\">",
"      Common melanocytic nevi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/29/3540\" title=\"picture 2\">",
"      Longitudinal melanonychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/6/27745\" title=\"picture 3\">",
"      Longitudinal melanonychia - thumbs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/55/19313\" title=\"picture 4\">",
"      Junctional nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/52/42817\" title=\"picture 5\">",
"      Compound nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/26/5540\" title=\"picture 6\">",
"      Intradermal nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/39/23153\" title=\"picture 7\">",
"      Atypical nevi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/62/30693\" title=\"picture 8\">",
"      Multiple atypical nevi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/49/18199\" title=\"picture 9A\">",
"      Eclipse nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/22/12645\" title=\"picture 9B\">",
"      Eclipse nevus 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/49/14099\" title=\"picture 10\">",
"      Atypical nevi borders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/52/8006\" title=\"picture 11\">",
"      Atypical nevi size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/14/19682\" title=\"picture 12\">",
"      Halo nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/28/34240\" title=\"picture 13\">",
"      Halo nevus 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/34/12834\" title=\"picture 14\">",
"      Spitz nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/49/37651\" title=\"picture 15\">",
"      Pyogenic granuloma lip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4846|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/19/27966\" title=\"table 1\">",
"      Disorders with lentigines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/17/43287?source=related_link\">",
"      Benign pigmented skin lesions other than melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7447?source=related_link\">",
"      Congenital melanocytic nevi and speckled lentiginous nevi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=related_link\">",
"      Primary prevention of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=related_link\">",
"      Skin examination and clinical features of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_1_44057="Future therapies for food allergy";
var content_f43_1_44057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Future therapies for food allergy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44057/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44057/contributors\">",
"     Anna Nowak-W��grzyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44057/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44057/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44057/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/1/44057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food allergy encompasses a variety of immune-mediated adverse reactions to foods that occur in genetically predisposed individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. No cure for food allergy is available. Strict avoidance of the food allergen is the only therapeutic option. Strategies described in this topic are experimental. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Novel therapeutic approaches to food allergy can be classified as food allergen-specific (eg, immunotherapy with native or modified recombinant allergens, or oral desensitization) or food allergen-nonspecific (eg, anti-IgE, Traditional Chinese Medicine) and are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef80640 \" href=\"mobipreview.htm?29/13/29918\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some therapies in development appear to only temporarily desensitize or protect patients, requiring continued treatment to maintain efficacy. Other therapies appear to induce permanent tolerance to the food allergen, where the allergy will not recur upon reexposure after a period of abstinence.",
"   </p>",
"   <p>",
"    Before these new approaches are applied in clinical practice, they must be carefully evaluated for side effects, such as acute adverse reactions, toxicity, and overstimulation of Th1 immune responses that could prime for autoimmunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FOOD ALLERGEN-SPECIFIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of allergen-specific therapies is to alter the allergic response to the food allergen so that the patient becomes desensitized or, preferably, tolerant to the specific food. Possible future food allergen-specific therapies include oral, sublingual, and subcutaneous immunotherapy. Allergens used for subcutaneous immunotherapy have been modified to retain immunogenicity, but decrease allergenicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oral immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral immunotherapy (OIT) to food is generating increasing interest as a potential approach to the treatment of food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. A high rate of desensitization has been demonstrated in both randomized trials and observational studies of OIT. Fewer treated patients become tolerant, but the rate of acquisition of tolerance is higher than that seen in patients who completely avoid the allergen. Published studies reporting experience with OIT for food allergy are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef51554 \" href=\"mobipreview.htm?3/23/3442\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The rationale for using the oral route is that ingestion of a food antigen preferentially results in an active immune system response, but one that does not trigger an allergic reaction towards that antigen (ie, oral tolerance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Oral tolerance is thought to be mediated by induction of regulatory T cells with low dose antigen exposure, or lymphocyte anergy or deletion with high antigen doses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link&amp;anchor=H29#H29\">",
"     \"Pathogenesis of food allergy\", section on 'Factors influencing sensitization or tolerance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The humoral immunologic changes include a gradual increase in serum levels of specific immunoglobulin G4 (IgG4) antibodies and in saliva levels of specific-immunoglobulin A (IgA) antibodies. In addition, an initial increase in serum levels of specific immunoglobulin E (IgE) antibodies is seen in the first 12 months, followed by a subsequent decrease. Specific T regulatory cells increase and peak at about 12 months with a subsequent decrease. Basophil reactivity, skin prick test responses, and serum levels of T helper type 2 (Th2) cytokines decrease gradually, whereas interferon (IFN)-gamma, macrophage inflammatory protein (MIP)-1 alpha and monocyte chemotactic protein (MCP)-1 increase over the course of OIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/1-3,13,14\">",
"     1-3,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral immunotherapy protocols have been reported for cow's milk (CM), egg white, fish, apple, orange, celery, and peanut [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/7,8,15-25\">",
"     7,8,15-25",
"    </a>",
"    ]. Patients are generally started on a very small daily dose (eg, 4 drops per day of a solution of 10 drops of CM in 10 mL of water) and advanced to a maintenance dose (eg, 150 mL of undiluted CM) over several months. An alternative approach is to combine oral immunotherapy with administration of anti-IgE antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/26\">",
"     26",
"    </a>",
"    ]. This approach could theoretically decrease the risk of adverse reactions during initial treatment. Controlled trials are needed to evaluate this approach and to determine if there is an influence on treatment outcomes.",
"   </p>",
"   <p>",
"    Introduction of extensively-heated milk and egg in baked products may represent an alternative approach to accelerating development of oral tolerance for a large subset of children (approximately 75 percent). Humoral and cellular immunologic changes seen in children with a history of milk",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    egg allergy who passed oral food challenges to milk",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    egg in baked goods parallel the changes reported in OIT trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In one study, the group of children (n = 88) with milk allergy who underwent challenges to baked milk and incorporated baked milk into their diet if the challenge was passed were more than twice as likely to develop tolerance to unheated milk over a period of approximately three years than another group of children (n = 60) who follow the standard avoidance approach (47 versus 22 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, children who were initially tolerant to baked milk were more likely to become unheated milk-tolerant compared with baked milk-reactive children (60 percent versus 9 percent). Randomized trials are underway to determine if introduction of egg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    milk in baked goods hastens the complete resolution of the allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Milk OIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review and meta-analysis of trials evaluating the effectiveness of milk oral immunotherapy published through May 2011 found that the likelihood of developing full tolerance to cow&rsquo;s milk was 10-fold higher (95% CI 4.1-24.2) and partial tolerance 5-fold higher (95% CI 1.2-24.5) in 218 children treated with milk OIT compared with a milk elimination diet in four randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/31\">",
"     31",
"    </a>",
"    ]. Results were similar for full milk tolerance in another systematic review and meta-analysis that included 196 patients from five randomized trials published through October 2012 (RR 6.6, 95% CI 3.5-12.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/32\">",
"     32",
"    </a>",
"    ] and were consistent with results from observational studies. The risk of an adverse reaction was 34-fold higher (95% CI 4.8-244.7) in children receiving OIT compared with an elimination diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/31\">",
"     31",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Lip/mouth",
"    </span>",
"    pruritus was the most common symptom, but rates of systemic reactions and use of epinephrine were also higher with OIT than avoidance. The second review found that 1 in every 11 patients on milk OIT was treated with epinephrine. The authors of both meta-analyses felt the quality of the evidence was low and therefore the effect of OIT uncertain. In addition, the rate of permanent tolerance appears to be lower than the rate of desensitization. Thus, further randomized trials are needed. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Limitations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specific findings of concern from randomized trials and observational studies of milk OIT are highlighted below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nine subjects (36 percent) in one randomized trial were not able to tolerate OIT due to flares of atopic dermatitis or recurrent acute adverse effects (eg, urticaria, abdominal pain, emesis). In addition, some children experienced allergic reactions to the dosing, even while on a stable regimen, in the setting of exercise or infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another randomized study, two children required treatment, including epinephrine, in the emergency department during home dosing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third randomized trial, one patient who had milk removed from her diet for three to four days in the setting of viral gastroenteritis had symptoms suggestive of eosinophilic esophagitis upon reintroduction of milk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/33\">",
"       33",
"      </a>",
"      ]. Another three cases of eosinophilic esophagitis were reported from a clinic that had performed milk OIT in 110 patients over a five year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is one case report of life-threatening anaphylaxis in a patient during the dose-escalation phase of milk OIT, when dose escalation was continued despite a serious reaction that occurred earlier on the same day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Egg OIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Egg OIT, as with OIT for other foods, appears to be effective in desensitizing most patients. Permanent tolerance is induced less frequently than desensitization, but occurs at a higher rate in OIT-treated patients than in patients who follow a strict elimination diet. These findings were demonstrated in a randomized trial of 55 children aged 5 to 11 years (median age 7 years) who received either egg-white powder OIT with a maintenance dose goal of 2 grams (n = 40) or placebo (n = 15) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/36\">",
"     36",
"    </a>",
"    ]. Egg was otherwise avoided by all subjects. Intention-to-treat analysis was used to assess all clinical outcomes. Five children in the OIT group and two in the placebo group withdrew from the study prior to the first oral food challenge (OFC). All remaining children underwent an OFC with 5 grams of egg-white powder at 10 months. Twenty-two children (55 percent) in the OIT group passed the challenge compared with none in the placebo group.",
"   </p>",
"   <p>",
"    The study was unblinded after the OFC at 10 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/36\">",
"     36",
"    </a>",
"    ]. The OIT group continued on maintenance dosing and the placebo group continued complete egg avoidance until the second challenge with 10 grams of egg-white powder at 22 months (one OIT patient withdrew prior to the second OFC). Thirty children (75 percent) in the OIT group passed the 22 month OFC, and the one eligible child in the placebo group (egg white-specific IgE",
"    <span class=\"nowrap\">",
"     &lt;2kU/L)",
"    </span>",
"    failed the challenge. The other children in the placebo group were considered still allergic to egg (egg white-specific IgE &ge;2",
"    <span class=\"nowrap\">",
"     kU/L).",
"    </span>",
"   </p>",
"   <p>",
"    OIT was discontinued for two months in the children who passed the 22 month OFC and egg was completely avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/36\">",
"     36",
"    </a>",
"    ]. Eleven of 29 patients (27.5 percent of the original 40 on OIT) who underwent the OFC challenge at 24 months passed, demonstrating sustained unresponsiveness. Egg was introduced into the diet ad libitum in these children. No adverse events were noted at 30 and 36 months of follow-up. Laboratory markers associated with tolerance at the 24 month OFC included increased egg-specific IgG4 and small skin prick test wheal diameter, but not egg-specific IgE or basophil activation.",
"   </p>",
"   <p>",
"    Similar findings were reported in several observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/21,37-39\">",
"     21,37-39",
"    </a>",
"    ], although egg OIT was not found to expedite the natural acquisition of tolerance in one randomized but unblinded study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No severe adverse events were reported in the randomized trial discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/36\">",
"     36",
"    </a>",
"    ]. Mild allergic symptoms, mainly oropharyngeal, were common, particularly in the first 10 months of dosing. In another study, one patient was diagnosed with eosinophilic esophagitis after developing acute symptoms of dyspepsia and solid food dysphagia five months after completing egg OIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Peanut OIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peanut allergy is rarely outgrown, unlike cow's milk and hen's egg allergies. Uncontrolled studies of oral immunotherapy for peanut allergy have demonstrated successful desensitization to peanut in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/25,41-43\">",
"     25,41-43",
"    </a>",
"    ]. In one randomized trial, 28 children aged 1 to 16 years received OIT with peanut flour (n = 19) or placebo (n = 9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Three subjects in the treatment group dropped out due to allergic side effects. DBPCFCs were performed approximately one year after the onset of treatment, four weeks after reaching maintenance therapy. The 16 remaining subjects on peanut OIT all tolerated the maximum total dose of 5000 mg of peanut protein, whereas the median dose reached by the placebo subjects was 280 mg. Peanut-specific IgG4 increased significantly in the treatment group compared with placebo, and skin prick test size, IL-5, and IL-13 decreased. This study is ongoing and there are plans to evaluate whether treated patients have developed tolerance to peanut.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of limitations and unanswered questions with regard to oral immunotherapy. It is difficult to discern the actual effects of oral desensitization versus the natural resolution of food allergies that are typically outgrown, such as cow's milk and egg allergies. The full maintenance dose cannot be achieved in some patients due to allergic symptoms. These patients may nevertheless benefit from an increase in the threshold dose of food required to cause an allergic reaction, which would potentially provide some protection from accidental exposures. This enhanced safety could also improve quality of life. These patients need to continue to ingest the food on a daily basis to maintain the desensitized state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that nonreactivity to food is achieved and maintained for periods up to six months in a large subset of patients, as long as the food is ingested regularly (ie, oral desensitization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/18,46\">",
"     18,46",
"    </a>",
"    ]. However, allergic symptoms recur in some patients who reach the maintenance dose if the food is not ingested on a regular basis, highlighting a concern of whether oral immunotherapy is capable of inducing permanent oral tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link\">",
"     \"The natural history of childhood food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issues surrounding home dosing of food immunotherapy were highlighted by a trial of peanut OIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/25\">",
"     25",
"    </a>",
"    ]. Twenty children completed all phases of the study. The risk of mild wheezing was 18 percent during the initial escalation. The probability of having any symptoms after a build-up dosing phase was 46 percent (29 and 24 percent for upper respiratory tract and skin symptoms, respectively). The risk of reaction with any home dose was 3.5 percent, with upper respiratory tract and skin symptoms being the most common (each about 1 percent). Treatment was given for 0.7 percent of home doses. Two subjects received epinephrine after one home dose each.",
"   </p>",
"   <p>",
"    Allergic reactions during home dosing were more common during an open-label maintenance phase of milk OIT, from 3 to 96 percent of doses per subject in the first three months compared with 0 to 80 percent in the subsequent three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/47\">",
"     47",
"    </a>",
"    ]. Local and multisystem reactions decreased during the study, whereas all other reactions remained unchanged. Several systemic reactions occurred at previously tolerated doses in the setting of exercise or viral illness, a finding that has been reported in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The risk of an allergic reaction to a previously tolerated dose of food is associated with physical exertion after dosing, dosing on an empty stomach, dosing during menses, concurrent febrile illness, and having suboptimally controlled asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, the full maintenance dose cannot be achieved due to allergic symptoms. These patients nevertheless benefit from an increase in the threshold dose of food required to cause an allergic reaction, as they have some protection from accidental exposures. This enhanced safety often also improves quality of life. Partial reintroduction of the food may have some nutritional value as well. These patients do need to continue to ingest the food on a daily basis to guarantee maintenance of the desensitization state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concept of oral immunomodulation and tolerance induction for therapy of food allergy is attractive, especially considering the relatively low rate of serious adverse reactions and comfort of home administration once maintenance therapy is reached [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/49\">",
"     49",
"    </a>",
"    ]. However, further randomized trials are necessary to fully evaluate the role of oral desensitization as a definitive treatment. Finally, mechanistic studies are needed to understand the immunologic changes induced by oral desensitization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sublingual immunotherapy (SLIT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to food immunotherapy is sublingual immunotherapy (SLIT) with food extracts. There are few effector cells, such as mast cells, in the sublingual mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/50\">",
"     50",
"    </a>",
"    ]. Allergen extracts given sublingually are not systemically absorbed. Rather they are taken up by dendritic cells in the mucosa and presented to T cells in the draining lymph nodes. Likely mechanisms of action include downregulation of mast cells and activation of T regulatory cells. SLIT has been attempted for peanut, hazelnut, cow's milk, and kiwi allergies.",
"   </p>",
"   <p>",
"    Both oral immunotherapy and SLIT are expected to be safer than subcutaneous administration, with lower rates of systemic reactions reported for SLIT than OIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. However, some studies suggest that OIT is more effective at desensitization and induction of tolerance than SLIT. Additional studies are needed to determine optimal dosing and duration of SLIT and whether the protective effect persists after SLIT is discontinued. In addition SLIT trials with different food allergens and in different patient populations (eg, children versus adults, subjects with well-defined anaphylactic reactivity to foods) must be conducted before final assessment of the role of SLIT in treatment of food allergy can be made.",
"   </p>",
"   <p>",
"    The following randomized trials and observational studies are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An open-label, randomized trial of SLIT alone (daily maintenance dose 7 mg) versus SLIT followed by low or high dose OIT (daily maintenance dose 1000 mg or 2000 mg) for treatment of milk allergy in school-aged children showed a higher rate of desensitization, but also a higher rate of systemic reactions, in the two groups that received OIT compared with SLIT alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/53\">",
"       53",
"      </a>",
"      ]. One of ten patients in the SLIT only group passed the 8 g milk challenge after 12 weeks of therapy, whereas seven of ten and nine of ten on low and high dose OIT, respectively, passed the challenge. The rates of tolerance after six weeks off of therapy were 10, 30, and 50 percent for SLIT only, low dose OIT, and high dose OIT respectively.",
"     </li>",
"     <li>",
"      A randomized trial of SLIT was conducted with commercial hazelnut extract for treatment of hazelnut allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/51\">",
"       51",
"      </a>",
"      ]. Adult subjects with hazelnut allergy confirmed by DBPCFC were assigned into two treatment groups: hazelnut SLIT (n = 12) or placebo SLIT (n = 11). All patients receiving hazelnut SLIT reached the planned maximum dose in four days according to a rush schedule under clinician supervision in the hospital. This was followed by home administration of a daily maintenance dose of five drops of hazelnut extract concentrate over five months (at a time of year when birch pollen was absent). In a second phase of the study, the aim was to treat patients in the active group for an additional year, followed by another DBPCFC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/55\">",
"       55",
"      </a>",
"      ]. Seven patients participated in the second phase. Three completed six months or less of SLIT and two were not consistent with daily therapy, although all seven performed the final DBPCFC.",
"      <br/>",
"      <br/>",
"      In the primary study, systemic reactions were observed rarely, were limited to the rush build up phase, and were successfully treated with oral antihistamines alone. The mean threshold dose of ingested hazelnut required to trigger objective symptoms increased from 2.3 g to 11.6 g in the active group versus 3.5 g to 4.1 g in the placebo group at follow-up evaluation. In the second phase, this threshold increased further to 14.6 g. Almost 50 percent of patients who underwent active treatment reached the highest dose (20 g) of hazelnut during follow-up DBPCFC, compared to 9 percent in the placebo group. In the second phase, more than 70 percent tolerated the 20 g dose. Levels of serum hazelnut-specific IgG4 antibody and total serum IL-10 increased only in the active group, but there were no differences in hazelnut-specific IgE antibody levels pre- and post-immunotherapy.",
"     </li>",
"     <li>",
"      A randomized trial of SLIT was conducted in children aged 1 to 11 years with peanut allergy (history of a reaction within 60 minutes of ingestion and peanut-specific IgE level of &ge;7",
"      <span class=\"nowrap\">",
"       kU/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/54\">",
"       54",
"      </a>",
"      ]. Children received crude peanut extract (n = 11) or placebo (n = 7), with a dose escalation phase over about six months and then six months of maintenance therapy (2000 mcg peanut protein daily). All subjects then underwent a DBPCFC to peanut. The median cumulative dose tolerated by the treatment group was significantly higher than in the control group (1710 versus 85 mg, respectively; an average size peanut contains about 200 mg of protein and two tablespoons of peanut butter contains 8 grams). Peanut-specific IgE increased significantly the first four months, but then steadily decreased over the remaining eight months. Peanut-specific IgG4, skin prick test wheal, basophil responsiveness, and IL-5 levels all decreased.",
"     </li>",
"     <li>",
"      A second randomized trial of peanut SLIT was performed in 40 patients 12 to 37 years of age who had a positive baseline challenge to peanut [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/56\">",
"       56",
"      </a>",
"      ]. The dose escalation phase occurred over approximately 16 weeks, with a target maintenance dose of 1386 micrograms of peanut protein. Daily maintenance dosing was continued until the DBPCFC at 44 weeks. Patients were considered to be responders if they successfully consumed the full 5 grams of peanut powder or at least 10-fold more peanut powder than at baseline. In an intent-to-treat analysis with subjects who withdrew from the study treated as nonresponders, significantly more patients on peanut SLIT than placebo were responders (14 of 20 versus 3 of 20, respectively). The median successfully consumed dose increased from 21 to 371 mg in the peanut SLIT group, although none in this group were able to consume the full 5 gram dose. Two patients in the placebo group tolerated the full 5 grams and were able to consume peanuts thereafter.",
"      <br/>",
"      <br/>",
"      The remaining patients in the placebo group (n = 17) were then started on high-dose peanut SLIT (dose escalation over 26 weeks), with a target dose of 3696 micrograms of peanut protein, and underwent a 5 gram DBPCFC 44 weeks after the onset of therapy. Seven of these crossover subjects were responders to the DBPCFC. Patients in the original peanut SLIT group continued on their maintenance therapy for an additional 24 weeks and then underwent a second DBPCFC with a target total dose of 10 grams of peanut powder. In this group, there were no new responders and all previous responders were still responders, with an increased median successfully consumed dose of 996 mg. Two subjects were able to consume the full 10 grams and three others consumed 5 grams of peanut powder.",
"      <br/>",
"      <br/>",
"      Symptoms occurred with about 33 to 40 percent of doses, but were primarily isolated to the oropharynx. One patient was treated with epinephrine.",
"     </li>",
"     <li>",
"      A case report and a case series were reported for SLIT for kiwi and cow's milk allergies, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/52,57,58\">",
"       52,57,58",
"      </a>",
"      ]. The patient with kiwi anaphylaxis underwent successful kiwi SLIT. Therapy was discontinued for four months for unrelated medical reasons after five years of daily treatment. The patient was asymptomatic upon oral provocation with her previous maintenance dose of kiwi SLIT, suggesting a persistent state of tolerance. In the case of cow's milk allergy, eight children over six years of age were treated with cow's milk SLIT for six months. The dose eliciting objective or recurrent subjective symptoms increased from a mean of 39 mL pretreatment to 143 mL after SLIT. Four patients were able to fully introduce cow's milk into their diet after therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Epicutaneous immunotherapy (EPIT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epicutaneous delivery of protein for immunotherapy has been studied in children with cow's milk allergy. An epicutaneous delivery system (EDS) was developed that solubilizes the allergen by perspiration and disseminates it into the thickness of the stratum corneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/59\">",
"     59",
"    </a>",
"    ]. Epicutaneous delivery is less invasive than subcutaneous injection and may have a lower risk for systemic reactions than subcutaneous, oral, or sublingual food allergen delivery.",
"   </p>",
"   <p>",
"    In a pilot study, 18 children (mean age 3.8 years, range 10 months to 7.7 years) with cow's milk allergy (CMA) were randomized 1:1 to receive active or placebo treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/60\">",
"     60",
"    </a>",
"    ]. CMA was confirmed by a clinician-supervised oral food challenge at baseline and the cumulative tolerated dose of milk was established. Children received three 48-hour applications (1 mg skimmed milk powder or 1 mg glucose as placebo) via the EDS per week for three months. Treated children showed a trend toward increased cumulative tolerated dose at the follow-up oral milk challenge following three months of epicutaneous immunotherapy, from a mean 1.77 mL at baseline to 23.61 mL at three months. The mean cumulative tolerated dose did not change in the placebo-treated group. There were no significant changes in cow's milk-specific IgE levels from baseline to three months in either group. The most common side effects were local pruritus and eczema at the site of application. There were no severe systemic adverse reactions; however, one subject in the active group had repeated episodes of diarrhea following EDS with milk.",
"   </p>",
"   <p>",
"    Reports from earlier mouse studies have demonstrated increased potential for the development of IgE sensitization to peanut via the epicutaneous route compared to ingestion, raising concerns as to whether epicutaneous delivery may worsen food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/61\">",
"     61",
"    </a>",
"    ]. It is impossible to fully understand the effect of EDS on milk allergy from this small pilot study, due to the small sample size and short duration of the study, as well as limited information about immunologic parameters. However, this preliminary report suggests that further investigation of the novel epicutaneous antigen delivery for food allergy immunotherapy is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Subcutaneous immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early clinical trials with subcutaneous peanut immunotherapy demonstrated that immunomodulation can be effectively used to induce oral tolerance to peanut, but at the same time highlighted the serious side effects associated with food allergen immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Systemic allergic reactions were common both during the build-up phase and with maintenance injections. Subsequent studies have focused on minimizing adverse side effects that are largely IgE-mediated. New therapies have been tested in animal models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Peptide immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elimination of IgE-binding can be achieved with vaccines consisting of overlapping peptides (protein fragments 10 to 20 amino acids long), that represent the entire sequence of a specific protein. Antigen presenting cells are provided with all possible allergenic epitopes, but mast cells are not activated because the short peptides are unable to cross-link two IgE molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/64\">",
"     64",
"    </a>",
"    ]. Peptide immunotherapy appears to induce T cell unresponsiveness and production of IFN-gamma in a concentration-dependent manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major peanut protein Ara h 2 peptide mixture was evaluated in a mouse model of peanut allergy. Pretreatment with two doses of the major peanut protein Ara h 2 peptide mixture prior to peanut challenge prevented anaphylactic reactions, lowered plasma histamine levels, and increased IFN-gamma production in peanut sensitized mice compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although promising, at this time peptide immunotherapy is not a practical option for human therapy because standardization of a vaccine containing over a hundred peptides is extremely difficult. A more refined vaccine containing only the most relevant (tolerogenic) peptides is a more feasible option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Engineered recombinant protein immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of the most relevant food allergen proteins was followed by generation of recombinant proteins, including major peanut allergens (Ara h 1, 2, 3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. These peanut proteins were tested in animal models of food allergy with mixed results. Subsequent studies concentrated on generation of \"hypoallergenic\" recombinant peanut proteins that lost the ability to interact with IgE antibodies directed against native peanut (ie, allergenicity), but retained the ability to interact with T cells (ie, immunogenicity). Such engineered recombinant peanut proteins were expected not to activate mast cells, thus improving the safety profile of the therapy.",
"   </p>",
"   <p>",
"    Two main techniques have been used to modified food allergens, site-directed mutagenesis and polymerization. Site-directed mutagenesis can be used to introduce point mutations in known IgE-binding epitopes of food allergens. Hypoallergenic mutants of peanut, fish, and apple allergens were generated using this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three major peanut allergens, Ara h 1, 2, and 3, were cloned and characterized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Amino acids critical to each IgE binding site (ie, epitope) were identified and site-directed mutagenesis was used to produce engineered recombinant allergens. Mutated peanut allergens with decreased IgE-reactivity, but retained ability to stimulate proliferation of peripheral blood mononuclear cells, were identified and their in vivo efficacy was tested in a murine model of peanut anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Desensitization with the engineered recombinant Ara h 2 protein suppressed synthesis of Ara h 2-IgE and resulted in significantly decreased symptoms on oral peanut challenge compared to a control group treated with unmutated Ara h 2.",
"   </p>",
"   <p>",
"    Similar modification of a recombinant major fish allergen (parvalbumin from carp, rCyp c 1) reduced IgE binding by 95 percent, but did not affect IgG binding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymerization is another technique used to modify food allergens to reduce IgE binding, but preserve immunogenicity. This method has been applied to apple and carrot allergens, but probably is less effective than allergen modification or site-directed mutation.",
"   </p>",
"   <p>",
"    Hypoallergenic engineered recombinant protein immunotherapy appears more promising and practical than peptide immunotherapy. These modified proteins are more potent when applied together with immunomodulatory adjuvants. Human studies are planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Immunomodulatory adjuvants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteria are potent stimulants of Th1 immune responses. Modified bacterial products can be used as adjuvants in immunotherapy. Immunosuppressant medications are other possible adjuvants.",
"   </p>",
"   <p>",
"    Heat-killed Listeria monocytogenes (HKLM) was shown to reverse established allergic airway hyperreactivity in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/78\">",
"     78",
"    </a>",
"    ]. In a dog model of food allergy, a single subcutaneous treatment with a mixture of HKLM and either peanut, or milk and wheat, significantly reduced immediate skin test reactions and anaphylactic symptoms on oral food challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/79\">",
"     79",
"    </a>",
"    ]. A mixture of HKLM and modified peanut proteins (Ara h 1, 2, and 3) was tested in a mouse model of peanut allergy. Significant changes in anaphylaxis symptom scores, plasma histamine levels, bronchial constriction, and peanut-specific IgE levels were seen in treated mice compared to sham-treated mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety concerns about using potentially pathogenic bacteria in humans resulted in selecting a non-pathogenic strain of Escherichia coli instead of HKLM as a bacterial adjuvant. Lower doses of subcutaneously administered modified peanut proteins were required for desensitization when coadministered with heat-killed E. coli (HKE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, concerns still remained regarding potential complications resulting from subcutaneous administration of a bacterial vaccine in humans. Therefore, further studies focused on vaccine administered per rectum. It was assumed that rectal delivery would provide superior safety regarding possible infectious complications, since non-pathogenic E. coli bacteria reside in the colon. In addition, rectal administration was anticipated to be associated with lower rates of severe adverse reactions. Finally, the rectal route was less invasive and could be safely used in young children, the primary target group for this vaccine.",
"   </p>",
"   <p>",
"    The long-term immunomodulatory effect of HKE producing mutated Ara h 1, 2, and 3 (HKE-MP123) administered rectally was investigated in a murine model of peanut anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/82\">",
"     82",
"    </a>",
"    ]. Peanut-allergic mice received low (0.9 mcg), medium (9 mcg), or high dose (90 mcg) HKE-MP123, HKE-containing vector (HKE-V) alone, or vehicle alone (sham) by rectum weekly for three weeks. Mice were challenged two weeks later. Second and third challenges were performed at four week intervals.",
"   </p>",
"   <p>",
"    All three HKE-MP123 groups and the HKE-V group exhibited reduced symptom scores after the initial challenge, compared with the sham-treated group. Only the medium- and high-dose HKE-MP123-treated mice remained protected for up to 10 weeks after treatment. This prolonged protective effect was accompanied by a significant reduction in plasma histamine levels compared with sham-treated mice. IgE levels were significantly lower in all HKE-MP123-treated groups, with the greatest reduction seen in the high-dose treated group. In vitro IL-4, IL-13, IL-5 and IL-10 production by peanut-stimulated splenocytes of high-dose treated mice were significantly decreased, and IFN-gamma and TGF-beta production were significantly increased compared with sham-treated mice at the time of the last challenge.",
"   </p>",
"   <p>",
"    Treatment with rectal HKE-MP123 can induce long-term \"down-regulation\" of peanut hypersensitivity. This effect may be secondary to decreased antigen-specific Th2 and increased Th1 and T regulatory cytokine production. The rectal vaccine is being standardized in preparation for a phase I human clinical trial.",
"   </p>",
"   <p>",
"    The concept of potentiation of Th1 responses by the synthetic immunostimulatory oligodeoxynucleotides containing unmethylated CpG motifs (immunostimulatory sequences, ISS), rather than whole bacteria, was also explored. Peanut allergic mice were immunized intradermally with ISS-linked Ara h 2, or ISS-linked Amb a 1 (major ragweed allergen) as a control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/83\">",
"     83",
"    </a>",
"    ]. ISS-Ara h 2-treated mice did not develop symptoms of anaphylaxis and had significantly lower plasma histamine levels following oral peanut challenge compared to the control mice. In another study, intradermal immunization with a mixture of ISS and beta-galactosidase (beta-gal), but not with either alone, provided protection against fatal anaphylaxis induced by intraperitoneal beta-gal sensitization and challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results suggest that antigen ISS immunization may have a prophylactic effect against allergy. However, the ability of this therapy to reverse established food allergy is unknown.",
"   </p>",
"   <p>",
"    Additional approaches to allergen specific therapy for food allergy include immunoglobulin Fc-Fc fusion protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/85-87\">",
"     85-87",
"    </a>",
"    ], sugar-conjugated bovine serum albumin (BSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/88\">",
"     88",
"    </a>",
"    ], and Lactococcus lactis transfected with IL-12 and &beta;-lactoglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NONSPECIFIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of nonspecific therapies for food allergy is primarily to downregulate the allergic immune response. Some therapies in development have only a transient effect, but others may be curative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Humanized monoclonal anti-IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen-specific IgE antibodies play an important role in the pathophysiology of food allergy. IgE antibodies bind to high affinity receptors (Fc epsilon RI) on the surface of mast cells and basophils. Cross-linking of IgE molecules on the surface of mast cells by allergen leads to the release of preformed mast cell mediators (the early phase of an allergic reaction) as well as synthesis of pro-inflammatory cytokines and chemokines that result in late phase reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31848?source=see_link\">",
"     \"The biology of IgE\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Humanized monoclonal anti-IgE antibodies bind to the constant region (third domain of the Fc region) of IgE molecules and prevent the IgE molecules from binding to receptors (Fc epsilon RI and Fc epsilon RII). Anti-IgE cannot interact with IgE molecules once they are already bound to the IgE receptor, and thus anti-IgE is not capable of cross-linking IgE. Furthermore, anti-IgE downregulates the expression of Fc epsilon RI receptor on mast cells and decreases basophil histamine release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multi-center randomized trial evaluated humanized monoclonal anti-IgE mouse IgG1 antibody (TNX-901) in 84 patients with a history of immediate hypersensitivity to peanut [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/93\">",
"     93",
"    </a>",
"    ]. Peanut hypersensitivity was confirmed and the threshold dose of peanut protein established by a DBPCFC at screening. Patients were randomly assigned to receive either TNX-901 (150, 300, or 450 mg) or placebo subcutaneously every four weeks for four doses. Patients underwent a second oral peanut challenge within two to four weeks after the fourth dose.",
"   </p>",
"   <p>",
"    The mean baseline threshold of sensitivity increased in all groups, with an apparent dose response, but was only significant in the 450 mg group. In this group, the sensitivity threshold increased from a level equal to approximately half a peanut (178 mg) to one equal to almost nine peanuts (2805 mg), an effect that should provide protection against most accidental ingestion. However, even at the highest dose of TNX-901, approximately 25 percent were not protected. It remains to be determined whether further dose increases might confer protective effect in these patients.",
"   </p>",
"   <p>",
"    A controlled trial of different anti-IgE humanized IgG1 antibody (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    ) in children older than six years with peanut anaphylaxis was discontinued prematurely because of safety issues related to anaphylactic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/94\">",
"     94",
"    </a>",
"    ]. Further studies are currently on hold as alternative study designs are considered.",
"   </p>",
"   <p>",
"    Combined treatment with anti-IgE and specific food allergen immunotherapy is also a consideration because of the potential of anti-IgE to decrease life-threatening side effects of allergen immunotherapy. Evaluation of combination therapy has begun with environmental allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/95\">",
"     95",
"    </a>",
"    ], and trials of combined milk oral immunotherapy and anti-IgE in patients with milk allergy are also underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-IgE therapy is not a cure and protection would require administration at regular intervals indefinitely. However, it should be useful for patients with food anaphylaxis regardless of the offending food. Prior to clinical application, further studies are necessary to confirm and optimize the protective effect of anti-IgE against food anaphylaxis, establish a safety profile in young children, and identify markers for selecting food-allergic subjects most likely to benefit from anti-IgE therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Traditional Chinese medicine (TCM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbs have been successfully used in Asia for centuries for treatment of various ailments, including asthma and environmental allergies. Traditional Chinese medicine (TCM) is attracting increasing interest because of its reported effectiveness, favorable safety profile, and low cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. The mechanism of action of TCM is largely unknown, in spite of extensive clinical experience with TCM in Asia. In addition, TCM has not been rigorously evaluated in randomized clinical trials. The use of Chinese herbs for the treatment of food allergy is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31496?source=see_link\">",
"     \"Chinese herbal medicine for the treatment of allergic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional novel approaches to allergen-nonspecific therapy for food allergy include monoclonal anti-IgE antibody for eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/98\">",
"     98",
"    </a>",
"    ], Trichuris suis ova therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/99,100\">",
"     99,100",
"    </a>",
"    ], and human Toll-like receptor 9 (TLR9) agonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Blockade of vasoactive mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of anaphylaxis are associated with release of vasoactive mediators, such as histamine, proteases, leukotrienes, and platelet-activating factor (PAF), from mast cells and basophils. In a mouse model of peanut-induced anaphylaxis, treatment with a PAF receptor antagonist prior to peanut challenge decreased the severity and duration of anaphylactic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44057/abstract/102\">",
"     102",
"    </a>",
"    ]. Combined PAF and histamine blockade was more effective than PAF antagonism alone. Treatments targeting either histamine or leukotrienes alone were not effective. The efficacy of PAF receptor antagonists given after the onset of anaphylaxis is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;No cure for food allergy is available. Strict avoidance of the food allergen is the only current therapeutic option. The following experimental strategies are described in this topic:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Food allergen-specific therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral immunotherapy &mdash; Patients have been successfully desensitized with this approach, but a smaller percentage achieve oral tolerance. The rate of allergic reactions is low and home administration is possible. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Oral immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sublingual immunotherapy &mdash; Most patients are at least partially desensitized, but persistent tolerance after discontinuation of therapy is uncommon. Systemic reactions are rare and generally mild. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sublingual immunotherapy (SLIT)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peptide immunotherapy &mdash; This approach minimizes the risk of IgE-mediated reactions because the peptides are too small to bind to and cross-link IgE. Standardization issues make this option less viable. There are no human studies. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Peptide immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Engineered recombinant protein immunotherapy &mdash; IgE-binding epitopes are first identified and then altered to avoid activation of IgE. Human studies are planned. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Engineered recombinant protein immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunotherapy with adjuvants &mdash; Modified bacterial products, such as heat-killed E. coli (HKE), are used as immunomodulatory adjuvants. Human trials are planned with rectally administered HKE producing recombinant hypoallergenic peanut proteins. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Immunomodulatory adjuvants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nonspecific therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Humanized monoclonal anti-IgE &mdash; This approach can be used for any food allergen, but it is not curative. Protection is not uniform. Human studies are on hold due to safety issues. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Humanized monoclonal anti-IgE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional Chinese medicine &mdash; The exact mechanism(s) of this herbal therapy is unclear. Preclinical studies in a murine model of peanut-induced anaphylaxis demonstrate a protective effect that may be prolonged. Human safety and efficacy trials are underway. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Traditional Chinese medicine (TCM)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31496?source=see_link\">",
"       \"Chinese herbal medicine for the treatment of allergic diseases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/1\">",
"      Sampson HA. Update on food allergy. J Allergy Clin Immunol 2004; 113:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/2\">",
"      Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol 2010; 126:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/3\">",
"      Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2007. J Allergy Clin Immunol 2008; 121:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/4\">",
"      Eigenmann PA, Beyer K, Wesley Burks A, et al. New visions for food allergy: an iPAC summary and future trends. Pediatr Allergy Immunol 2008; 19 Suppl 19:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/5\">",
"      Sicherer SH, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Annu Rev Med 2009; 60:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/6\">",
"      Nowak-W��grzyn A, Sampson HA. Future therapies for food allergies. J Allergy Clin Immunol 2011; 127:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/7\">",
"      Rolinck-Werninghaus C, Staden U, Mehl A, et al. Specific oral tolerance induction with food in children: transient or persistent effect on food allergy? Allergy 2005; 60:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/8\">",
"      Niggemann B, Staden U, Rolinck-Werninghaus C, Beyer K. Specific oral tolerance induction in food allergy. Allergy 2006; 61:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/9\">",
"      Beyer K, Wahn U. Oral immunotherapy for food allergy in children. Curr Opin Allergy Clin Immunol 2008; 8:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/10\">",
"      Vickery BP, Burks W. Oral immunotherapy for food allergy. Curr Opin Pediatr 2010; 22:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/11\">",
"      Ko J, Mayer L. Oral tolerance: lessons on treatment of food allergy. Eur J Gastroenterol Hepatol 2005; 17:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/12\">",
"      Vickery BP, Burks AW. Immunotherapy in the treatment of food allergy: focus on oral tolerance. Curr Opin Allergy Clin Immunol 2009; 9:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/13\">",
"      Glez PP, Franco YB, Matheu V. MIP-1&alpha;, MCP-1, and desensitization in anaphylaxis from cow's milk. N Engl J Med 2012; 367:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/14\">",
"      Thyagarajan A, Jones SM, Calatroni A, et al. Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children. Clin Exp Allergy 2012; 42:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/15\">",
"      Patriarca C, Romano A, Venuti A, et al. Oral specific hyposensitization in the management of patients allergic to food. Allergol Immunopathol (Madr) 1984; 12:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/16\">",
"      Patriarca G, Schiavino D, Nucera E, et al. Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology 1998; 45:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/17\">",
"      Nucera E, Schiavino D, D'Ambrosio C, et al. Immunological aspects of oral desensitization in food allergy. Dig Dis Sci 2000; 45:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/18\">",
"      Patriarca G, Nucera E, Roncallo C, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 2003; 17:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/19\">",
"      Patriarca G, Nucera E, Pollastrini E, et al. Oral rush desensitization in peanut allergy: a case report. Dig Dis Sci 2006; 51:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/20\">",
"      Ru&euml;ff F, Eberlein-K&ouml;nig B, Przybilla B. Oral hyposensitization with celery juice. Allergy 2001; 56:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/21\">",
"      Buchanan AD, Green TD, Jones SM, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 2007; 119:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/22\">",
"      Staden U, Rolinck-Werninghaus C, Brewe F, et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 2007; 62:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/23\">",
"      Longo G, Barbi E, Berti I, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 2008; 121:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/24\">",
"      Morisset M, Moneret-Vautrin DA, Guenard L, et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. Eur Ann Allergy Clin Immunol 2007; 39:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/25\">",
"      Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009; 124:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/26\">",
"      Nadeau KC, Schneider LC, Hoyte L, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 2011; 127:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/27\">",
"      Nowak-Wegrzyn A, Bloom KA, Sicherer SH, et al. Tolerance to extensively heated milk in children with cow's milk allergy. J Allergy Clin Immunol 2008; 122:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/28\">",
"      Lemon-Mul&eacute; H, Sampson HA, Sicherer SH, et al. Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 2008; 122:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/29\">",
"      Shreffler WG, Wanich N, Moloney M, et al. Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein. J Allergy Clin Immunol 2009; 123:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/30\">",
"      Kim JS, Nowak-W��grzyn A, Sicherer SH, et al. Dietary baked milk accelerates the resolution of cow's milk allergy in children. J Allergy Clin Immunol 2011; 128:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/31\">",
"      Bro��ek JL, Terracciano L, Hsu J, et al. Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis. Clin Exp Allergy 2012; 42:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/32\">",
"      Yeung JP, Kloda LA, McDevitt J, et al. Oral immunotherapy for milk allergy. Cochrane Database Syst Rev 2012; 11:CD009542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/33\">",
"      Skripak JM, Nash SD, Rowley H, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 2008; 122:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/34\">",
"      S&aacute;nchez-Garc&iacute;a S, Rodr&iacute;guez Del R&iacute;o P, Escudero C, et al. Possible eosinophilic esophagitis induced by milk oral immunotherapy. J Allergy Clin Immunol 2012; 129:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/35\">",
"      Nieto A, Fernandez-Silveira L, Mazon A, Caballero L. Life-threatening asthma reaction caused by desensitization to milk. Allergy 2010; 65:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/36\">",
"      Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 2012; 367:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/37\">",
"      Burks AW, Jones SM. Egg oral immunotherapy in non-anaphylactic children with egg allergy: follow-up. J Allergy Clin Immunol 2008; 121:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/38\">",
"      Vickery BP, Pons L, Kulis M, et al. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol 2010; 105:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/39\">",
"      Garc&iacute;a Rodr&iacute;guez R, Urra JM, Feo-Brito F, et al. Oral rush desensitization to egg: efficacy and safety. Clin Exp Allergy 2011; 41:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/40\">",
"      Ridolo E, De Angelis GL, Dall'aglio P. Eosinophilic esophagitis after specific oral tolerance induction for egg protein. Ann Allergy Asthma Immunol 2011; 106:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/41\">",
"      Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol 2008; 121:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/42\">",
"      Blumchen K, Ulbricht H, Staden U, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 2010; 126:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/43\">",
"      Anagnostou K, Clark A, King Y, et al. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 2011; 41:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/44\">",
"      Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011; 127:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/45\">",
"      Nurmatov U, Venderbosch I, Devereux G, et al. Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev 2012; 9:CD009014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/46\">",
"      Meglio P, Bartone E, Plantamura M, et al. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy 2004; 59:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/47\">",
"      Narisety SD, Skripak JM, Steele P, et al. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy. J Allergy Clin Immunol 2009; 124:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/48\">",
"      Varshney P, Steele PH, Vickery BP, et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol 2009; 124:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/49\">",
"      Hofmann AM, Scurlock AM, Jones SM, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 2009; 124:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/50\">",
"      Frati F, Moingeon P, Marcucci F, et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc 2007; 28:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/51\">",
"      Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005; 116:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/52\">",
"      Mempel M, Rakoski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy. J Allergy Clin Immunol 2003; 111:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/53\">",
"      Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol 2012; 129:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/54\">",
"      Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011; 127:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/55\">",
"      Enrique E, Malek T, Pineda F, et al. Sublingual immunotherapy for hazelnut food allergy: a follow-up study. Ann Allergy Asthma Immunol 2008; 100:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/56\">",
"      Fleischer DM, Burks AW, Vickery BP, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013; 131:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/57\">",
"      Kerzl R, Simonowa A, Ring J, et al. Life-threatening anaphylaxis to kiwi fruit: protective sublingual allergen immunotherapy effect persists even after discontinuation. J Allergy Clin Immunol 2007; 119:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/58\">",
"      de Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy 2006; 61:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/59\">",
"      Mondoulet L, Dioszeghy V, Ligouis M, et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 2010; 40:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/60\">",
"      Dupont C, Kalach N, Soulaines P, et al. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010; 125:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/61\">",
"      Strid J, Hourihane J, Kimber I, et al. Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization. Clin Exp Allergy 2005; 35:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/62\">",
"      Oppenheimer JJ, Nelson HS, Bock SA, et al. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992; 90:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/63\">",
"      Nelson HS, Lahr J, Rule R, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997; 99:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/64\">",
"      Briner TJ, Kuo MC, Keating KM, et al. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci U S A 1993; 90:7608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/65\">",
"      Hong SJ, Michael JG, Fehringer A, Leung DY. Pepsin-digested peanut contains T-cell epitopes but no IgE epitopes. J Allergy Clin Immunol 1999; 104:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/66\">",
"      Li S, Li XM, Burks AW, Sampson HA. Modulation of peanut allergy by peptide-based immunotherapy. J Allergy Clin Immunol 2001; 107:S233 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/67\">",
"      Prickett SR, Voskamp AL, Dacumos-Hill A, et al. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol 2011; 127:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/68\">",
"      Valenta R, Vrtala S, Laffer S, et al. Recombinant allergens. Allergy 1998; 53:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/69\">",
"      Li X, Huang CK, Schofield BH, et al. Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J Immunol 1999; 162:3045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/70\">",
"      Nowak-Wegrzyn A. New perspectives for use of native and engineered recombinant food proteins in treatment of food allergy. Immunol Allergy Clin North Am 2007; 27:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/71\">",
"      Burks AW, Cockrell G, Stanley JS, et al. Recombinant peanut allergen Ara h I expression and IgE binding in patients with peanut hypersensitivity. J Clin Invest 1995; 96:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/72\">",
"      Eigenmann PA, Burks AW, Bannon GA, Sampson HA. Identification of unique peanut and soy allergens in sera adsorbed with cross-reacting antibodies. J Allergy Clin Immunol 1996; 98:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/73\">",
"      Stanley JS, King N, Burks AW, et al. Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Arch Biochem Biophys 1997; 342:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/74\">",
"      Rabjohn P, Helm EM, Stanley JS, et al. Molecular cloning and epitope analysis of the peanut allergen Ara h 3. J Clin Invest 1999; 103:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/75\">",
"      Bannon GA, Cockrell G, Connaughton C, et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 2001; 124:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/76\">",
"      Srivastava KD, Li XM, King N, et al. Immunotherapy with modified peanut allergens in a murine model of peanut allergy. J Allergy Clin Immunol 2002; 109:S287 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/77\">",
"      Swoboda I, Bugajska-Schretter A, Linhart B, et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol 2007; 178:6290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/78\">",
"      Yeung VP, Gieni RS, Umetsu DT, DeKruyff RH. Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol 1998; 161:4146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/79\">",
"      Frick OL, Teuber SS, Buchanan BB, et al. Allergen immunotherapy with heat-killed Listeria monocytogenes alleviates peanut and food-induced anaphylaxis in dogs. Allergy 2005; 60:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/80\">",
"      Li XM, Srivastava K, Huleatt JW, et al. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol 2003; 170:3289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/81\">",
"      Stanley JS, Buzen F, Cockrell G, et al. Immunotherapy for peanut allergy using modified allergens and a bacterial adjuvant. J Allergy Clin Immunol 2002; 109:S93 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/82\">",
"      Li XM, Srivastava K, Grishin A, et al. Persistent protective effect of heat-killed Escherichia coli producing \"engineered,\" recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 2003; 112:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/83\">",
"      Srivastava K, Li XM, Bannon GA, et al. Investigation of the use of ISS-linked Ara h2 for the treatment of peanut-induced allergy. J Allergy Clin Immunol 2001; 107:S233 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/84\">",
"      Nguyen MD, Cinman N, Yen J, Horner AA. DNA-based vaccination for the treatment of food allergy. Allergy 2001; 56 Suppl 67:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/85\">",
"      Zhang K, Kepley CL, Terada T, et al. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J Allergy Clin Immunol 2004; 114:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/86\">",
"      Kepley CL, Taghavi S, Mackay G, et al. Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J Biol Chem 2004; 279:35139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/87\">",
"      Zhang K, Zhu D, Kepley C, et al. Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy. Immunol Allergy Clin North Am 2007; 27:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/88\">",
"      Zhou Y, Kawasaki H, Hsu SC, et al. Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1. Nat Med 2010; 16:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/89\">",
"      Cortes-Perez NG, Ah-Leung S, Berm&uacute;dez-Humar&aacute;n LG, et al. Intranasal coadministration of live lactococci producing interleukin-12 and a major cow's milk allergen inhibits allergic reaction in mice. Clin Vaccine Immunol 2007; 14:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/90\">",
"      Cortes-Perez NG, Ah-Leung S, Berm&uacute;dez-Humar&aacute;n LG, et al. Allergy therapy by intranasal administration with recombinant Lactococcus lactis Producing bovine beta-lactoglobulin. Int Arch Allergy Immunol 2009; 150:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/91\">",
"      Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/92\">",
"      MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/93\">",
"      Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/94\">",
"      Kattan JD, Srivastava KD, Zou ZM, et al. Pharmacological and immunological effects of individual herbs in the Food Allergy Herbal Formula-2 (FAHF-2) on peanut allergy. Phytother Res 2008; 22:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/95\">",
"      Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/96\">",
"      Bielory L, Lupoli K. Herbal interventions in asthma and allergy. J Asthma 1999; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/97\">",
"      Ziment I, Tashkin DP. Alternative medicine for allergy and asthma. J Allergy Clin Immunol 2000; 106:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/98\">",
"      Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010; 59:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/99\">",
"      Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005; 128:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/100\">",
"      Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy in Crohn's disease. Gut 2005; 54:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/101\">",
"      Zhu FG, Kandimalla ER, Yu D, Agrawal S. Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. J Allergy Clin Immunol 2007; 120:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44057/abstract/102\">",
"      Arias K, Baig M, Colangelo M, et al. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. J Allergy Clin Immunol 2009; 124:307.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2410 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44057=[""].join("\n");
var outline_f43_1_44057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FOOD ALLERGEN-SPECIFIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oral immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Milk OIT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Egg OIT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Peanut OIT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sublingual immunotherapy (SLIT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Epicutaneous immunotherapy (EPIT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Subcutaneous immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Peptide immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Engineered recombinant protein immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Immunomodulatory adjuvants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NONSPECIFIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Humanized monoclonal anti-IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Traditional Chinese medicine (TCM)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Blockade of vasoactive mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Food allergen-specific therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nonspecific therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2410\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2410|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/13/29918\" title=\"table 1\">",
"      Novel rx food allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/23/3442\" title=\"table 2\">",
"      OIT food allergy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31496?source=related_link\">",
"      Chinese herbal medicine for the treatment of allergic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_1_44058="Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations";
var content_f43_1_44058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44058/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44058/contributors\">",
"     Jeffrey W Clark, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44058/contributors\">",
"     Axel Grothey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44058/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44058/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/1/44058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/1/44058/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/1/44058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The last 5 to 10 years have seen unprecedented advances in the treatment of metastatic colorectal cancer (mCRC). In the era when 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU) was the sole active agent, overall survival in phase III trials was approximately 11 to 12 months. In the modern era, the average median survival duration has doubled, and patients routinely live longer than two years. This increase has been mainly driven by the availability of new active agents.",
"   </p>",
"   <p>",
"    There are now seven different classes of drugs with significant antitumor activity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluoropyrimidines (5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      [5-FU] which is usually given with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      [LV],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      , tegafur plus uracil [UFT]). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H10#H10\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Leucovorin plus 5-FU'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       Irinotecan",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       Oxaliplatin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       Cetuximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      , two monoclonal antibodies (MoAbs) directed against the epidermal growth factor receptor (EGFR)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      , a MoAb targeting vascular endothelial growth factor (VEGF)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       aflibercept",
"      </a>",
"      , a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF) binding portions from the human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1, functions as a decoy receptor that prevents intravascular and extravascular VEGF-A, VEGF-B, and PlGF (placenta growth factor) from binding to their receptors",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       Regorafenib",
"      </a>",
"      , an orally active inhibitor of angiogenic tyrosine kinases (including the VEGF receptors 1 to 3), as well as other membrane and intracellular kinases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the rapid pace of clinical research, the best way to combine and sequence all of these drugs to optimize treatment is not yet established. Because of the heterogeneity of CRCs, different strategies may be better for different individuals. In some cases, predictive biomarkers are influencing the choice of treatment. As an example, K-ras mutation status permits the selection of individuals who might benefit from strategies targeting the EGFR. However, there are no accepted biologic or molecular markers of responsiveness to antiangiogenic therapy or to conventional cytotoxics, although these are active areas of research. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Predictive markers for response'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The goals of chemotherapy differ according to the clinical scenario. For most patients, treatment will be palliative and not curative, and the treatment goals are to prolong overall survival and maintain quality of life (QOL) for as long as possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H9654617#H9654617\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Treatment goals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients with stage IV disease (particularly those with liver-limited metastases) can be surgically cured of their disease. Even selected patients with initially unresectable liver metastases may become eligible for resection if the response to chemotherapy is sufficient, although this is uncommon.",
"   </p>",
"   <p>",
"    This approach has been termed \"conversion therapy\" to distinguish it from neoadjuvant therapy that is given to patients who present upfront with apparently resectable disease. The key parameter for selecting the specific regimen in this scenario is not survival or improved QOL, but instead, response rate (ie, the ability of the regimen to shrink metastases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Conversion therapy for initially unresectable metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will address the practical issues that arise when choosing the appropriate treatment strategy for individual patients with inoperable mCRC. General principles of chemotherapy treatment for metastatic colorectal cancer, data from the clinical trials that support the recommendations, recommendations for systemic chemotherapy in elderly patients with mCRC, management of patients with potentially resectable liver metastases, and a compilation of chemotherapy regimens used for advanced CRC are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41466?source=see_link\">",
"     \"Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6686747\">",
"    <span class=\"h1\">",
"     PREDICTIVE MARKERS FOR RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evolving understanding of the genetic heterogeneity of CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/2\">",
"     2",
"    </a>",
"    ] has led to an emerging paradigm that different treatment strategies may be preferable for different individuals. Genetically tailored clinical management entails the use of genetic tests as biomarkers to guide specific clinical decisions. Although this field is in its infancy in colorectal cancer, there are some biomarkers with an established role in clinical CRC management. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with stage II colon cancer, deficiency of mismatch repair proteins (for which the biologic footprint is microsatellite instability) is used to help guide decisions on whether to administer adjuvant single agent fluoropyrimidine therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=see_link&amp;anchor=H589530422#H589530422\">",
"       \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'MSI and mismatch repair enzyme deficiency'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Among patients with metastatic CRC, K-ras mutation status permits the selection of individuals who might benefit from strategies targeting the epidermal growth factor receptor (EGFR). Unfortunately, there are no accepted biologic or molecular markers of responsiveness to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      or to conventional cytotoxics, although these are active areas of research.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections will review the available data on predictive biomarkers for selecting therapy in metastatic CRC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6688281\">",
"    <span class=\"h2\">",
"     Agents targeting the EGFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Particularly in view of their expense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/3\">",
"     3",
"    </a>",
"    ], the identification of patients who are most likely to respond to the anti-EGFR monoclonal antibodies",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    is an important clinical question. Selection or exclusion of patients for either drug based upon IHC for EGFR expression is not justified, since only a minority of otherwise unselected EGFR-positive tumors respond (see",
"    <a class=\"local\" href=\"#H6687373\">",
"     'EGFR amplification'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/4-7\">",
"     4-7",
"    </a>",
"    ], and objective responses are seen with EGFR-negative tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. Likewise, somatic mutations in the EGFR tyrosine kinase domain are not associated with cetuximab sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21096055\">",
"    <span class=\"h3\">",
"     K-ras",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor overexpression of several genes involved in the EGFR signaling pathway and downstream events might identify patients who are most likely to respond to anti-EGFR agents. It is now well established that activating mutations in K-ras, which result in constitutive activation of the RAS-RAF-ERK pathway, result in resistance to anti-EGFR therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/11-22\">",
"     11-22",
"    </a>",
"    ]. Activating mutations in K-ras are detected in approximately 40 percent of mCRCs, with good concordance between the primary and distant metastases (but not lymph node metastases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US and elsewhere,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    are approved only for patients with wild type (WT) K-ras tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/24\">",
"     24",
"    </a>",
"    ]. An ASCO provisional clinical opinion recommends against the use of either drug if the tumor is not WT K-ras [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/25\">",
"     25",
"    </a>",
"    ]. Compared to a strategy of treating all patients with anti-EGFR therapies, the use of molecular testing to select patients for treatment with these agents has the potential to improve survival by identifying responders, and to generate cost savings by identifying nonresponders. However, because these agents are considerably more expensive than other existing treatments, and the incremental improvement in survival gained by use of these drugs is relatively small, these cost-savings do not necessarily translate into a favorable cost-effectiveness ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In CRC, K-ras mutations are mainly found in codons 12, 13, and 61 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The FDA has approved a polymerase chain reaction assay, the Quiagen Therascreen KRAS RCQ PCR kit, that detects seven different mutations of the K-ras gene in a tumor specimen. Tumors that are K-ras mutation-negative in this assay are commonly referred to as &ldquo;wild type&rdquo;.",
"   </p>",
"   <p>",
"    However, whether all mutations confer resistance to EGFR-targeted agents is unclear; the data are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a pooled, retrospective analysis of 579 patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      for mCRC, patients who had a specific mutation in codon 13 (called p.G13D) survived longer than patients with other K-ras mutations who received cetuximab (medians of 7.6 versus 5.7 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/29\">",
"       29",
"      </a>",
"      ]. In addition, overall survival was similar between patients with the p.G13D mutation and patients with wild type K-ras. Similar results (benefit from cetuximab in patients with the p.G13D K-ras mutation) were noted in a second analysis of patients enrolled on the CRYSTAL and OPUS trials of first-line cetuximab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      On the other hand, others report no benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      in patients with mCRC and a p.G13D mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A meta-analysis of data from 10 studies, which included 1487 patients with mCRC, concluded that patients with the KRAS p.G13D mutation (n=99 patients) appeared to benefit more from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      than did those who had tumors harboring KRAS codon 12 mutations (n=514 patients). The relative risk for objective overall response was 1.642 (95% CI 1.131-2.384). Of the three studies comparing progression-free and overall survival between individuals with the p.G13D mutation and a codon 12 mutation, only one showed a statistically significant survival benefit for cetuximab in patients with a p.G13D mutation compared to a codon 12 mutation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, all of these analyses represent data on the evidence level of a retrospective observational study; prospective randomized trials in patients with the p.G13D mutation are needed before conclusions can be made about the potential for benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in subgroups of patients with K-ras mutations.",
"   </p>",
"   <p>",
"    An important point is that WT K-ras does not guarantee benefit from agents targeting the EGFR, since even in these cohorts, response rates to either drug are 40 percent or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/17,32,33\">",
"     17,32,33",
"    </a>",
"    ]. Among WT K-ras tumors, mutation of other genes, such as BRAF (see below), PIK3CA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/34\">",
"     34",
"    </a>",
"    ], p53 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/35\">",
"     35",
"    </a>",
"    ], PTEN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/36\">",
"     36",
"    </a>",
"    ], or polymorphisms in EGF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/33\">",
"     33",
"    </a>",
"    ] or in genes involved in the insulin-like growth factor 1 (IGF1) signaling pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], or a low fraction of cells staining for EGFR by IHC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/39,40\">",
"     39,40",
"    </a>",
"    ] may be associated with resistance to anti-EGFR therapies. However, all of these additional biomarkers require further validation before being incorporated into clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. It seems likely that a comprehensive biomarker analysis will be required to identify the subgroup of patients with mCRC who will truly benefit from treatment with an anti-EGFR agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6687366\">",
"    <span class=\"h3\">",
"     BRAF",
"    </span>",
"    &nbsp;&mdash;&nbsp;BRAF is a component of the RAS-RAF-MAPK signaling pathway. Activating mutations, which are mutually exclusive with K-ras mutations, are found in about 5-10 percent of mCRCs. BRAF mutations (most of which are V600E mutations) have consistently been associated with poor prognosis overall, and in single-arm studies of patients treated in the second-line setting and beyond, potential resistance to EGFR-targeted agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/20,32,36\">",
"     20,32,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, data from randomized trials confirm the prognostic but not the predictive value of BRAF mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. As an example, in data from the first-line CRYSTAL (FOLFIRI with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) and OPUS (FOLFOX4 with or without cetuximab) trials, BRAF mutations were associated with a poor prognosis overall, but BRAF mutation status did not appear to be a strong predictive biomarker for lack of benefit from cetuximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. Among 70 patients with WT K-ras, BRAF mutant tumors, the addition of cetuximab to FOLFIRI provided some benefit in terms of numerically increased PFS, response rate and overall survival, but it was not statistically significant.",
"   </p>",
"   <p>",
"    A test for BRAF mutations is commercially available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/47\">",
"     47",
"    </a>",
"    ]. However, at present, the available data suggest that it should not be used as a selection factor for treatment with EGFR-targeted agents in patients with WT K-ras tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6687373\">",
"    <span class=\"h3\">",
"     EGFR amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/36,48,49\">",
"     36,48,49",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/15,50,51\">",
"     15,50,51",
"    </a>",
"    ] suggest an association between EGFR copy number and response to anti-EGFR therapy. The clinical use of EGFR amplification to select patients for therapy is limited by the lack of standardization of fluorescence in situ hybridization technology and scoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/36,51\">",
"     36,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6688341\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts to discover molecular or pathologic predictive factors for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    efficacy in order to identify subgroups of patients who gain greater or lesser degrees of benefit from the drug have not been successful to date, although this is an active area of research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/52\">",
"     52",
"    </a>",
"    ]. An important issue is that it is not tumor tissue that is the target for bevacizumab but instead host endothelial cells which interact with tumor on the microenvironmental level.",
"   </p>",
"   <p>",
"    Thus, there are no criteria for the selection of patients who will or will not benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to front-line therapy. There are, however, patients in whom the risks associated with bevacizumab might outweigh potential benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H50#H50\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4881461\">",
"    <span class=\"h2\">",
"     Cytotoxic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospectively validated predictive biomarkers for conventional cytotoxic agents, although this is an area of active research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/53-57\">",
"     53-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4881480\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with metastatic CRC, K-ras mutation status permits the selection of individuals who might benefit from strategies targeting the epidermal growth factor receptor (EGFR). Unfortunately, there are no accepted biologic or molecular markers of responsiveness to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or to conventional cytotoxics, although these are active areas of research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4881383\">",
"    <span class=\"h1\">",
"     CONTINUUM OF CARE MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The model of distinct \"lines\" of chemotherapy (in which regimens containing noncross-resistant drugs are each used in succession until disease progression) is being abandoned in favor of a \"continuum of care\" approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/58\">",
"     58",
"    </a>",
"    ]. This approach emphasizes an individualized treatment strategy for mCRC that might include phases of maintenance chemotherapy interspersed with more aggressive treatment protocols, rechallenging patients who responded to first-line treatment with the same agents used first-line [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/59-63\">",
"     59-63",
"    </a>",
"    ], as well as reutilization of previously administered chemotherapy agents in combination with other active drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL DOUBLET COMBINATIONS VERSUS SEQUENTIAL SINGLE AGENT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the three active conventional chemotherapy agents for mCRC are fluoropyrimidines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . The proportion of patients exposed to all three drug classes during the course of therapy correlates strongly with median survival in all large published phase III trials over the last decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In view of this observation, it has been argued that sequential use of active single agents might be preferable to initial combination chemotherapy. This approach could conceivably reduce the overall toxicity of therapy while at the same time providing comparable overall survival since patients would eventually be exposed to all active agents.",
"   </p>",
"   <p>",
"    There are three important caveats:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not all drugs have documented single-agent activity. Only fluoropyrimidines,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      have intrinsic antitumor activity, while",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      have little activity by themselves and are best used in combination.",
"      <br/>",
"      <br/>",
"      Thus, any treatment sequence starting with oxaliplatin must be based on a combination such as FOLFOX (oxaliplatin plus short-term infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ). On the other hand, it could be argued that fluoropyrimidines and irinotecan could be used sequentially as an alternative to the combination of both agents upfront (eg, FOLFIRI) (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Sequential single agent therapy does not exploit the synergistic potential that has been seen with at least some drug combinations. As an example,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      is superior to cetuximab alone in patients with prior irinotecan-refractory mCRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56#H56\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Cetuximab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When patients are treated with serial single agents, there is always some dropout between first and second-line and especially between second and third-line therapy, due to patient or clinician preference or clinical deterioration that precludes further treatment. Consistently, only approximately 50 to 70 percent of patients starting one regimen for metastatic disease receive subsequent \"next-line\" therapy. Many of these patients will lose the opportunity for exposure to all three active agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of initial combination versus single agent therapy was directly addressed in two European trials (FOCUS and CAIRO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Data from these trials are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H65#H65\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Combination versus sequential single agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     FOCUS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United Kingdom Medical Research Council's FOCUS (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     Fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    , CPT-11: Use and Sequencing) trial, patients were randomly assigned to one of the following groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The control arm (strategy A) received sequential single agent therapy",
"      <span class=\"nowrap\">",
"       (5-FU/LV",
"      </span>",
"      followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      monotherapy at the time of progression).",
"     </li>",
"     <li>",
"      Experimental strategy B was",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      followed by combination chemotherapy (5-FU plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ) at progression.",
"     </li>",
"     <li>",
"      Experimental strategy C was initial combination therapy with either FOLFOX or FOLFIRI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The median overall survival was 13.9 months for strategy A, 15 months for strategy B, and 16.4 months for strategy C. Only the comparison of initial FOLFIRI versus sequential single agent therapy was statistically significant (median survival 16.7 versus 13.9 months). However, the median survival in all groups was lower than expected.",
"   </p>",
"   <p>",
"    The authors concluded that sequential single agent therapy did not compromise overall survival. However, an important finding was that despite a protocol amendment allowing the use of FOLFOX or FOLFIRI as a third-line salvage therapy, only 23 percent of all patients eventually received all three active agents, and the rate was disproportionately higher for patients allocated to strategy C than for strategy A (33 versus 16 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     CAIRO trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Dutch Colorectal Group CAIRO (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     CApecitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     IRinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    ) trial, 820 patients with previously untreated mCRC were randomly assigned to initial capecitabine followed by irinotecan monotherapy and then",
"    <span class=\"nowrap\">",
"     capecitabine/oxaliplatin",
"    </span>",
"    (XELOX, the sequential strategy), versus initial",
"    <span class=\"nowrap\">",
"     capecitabine/irinotecan",
"    </span>",
"    (XELIRI) followed by XELOX (combination strategy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As was seen in the FOCUS trial, the median overall survival was similar for sequential versus initial combination therapy (16.3 versus 17.4 months), although PFS was superior with combination therapy. Only 53 to 62 percent of all patients proceeded to second-line chemotherapy. Rates of grade 3 or 4 diarrhea were significantly higher with XELIRI as compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    alone (22 versus 10 percent), and in this group, 47 percent of the patients did not receive second-line chemotherapy, nearly one-half because of unacceptable toxicity or patient refusal. Excessive toxicity with XELIRI has also been reported by others. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H24#H24\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan plus capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While a survival benefit was not shown in either trial for initial combination therapy, the median survival duration for all groups in both trials was lower than expected. Modern combination therapy consistently achieves median overall survival durations that are 20 months or longer, even without the addition of biologic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/66-69\">",
"     66-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One plausible explanation for these findings is that the likelihood of receiving all active agents (which correlates with overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]) is lower with the sequential single-agent treatment strategy than when patients are treated using a sequence of rationally designed combination therapies. In fact, of those patients who began with monotherapy, only 19 (FOCUS) and 36 percent (CAIRO) eventually received all three drugs; the corresponding percentages for those receiving upfront combination chemotherapy in both trials were 33 and 55 percent. These data support the view that patients who receive first-line combination therapy are more likely to receive all three active agents in the course of their therapy than those who initiate treatment with a single agent.",
"   </p>",
"   <p>",
"    Another explanation is that the populations enrolled in these studies might differ from those in other studies, possibly if clinicians preferentially enrolled poorer-risk patients to these trials, choosing to treat more \"robust\" patients with upfront combination therapy. In fact, 10 percent of the patients enrolled in the FOCUS trial had an ECOG performance status (PS) of 2 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    ), higher than that usually seen in phase III trials of first-line chemotherapy for mCRC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, the available evidence continues to support initial combination chemotherapy for most patients with mCRC, particularly those who have limited liver metastases that might become potentially resectable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial combination therapy is also preferred for patients with nonoperable mCRC, in whom the palliative treatment strategy should aim to maximize the number of patients exposed to all active agents. This is best achieved by using well-established combination doublets (ie, FOLFOX, XELOX, or FOLFIRI) as the chemotherapy backbone, which would then only require one additional step to have all three active agents included in the treatment algorithm (eg, FOLFOX followed by FOLFIRI, or FOLFIRI followed by FOLFOX). This was the treatment model in the Tournigand trial, which still represents one of the longest median survivals (21 months) reported in the prebiologics era [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional support for pursuing the most active regimen first-line was provided in a retrospective analysis of data collected from the US Intergroup 9741 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/72\">",
"     72",
"    </a>",
"    ] The achievement of a complete response (CR) to upfront therapy (which was most likely with FOLFOX rather than IFL or IROX) was an independent predictor of survival. Second-line therapy rarely achieves a CR. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'FOLFOX versus FOLFIRI as first-line therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial three-drug combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach is to use a first-line chemotherapy regimen that contains all three active agents. This approach was pursued in two relatively small randomized trials comparing the Douillard regimen of",
"    <span class=\"nowrap\">",
"     5-FU/LV/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"      irinotecan",
"     </a>",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) versus FOLFOXIRI",
"    <span class=\"nowrap\">",
"     (5-FU/LV,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , and irinotecan, (",
"    <a class=\"graphic graphic_table graphicRef70559 \" href=\"mobipreview.htm?3/32/3599\">",
"     table 3",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/59,69,73\">",
"     59,69,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H41#H41\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Oxaliplatin plus irinotecan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Superiority for FOLFOXIRI was suggested in an Italian trial that randomly assigned 244 patients with previously untreated inoperable mCRC to the Douillard FOLFIRI regimen versus FOLFOXIRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/59,69\">",
"     59,69",
"    </a>",
"    ]. FOLFOXIRI was significantly superior in terms of response rate (the primary endpoint, 66 versus 41 percent), the number of patients able to undergo complete secondary surgical cytoreduction of liver metastases, median PFS, and median overall survival (23.4 versus 16.7 months); five-year survival rates were 15 versus 8 percent.",
"   </p>",
"   <p>",
"    While these data are intriguing, there are several reasons why FOLFOXIRI should not yet be adopted as routine first-line therapy in clinical practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Italian trial was small for a phase III trial, and the primary endpoint was response rate rather than PFS or survival.",
"     </li>",
"     <li>",
"      While FOLFOXIRI-related toxicity appeared manageable, this needs to be confirmed in larger, multinational trials.",
"     </li>",
"     <li>",
"      The control arm in both trials was the Douillard regimen of",
"      <span class=\"nowrap\">",
"       5-FU/LV/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"        irinotecan",
"       </a>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/74\">",
"       74",
"      </a>",
"      ] which utilizes a lower dose of 5-FU than was used in the FOLFOXIRI arm or in the more commonly used FOLFIRI regimen (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/68,75\">",
"       68,75",
"      </a>",
"      ]. Although the limitations of cross-trial comparisons are well known, the median survival in the FOLFIRI arm in a preliminary report of the BICC-C trial (23.1 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/75\">",
"       75",
"      </a>",
"      ] was similar to that reported for FOLFOXIRI in the Falcone trial (22.6 months). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H20#H20\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan plus 5-FU'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      How the addition of biologics such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      affects the activity and toxicity profile of FOLFOXIRI is just being studied [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. A phase III trial comparing bevacizumab plus either FOLFIRINOX or FOLFIRI concluded that FOLFOXIRI plus bevacizumab was associated with significantly higher response rates (65 versus 53 percent) and progression-free survival (median 12.2 versus 9.7 months), but also higher rates of severe neutropenia, diarrhea, stomatitis, and neurotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/76\">",
"       76",
"      </a>",
"      ]. Whether these results are better than can be achieved with FOLFOXIRI without bevacizumab is unclear.",
"     </li>",
"     <li>",
"      Contradictory data from a Hellenic Oncology group trial of 283 patients with previously untreated mCRC that noted no significant benefit for FOLFOXIRI over FOLFIRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/73\">",
"       73",
"      </a>",
"      ]; however, the doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      , and FU in the FOLFOXIRI arm were lower in this trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One possible exception is in the setting of conversion therapy in patients with initially unresectable liver metastases who might become candidates for surgical resection if the response to chemotherapy is sufficient. In the Italian trial described above, the rate of complete secondary resection of liver metastases with FOLFOXIRI versus FOLFIRI was 36 versus 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H43#H43\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'First-line IROX or FOLFOXIRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the vast majority of patients with noncurable mCRC, rationally designed doublet combinations, such as FOLFOX, XELOX, or FOLFIRI, should be considered the standard chemotherapy backbone for first-line palliative therapy. These regimens have well-documented activity and a tolerable toxicity profile. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In view of the very high reported response rates, an aggressive first-line regimen such as FOLFOXIRI could be considered in the setting of conversion therapy in patients with initially unresectable liver metastases who might become candidates for surgical resection if the response to chemotherapy is sufficient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Capecitabine as substitute for infusional 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is an orally active fluoropyrimidine carbamate that is absorbed intact through the intestinal wall and then converted to 5-FU in three sequential enzymatic reactions. The final requisite enzyme, thymidine phosphorylase, is present at consistently higher levels in tumor compared to normal tissue, providing the hypothetical basis for enhanced tumor cell selectivity and better tolerability. It was hoped that daily administration of capecitabine would mimic sustained exposure to continuously infused 5-FU without the need for a central venous access line and ambulatory infusion pump.",
"   </p>",
"   <p>",
"    Two identically designed phase III trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    monotherapy (1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily on days 1 to 14 every 21 days) versus the Mayo Clinic regimen of bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    demonstrating higher response rates but a similar TTP and overall survival with capecitabine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. In both studies, there was less neutropenia, stomatitis, nausea, and alopecia, but a higher rate of hand-foot syndrome and hyperbilirubinemia with capecitabine. No trial has directly compared capecitabine versus infusional 5-FU. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H14#H14\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, the attractiveness of oral dosing and the potential for eliminating the need for a central venous catheter and ambulatory infusion pump led to various trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    in regimens such as FOLFOX and FOLFIRI.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"      Capecitabine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"      oxaliplatin",
"     </a>",
"    </span>",
"    regimens are commonly referred to as XELOX or CAPOX;",
"    <span class=\"nowrap\">",
"     capecitabine/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"      irinotecan",
"     </a>",
"    </span>",
"    combinations are termed XELIRI or CAPIRI. While the actual doses and schedules of these regimens are variable, for the purpose of this overview, the abbreviations",
"    <span class=\"nowrap\">",
"     XELOX/CAPOX",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     XELIRI/CAPIRI",
"    </span>",
"    will be used interchangeably. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H33#H33\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Capecitabine plus oxaliplatin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H24#H24\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan plus capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     XELOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least five randomized phase III trials have directly compared XELOX versus FOLFOX (or other variants of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV)",
"    </span>",
"    for first-line [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/80-83\">",
"     80-83",
"    </a>",
"    ] or second-line [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/84\">",
"     84",
"    </a>",
"    ] chemotherapy in mCRC. None showed that XELOX was inferior to FOLFOX-type regimens in terms of response rate, PFS, or overall survival. However, in nearly all cases, the PFS and overall survival curves for XELOX trailed beneath the curves for FOLFOX. In no case was this effect statistically significant or clinically meaningful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H34#H34\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'First-line XELOX versus FOLFOX'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The single most influential trial addressing the relative benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    as a substitute for short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    is the Roche-sponsored NO16966 trial in which 634 patients were randomly assigned to XELOX versus FOLFOX4 (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) for first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/80\">",
"     80",
"    </a>",
"    ]. An additional 1400 patients were accrued after a protocol amendment added a second randomization to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    versus placebo. In a preliminary report, for the direct comparison of XELOX versus FOLFOX4, there were no relevant differences in PFS (8.0 versus 8.5 months) or overall survival (17.7 versus 18.8 months).",
"   </p>",
"   <p>",
"    Thus, the available evidence supports the view that XELOX can be considered as a noninferior substitute for FOLFOX in the palliative therapy of mCRC. Practicing oncologists should, however, consider the following issues before routinely adopting XELOX as an alternative to FOLFOX:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The appropriate dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      is not well defined, at least for American patients. The commonly applied dosing schedule of capecitabine in European trials (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily, for 14 of every 21 days) when added to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 of a three-week cycle) was unacceptably toxic in the US TREE-1 trial (",
"      <a class=\"graphic graphic_table graphicRef66587 \" href=\"mobipreview.htm?8/53/9053\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/85\">",
"       85",
"      </a>",
"      ]. Reduction of the capecitabine dose in the TREE-2 trial to 850",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily was associated with a markedly improved safety profile. We consider capecitabine 850",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily plus oxaliplatin 130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 of each cycle to represent a standard regimen for American patients (",
"      <a class=\"graphic graphic_table graphicRef61781 \" href=\"mobipreview.htm?13/60/14286\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H34#H34\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'First-line XELOX versus FOLFOX'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There appear to be large regional differences in the tolerance to capecitabine and other fluoropyrimidines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. These differences might in part be based on population-specific pharmacogenomic variability (eg, Asian patients seem to tolerate fluoropyrimidines better than non-Asians [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/86\">",
"       86",
"      </a>",
"      ]). However, lifestyle or dietary differences (eg, folate intake) could also contribute. Regardless, Asian oncologists usually use capecitabine 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily in conjunction with oxaliplatin 130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"     <li>",
"      A central venous access line is often needed for reasons other than infusional 5-FU in patients with mCRC. Because a significant number of patients report local pain when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      is infused via peripheral vein, many centers routinely infuse the drug centrally. Furthermore, recognizing that mCRC is a chronic disease with the need for multiple sequential chemotherapy regimens, many patients will undergo placement of a central venous line at some point in the course of treatment simply because of inadequate peripheral venous access.",
"     </li>",
"     <li>",
"      Reimbursement policies for oral cytotoxics such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      vary greatly between countries and regionally within the US. While the overall cost of therapy may be less [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/88,89\">",
"       88,89",
"      </a>",
"      ], the cost of capecitabine is often borne by the patient, particularly if Medicare-covered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/90\">",
"       90",
"      </a>",
"      ] (in contrast, IV 5-FU is typically covered by the third-party payer). This may influence treatment choice for individual patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     XELIRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;While XELOX may be regarded as a valid substitute for FOLFOX (with the above caveats), the situation is different for combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (XELIRI, CAPIRI) as an alternative to FOLFIRI (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ). Capecitabine and irinotecan have partially overlapping toxicity profiles, particularly with regard to diarrhea. The potential for greater toxicity reduces the therapeutic advantage of an",
"    <span class=\"nowrap\">",
"     irinotecan/capecitabine",
"    </span>",
"    combination and makes the selection of appropriate doses and schedules for this combination more crucial than for XELOX. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, the previously noted regional differences in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/86\">",
"     86",
"    </a>",
"    ] make it difficult to translate toxicity and efficacy findings generated in trials conducted outside of the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/65\">",
"     65",
"    </a>",
"    ] into American patients. This problem was particularly apparent in the phase III BICC-C trial which compared three different approaches to combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    with a fluoropyrimidine (infusional 5-FU [FOLFIRI], bolus 5-FU [modified IFL]), or capecitabine [XELIRI] using the standard European doses of irinotecan (250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) and capecitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily, on days 1 to 14 of every three-week cycle) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/75\">",
"     75",
"    </a>",
"    ]. No prespecified dose reduction for irinotecan and capecitabine for elderly patients (as suggested by other authors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/91\">",
"     91",
"    </a>",
"    ]) was implemented in the trials.",
"   </p>",
"   <p>",
"    FOLFIRI emerged as the undisputed winner of the head-to-head comparison of all three regimens in terms of efficacy and tolerability. On the other hand, XELIRI was similarly efficacious as modified IFL, but was associated with a high rate of grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    adverse events, in particular, diarrhea (48 percent), nausea (18 percent), vomiting (16 percent), and dehydration (19 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H24#H24\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan plus capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these issues, XELIRI cannot be routinely recommended, at least for American patients, and this regimen should not be regarded as a valid substitute for FOLFIRI. The question of whether dose reductions of both drugs can make XELIRI more tolerable, and perhaps more effective, will have to be explored in future clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     FOLFOX versus FOLFIRI as first-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of FOLFOX was initially established in the pivotal North Central Cancer Treatment Group",
"    <span class=\"nowrap\">",
"     (NCCTG)/US",
"    </span>",
"    Intergroup trial N9741, which compared IFL (weekly bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    for four of every six weeks) to the FOLFOX4 (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) regimen and to a combination of irinotecan plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    without 5-FU (IROX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/67\">",
"     67",
"    </a>",
"    ]. All efficacy parameters as well as the toxicity profile favored FOLFOX4 over IFL.",
"   </p>",
"   <p>",
"    The significant survival advantage of FOLFOX4 (19.5 versus 15 months) was initially thought to be related to the fact that patients in the FOLFOX arm were able to receive effective",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -salvage therapy, whereas most patients in the IFL arm did not receive salvage therapy because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    was not approved at the time. However, the objective response rate (45 versus 31 percent) and TTP (8.7 versus 6.9 months) also clearly favored FOLFOX4. Furthermore, a later analysis of a separate cohort of patients on this trial who received a modified, dose-reduced IFL regimen (rIFL) again demonstrated the superiority of FOLFOX4 over rIFL, despite no discrepancies in exposure to all three active agents between the groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Largely based upon these results, FOLFOX, in particular modified FOLFOX6, in which the entire 5-FU dose is given over 46 hours without a day 2 bolus dose of LV (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 6",
"    </a>",
"    ), has become the most commonly used first-line chemotherapy backbone for mCRC in the US.",
"   </p>",
"   <p>",
"    In contrast to bolus IFL, regimens that incorporate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus short-term infusional rather than bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (ie, the FOLFIRI regimen) (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) appear to be at least as effective as the FOLFOX regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III trial of 220 patients compared FOLFOX6 versus FOLFIRI; both groups were allowed crossover at progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/68\">",
"       68",
"      </a>",
"      ]. There were no differences in pertinent efficacy parameters (response rate, PFS, and overall survival, approximately 21 months in both groups).",
"     </li>",
"     <li>",
"      A phase III study of 336 patients randomized to FOLFOX4 versus FOLFIRI confirmed these findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, FOLFOX and FOLFIRI are both considered acceptable choices for first-line therapy, while the now obsolete IFL regimen should not be used. Results from these trials are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H31#H31\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Oxaliplatin/FU/LV versus irinotecan/FU/LV'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Treatment-related toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In practice, the choice between first-line FOLFIRI or FOLFOX is often based upon expected treatment-related toxicity. The main adverse events reported with FOLFIRI-type regimens are diarrhea, alopecia, and a moderate incidence of grade 3 or 4 neutropenia. In general, toxicity is not cumulative and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    can usually be continued until disease progression. Irinotecan is metabolized by the liver, and reduced doses are needed in the setting of hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H40#H40\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Irinotecan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    is less likely to cause diarrhea and alopecia. In conjunction with bolus 5-FU, neutropenia rates are relatively high, although febrile neutropenia is rare. Severe myelosuppression can be largely avoided if a non-bolus 5-FU containing regimen is used (eg, modified FOLFOX7, of which there are two versions) (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/95,96\">",
"     95,96",
"    </a>",
"    ] or XELOX. Oxaliplatin is safe in patients with hepatic or renal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose-limiting side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is a cumulative, late-onset predominantly sensory neuropathy which may require drug discontinuation despite ongoing tumor response. It occurs with increasing frequency above cumulative doses of 680",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/99\">",
"     99",
"    </a>",
"    ]. Patients with preexisting neuropathy and those for whom the development of a severe sensory neuropathy might jeopardize their livelihood (eg, a professional musician) might be better served with initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based rather than oxaliplatin-based therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link&amp;anchor=H15#H15\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    -free intervals as a means of reducing or delaying neuropathy are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     REDUCING DRUG TOXICITY WITH CHEMOTHERAPY HOLIDAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and the therapeutic monoclonal antibodies",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , 5-FU based chemotherapy was generally continued until unacceptable toxicity or disease progression. In clinical practice this meant that after about four to six months (the median time to tumor progression [TTP] with",
"    <span class=\"nowrap\">",
"     5-FU/LV),",
"    </span>",
"    supportive care was instituted and the patient routinely died within one year of starting treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This treatment paradigm can still be found in most ongoing study protocols for first-line treatment of mCRC. However, the introduction of new agents into the treatment of mCRC has changed the treatment \"landscape\" in a number of ways, leading many to question whether the paradigm of continuous therapy to disease progression is still applicable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metastatic CRC is now regarded as a chemosensitive, chronic rather than acute disease; patients with inoperable stage IV disease now routinely live longer than two years.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       Oxaliplatin",
"      </a>",
"      (cumulative sensory neuropathy) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      (diarrhea) are both associated with distinctive adverse events which may adversely impact quality of life (QOL) during treatment. Both of these adverse effects are reversible upon treatment discontinuation, permitting many patients (although not all) to recover from drug-related toxicity and regain some of their QOL.",
"      <br/>",
"      <br/>",
"      In some cases, particularly with oxaliplatin-based therapy, patients must discontinue treatment prematurely because of treatment-limiting neurologic or hematologic toxicity, despite an ongoing tumor response. Consistently, more than 50 percent of patients receiving FOLFOX (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ) discontinue treatment for reasons other than disease progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/64,79\">",
"       64,79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations have led to the concept of chemotherapy \"holidays\", which have the potential to reduce treatment-related side effects, improve QOL as well as convenience for patients, and reduce the financial burden of continuous therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the context of modern combination chemotherapy, a \"drug holiday\" can be defined as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete treatment-free interval with discontinuation of all medical therapy (chemotherapy and biologics)",
"     </li>",
"     <li>",
"      Discontinuation of certain components of the medical regimen (eg, agents like",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      that are associated with cumulative but reversible toxicities), with continuation of some form of \"maintenance therapy\" with or without biologics",
"     </li>",
"     <li>",
"      Discontinuation of all conventional cytotoxic agents but continuation of biologic agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these strategies have been the subject of clinical trials.",
"   </p>",
"   <p>",
"    Another point of variability in testing these treatment strategies has to do with the actual timing of the \"drug holiday\". A treatment stop can occur:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      After a predefined number of cycles",
"     </li>",
"     <li>",
"      When \"best response\" is achieved",
"     </li>",
"     <li>",
"      When long-lasting (eg, &gt;12 months) stable disease is documented",
"     </li>",
"     <li>",
"      When a certain toxicity threshold has been reached",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other side, reinitiation or re-intensification of therapy can be planned either after a pre-defined interval or when clinically relevant tumor progression has been noted. The best management in most of these clinical circumstances is still unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9660072\">",
"    <span class=\"h2\">",
"     Oxaliplatin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, FOLFOX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef62939 \" href=\"mobipreview.htm?30/6/30830\">",
"     table 7",
"    </a>",
"    ) has emerged as the most commonly used first-line therapy for mCRC. Accumulating data support the view that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -related toxicity, particularly neurotoxicity, limits the amount of effective therapy that can be administered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link&amp;anchor=H17#H17\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Cumulative sensory neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, regimens that incorporate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    are characterized by a time to treatment failure (TTF, largely synonymous with the discontinuation of oxaliplatin) of about six months whereas the TTP is approximately three months longer. As an example, in the pivotal trial which established the superiority of FOLFOX over bolus IFL (N9741), 63 percent of patients discontinued oxaliplatin for reasons other than progressive disease, the median TTF was 5.8 months, and the median TTP (mostly because of continued",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    without oxaliplatin) was 9.3 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether long-term neurotoxicity can by mitigated by intermittent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -free intervals has been addressed in multiple randomized trials. The design and results of these trials are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911634#H183911634\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Taken together, the results suggest that in responding patients, a full break in therapy is associated with shorter duration of PFS, and it is not routinely recommended. If a treatment break is negotiated in patients without a complete clinical response because of toxicity or patient preference, close follow-up with tumor assessment at two month intervals and early chemotherapy resumption at the first sign of progression is recommended. If a clinical complete response is achieved, a complete break in therapy is reasonable since at least some data suggest that continued treatment beyond two cycles after confirmation of the complete response is not associated with better survival than watchful observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, when FOLFOX with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is used for first-line therapy, the available data suggest that it is reasonable to discontinue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    temporarily while maintaining infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    plus bevacizumab. Treatment continuation is also an option if the patient is responding to therapy and there is no evidence of neuropathy.",
"   </p>",
"   <p>",
"    Another maneuver that may delay or mitigate cumulative (but not acute)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    neurotoxicity is supplemental infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    (1 gram) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    (1 gram) pre- and post-oxaliplatin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link&amp;anchor=H23#H23\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Pharmacologic approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the incidence of severe (grade 2 and 3) neurotoxicity increases above a cumulative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -dose of 680",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/99\">",
"     99",
"    </a>",
"    ], clinicians should be particularly vigilant about assessing sensory neuropathy after four months of therapy with a FOLFOX regimen containing 85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    oxaliplatin every two weeks (or three months of a regimen such as mFOLFOX7, which contains 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two weeks) (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ). Some patients can receive multiple months or even years of oxaliplatin-based therapy without the development of neuropathy, and this suggests the need for individualized decision-making on the duration of oxaliplatin.",
"   </p>",
"   <p>",
"    There are many unanswered questions including whether six to eight courses of an initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen are sufficient to achieve the full clinical benefits of oxaliplatin, the optimal type of maintenance therapy (particularly whether there is benefit to continuing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    with the",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    backbone in patients treated initially with FOLFOX), and the timing of oxaliplatin reintroduction. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911634#H183911634\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Irinotecan-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;While intermittent treatment approaches appear to be almost mandatory for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    because of cumulative neurotoxicity, the advantage of intermittent treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based regimens is unclear. An Italian trial demonstrated that patients started on FOLFIRI as first-line therapy had similar overall outcome (PFS and overall survival) whether or not the regimen was administered continuously until progression or toxicity, or in \"two months",
"    <span class=\"nowrap\">",
"     on/two",
"    </span>",
"    months off\" intervals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911627#H183911627\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Continuous versus intermittent'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data support the following conclusions regarding the optimal duration of initial (first-line) chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving FOLFOX chemotherapy with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , a full break in therapy after six to eight cycles is not routinely recommended because of the possibility of inferior cancer outcomes, but can be considered on a case-by-case basis if there is a good response to therapy and residual disease is neither symptomatic nor threatening to cause major organ dysfunction (eg, liver failure, bowel obstruction). If a treatment break is negotiated because of toxicity or patient preference, close follow-up with tumor assessment at two month intervals and early resumption of chemotherapy at the first sign of progression is recommended.",
"     </li>",
"     <li>",
"      On the other hand, when FOLFOX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      is being used for first-line therapy, the available data suggest that it is reasonable to discontinue the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      before the onset of severe neurotoxicity (after three to four months of therapy) while maintaining infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      plus bevacizumab and reintroducing oxaliplatin at the time of disease progression.",
"     </li>",
"     <li>",
"      For patients receiving FOLFIRI, the value of a drug holiday has been less well studied. However, the available data suggest that intermittent therapy does not compromise outcomes, although it does not necessarily improve treatment tolerability.",
"     </li>",
"     <li>",
"      Until more data are available, continuous therapy is an acceptable option for responding patients with metastatic colorectal cancer, particularly if chemotherapy is well tolerated and if disease is aggressive",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bulky. For patients who achieve a complete response (CR) to chemotherapy, at least some data support the view that continued treatment beyond two cycles after confirmation of the CR is not associated with better survival than watchful observation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56910059\">",
"    <span class=\"h1\">",
"     AGENTS TARGETING VEGF",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a humanized monoclonal antibody that targets vascular endothelial growth factor-A (VEGF-A), a member of a family of VEGF-receptor-activating ligands. CRC was the first malignancy for which clear evidence for efficacy of an anti-VEGF strategy was obtained in randomized trials. In a pivotal early trial, the addition of bevacizumab to the bolus IFL regimen significantly improved response rates (45 versus 35 percent), TTP (11 versus 6 months), and overall survival (20 versus 16 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/101\">",
"     101",
"    </a>",
"    ]. Since then, benefit for adding bevacizumab to a variety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing regimens used for first-line [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/75,85,102-104\">",
"     75,85,102-104",
"    </a>",
"    ] and second-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/105\">",
"     105",
"    </a>",
"    ] has been confirmed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H44#H44\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Agents targeting VEGF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediately following the approval of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in the US in 2004, FOLFOX plus bevacizumab (",
"    <a class=\"graphic graphic_table graphicRef62939 \" href=\"mobipreview.htm?30/6/30830\">",
"     table 7",
"    </a>",
"    ) emerged as the most commonly used combination regimen for palliative front-line therapy of mCRC despite the absence of phase II or phase III data confirming the superiority of this regimen over any other. This development was promoted by the relatively open FDA labeling which allowed bevacizumab to be used \"as part of first-line therapy in combination with an IV 5-FU-based regimen\", which, by definition, included FOLFOX.",
"   </p>",
"   <p>",
"    The significant difference in outcome favoring FOLFOX over bolus IFL reported shortly thereafter in the US Intergroup N9741 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/67\">",
"     67",
"    </a>",
"    ] led many oncologists to choose FOLFOX as the chemotherapy backbone for the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , despite the lack of clinical trial results on this combination. To date, there are still only limited data on the benefit of adding bevacizumab to an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen and no published trials for first-line therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H46#H46\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Oxaliplatin regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, since 2004, the majority of patients with mCRC in the US have received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    as a component of first-line therapy regardless of the specific regimen chosen for the chemotherapy backbone (FOLFOX, FOLFIRI,",
"    <span class=\"nowrap\">",
"     5-FU/LV).",
"    </span>",
"    The situation differs in other parts of the world where fewer than 50 percent of patients are treated with bevacizumab first-line, conceivably due, in part, to different reimbursement policies. Bevacizumab is expensive and associated with a number of potentially serious side effects, including proteinuria, hypertension, bleeding, bowel perforation, impaired wound healing, arterial (but not venous) thromboembolic events (such as transient ischemic attack, stroke, angina, myocardial infarction), and reversible posterior multifocal leucoencephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H50#H50\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H34#H34\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'VEGF pathway inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=see_link\">",
"     \"Overview of angiogenesis inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These issues have prompted debate as to whether there is enough evidence to justify the routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    as a component of first-line chemotherapy in patients with inoperable metastatic CRC, whether there are subgroups of patients for whom the benefit of bevacizumab does not outweigh its risks, and whether there are patients who should not receive bevacizumab at all.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Should all patients receive first-line bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;When added to cytotoxic 5-FU-based chemotherapy for mCRC,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    routinely improves outcomes, regardless of the specific chemotherapy backbone that is chosen. However, in some trials, bevacizumab appears to provide greater incremental gain in PFS when it is added to \"weaker\" chemotherapy regimens such as",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    or bolus IFL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/101,103\">",
"     101,103",
"    </a>",
"    ] than to more active regimens such as FOLFOX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/102\">",
"     102",
"    </a>",
"    ]. However, the NO16966 trial, which in a preliminary report noted only a marginal increase in PFS when bevacizumab was added to an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based first-line regimen (XELOX or FOLFOX4) was somewhat flawed by the discontinuation of chemotherapy before evidence of tumor progression in a substantial number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/102\">",
"     102",
"    </a>",
"    ]. Other data (although not derived from randomized trials evaluating oxaliplatin-based chemotherapy with or without bevacizumab) suggest a similar magnitude of benefit when bevacizumab is added to oxaliplatin-based as compared to nonoxaliplatin-based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H46#H46\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Oxaliplatin regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    also appears to provide a survival benefit even in the absence of an objective response to therapy. In the pivotal trial of IFL with or without bevacizumab, the gain from adding bevacizumab on PFS and overall survival was more profound than the impact on response rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/101\">",
"     101",
"    </a>",
"    ]. Further analysis showed that patients who were classified as \"nonresponders\" according to RECIST criteria (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 8",
"    </a>",
"    ) benefited as much from the addition of bevacizumab as did those who had an objective response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/106\">",
"     106",
"    </a>",
"    ]. This is a phenomenon which is not unique to bevacizumab, and it serves to underscore the relative lack of importance of objective response rate as a predictor of treatment benefit in patients undergoing palliative treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H9654617#H9654617\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Treatment goals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h4\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients have upfront contraindications to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    therapy, although these are not well defined. According to the product labeling, bevacizumab is contraindicated in the setting of recent hemoptysis of &gt;2.5 mL (although this applies mainly to patients with non-small cell lung cancer), major surgery within 28 days of treatment (and only following complete healing of the incision) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/107\">",
"     107",
"    </a>",
"    ]. The use of bevacizumab in patients with brain metastases is controversial (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29868651\">",
"    <span class=\"h5\">",
"     Arterial thromboembolic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major issue is whether to withhold",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    from elderly patients who have a history of an arterial thromboembolic event (ATE) within the past 6 to 12 months. Bevacizumab increases the risk of an ATE. In one meta-analysis, the risk appeared to be higher in those over the age of 65, and in those with a prior history of an ATE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/108\">",
"     108",
"    </a>",
"    ]. On the other hand, a pooled age subgroup analysis from two prospective trials of 5-FU-based chemotherapy with and without bevacizumab failed to show that the higher incidence of arterial thromboembolic events in patients receiving bevacizumab was of a greater magnitude in patients 65 and older as compared to younger individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, most clinicians consider that prior ATE within the last 6 to 12 months represents a relative contraindication to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , particularly in elderly patients. However, the decision as to whether to withhold bevacizumab in elderly patients with a history of prior ATE (stroke, myocardial infarction) must take into account the potential harm from less effective antitumor therapy. These patients have been routinely excluded from clinical trials testing the value of bevacizumab. However, there is no evidence that patients at highest risk for bevacizumab-related ATEs derive less benefit from the drug. In an exploratory analysis of the pivotal IFL bevacizumab trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/101\">",
"     101",
"    </a>",
"    ], the patient subgroup with both risk factors for ATEs gained a similar degree of benefit from bevacizumab as did the rest of the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other antiplatelet therapy can reduce the risk of ATEs in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is unclear; at least some data suggest that the use of aspirin does not increase the risk of bleeding during bevacizumab therapy. We tend to avoid bevacizumab in elderly patients with a history of an ATE within six months and consider the use of aspirin in other high-risk patients. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H291526440#H291526440\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Arterial thromboembolic events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29868658\">",
"    <span class=\"h5\">",
"     Wound healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    impairs wound healing. This fact, plus the relatively long half-life of bevacizumab (20 days) has prompted the general recommendation that elective surgical intervention (eg, liver resection) be deferred for at least 28 days (and preferably for six to eight weeks) after the last dose of the drug. Minor surgery (ie, the need for a central venous access catheter) can safely be performed in patients receiving bevacizumab, but at least two weeks should elapse before additional doses of the drug are administered. In the case of surgical emergencies (eg, bowel perforations), bevacizumab treatment should",
"    <strong>",
"     not",
"    </strong>",
"    be considered an absolute contraindication to surgery. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227437#H1651227437\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29868665\">",
"    <span class=\"h5\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two distinct patters of bleeding in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    : the most common is mild epistaxis, which affects about one-third of patients. The second is rare but serious (potentially fatal) hemorrhagic events including hemoptysis, gastrointestinal bleeding, hematemesis, intracerebral hemorrhage, epistaxis, and vaginal bleeding. Bevacizumab is contraindicated if there is a recent history of significant hemoptysis. An increased risk of pulmonary hemorrhage has not been described in patients with pulmonary metastases of non-lung primaries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227385#H1651227385\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bevacizumab and aflibercept'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    Concerns have been raised about a potential increase in the risk of intracerebral hemorrhage (ICH) in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    &nbsp;who have brain metastases. However, the available data suggest that patients with a history of treated nonhemorrhagic brain metastases probably should not be excluded from systemic therapy with bevacizumab as long as they are not on concurrent anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227407#H1651227407\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intracranial bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h4\">",
"     Drug discontinuation during treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    should be discontinued permanently in patients who develop severe adverse events during treatment, including gastrointestinal perforation (fistula formation, intraabdominal abscess), an arterial thromboembolic event, wound dehiscence requiring medical intervention, nephrotic syndrome, hypertensive crisis or encephalopathy, or a posterior leukoencephalopathy syndrome. The subject of bevacizumab side effects is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of validated predictive factors for treatment benefit, the default position in the palliative management of mCRC (intentionally neglecting financial considerations) is to add",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to the chemotherapy backbone chosen for the individual patient.",
"   </p>",
"   <p>",
"    For those who are at high risk for serious toxicity, in particular arterial thromboembolic events, where benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has to be balanced against a perceived risk for potentially life-threatening adverse events, a non-bevacizumab containing first-line regimen such as FOLFOX or FOLFIRI with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    may be preferred. The decision must be individualized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Continuation of bevacizumab beyond progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of continuing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    beyond progression on a first-line bevacizumab-containing regimen has been shown in several registry-based retrospective analyses, and in a preliminary report of a European trial (the TML study), which was presented at the 2012 meeting of the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/110\">",
"     110",
"    </a>",
"    ]. In the TML study, continuation of bevacizumab with a second line fluoropyrimidine-based chemotherapy regimen was associated with a significant improvement in overall survival (median 11.2 versus 9.8 months) without an increase in bevacizumab-related adverse events. This degree of benefit was more measured than the registry data had suggested. Nevertheless, as a result of these data, for patients treated with a first-line bevacizumab-containing chemotherapy regimen, the use of bevacizumab beyond progression in conjunction with a second-line fluoropyrimidine-based chemotherapy regimen can be considered a standard approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H48#H48\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Second-line bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is used as a component of the second-line chemotherapy regimen for patients with K-ras wild type disease, it should not be administered concurrently with an EGFR-targeting monoclonal antibody. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Dual antibody therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56909840\">",
"    <span class=\"h2\">",
"     Aflibercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    (VEGF Trap, Zaltrap) is a recombinant fusion protein, consisting of VEGF binding portions from key domains of human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1. It acts as a soluble &ldquo;decoy&rdquo; receptor that binds to human VEGF-A, VEGF-B, and placental growth factor (PIGF), thereby inhibiting the binding of these ligands and activation of their respective receptors.",
"    <br/>",
"    <br/>",
"    Aflibercept is approved in the United States for use in combination with FOLFIRI for the treatment of patients with mCRC that is resistant to or has progressed following an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing regimen. Approval was based on the placebo-controlled VELOUR trial, in which 1226 patients with oxaliplatin-refractory mCRC were randomly assigned to aflibercept (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) or placebo, plus FOLFIRI, every two weeks until progression. Median overall survival was significantly longer in patients treated with aflibercept (13.5 versus 12.1 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/111\">",
"     111",
"    </a>",
"    ]. Benefit and safety were similar regardless of prior",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H23212877#H23212877\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Aflibercept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the side effect profile of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    plus FOLFIRI in the VELOUR trial was consistent with other agents targeting VEGF (bleeding, hypertension, proteinuria, wound infection, arterial thromboembolic events), rates of diarrhea, mucositis, complicated neutropenia, infection, and fatigue associated with aflibercept in this trial were higher than usually seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , as were rates of treatment discontinuation for toxicity or refusal (30 versus 12 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Particularly given the data on benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    after progression on a first-line bevacizumab-containing regimen, whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    plus second-line FOLFIRI is the preferred approach after progression on first-line FOLFOX plus bevacizumab is unclear. In our view, FOLFIRI plus aflibercept is an alternative to FOLFIRI with bevacizumab (or FOLFIRI alone) in this setting, but may be more toxic and more costly. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Continuation of bevacizumab beyond progression'",
"    </a>",
"    above.) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , because of the risk of impaired wound healing, at least 28 days (and preferably six to eight weeks) should elapse between major surgery and administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , except in emergency situations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227429#H1651227429\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Delayed wound healing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4893926\">",
"    <span class=\"h2\">",
"     Regorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     Regorafenib",
"    </a>",
"    is an orally active inhibitor of angiogenic tyrosine kinases (including the VEGF receptors 1 to 3), as well as other receptor and intracellular kinases. Regorafenib is approved in the United States for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based chemotherapy, an anti-VEGF agent, and, if K-ras wild type, an anti-EGFR therapy. Approval was based up the results of the CORRECT trial, which compared best supportive care plus regorafenib (160 mg orally once daily for three of every four weeks) or placebo in 760 patients with chemotherapy refractory disease, and demonstrated a significant survival benefit for regorafenib (median 6.4 versus 5 months), albeit with little objective antitumor response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56909045#H56909045\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Regorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CETUXIMAB AND PANITUMUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both of the therapeutic monoclonal antibodies (MoAbs) that target the epidermal growth factor receptor (EGFR) have well documented, and in cross-trial comparisons, comparable single agent activity in patients with mCRC that is refractory to both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/113,114\">",
"     113,114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Predictive markers for response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Particularly in view of their expense, a means of identifying which patients stand to benefit from treatment strategies that target the EGFR could permit more individualized, tailored therapy. Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    are only effective in the subset of patients whose tumors have wild type and not mutated K-ras (approximately 40 percent of all mCRCs). A Provisional Clinical Opinion issued by the American Society of Clinical Oncology (ASCO) recommends that all patients being considered for anti-EGFR therapy undergo K-ras mutation testing of their tumors and that treatment with these agents be restricted to those whose tumors lack K-ras mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Whether all mutations in K-ras predict resistance to EGFR-targeted therapies is unknown. Prospective randomized trials are needed before conclusions can be made about the potential for benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in subgroups of patients with certain K-ras mutations. (See",
"    <a class=\"local\" href=\"#H21096055\">",
"     'K-ras'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cetuximab or panitumumab as a component of initial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    added to first-line or second-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -containing therapy has been addressed in two trials: the CRYSTAL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/12,44\">",
"     12,44",
"    </a>",
"    ] and OPUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/115\">",
"     115",
"    </a>",
"    ] trials.",
"   </p>",
"   <p>",
"    In the CRYSTAL trial, 1198 patients were randomly assigned to first-line FOLFIRI with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/12\">",
"     12",
"    </a>",
"    ]. Among patients with wild type K-ras, the benefits of cetuximab included a significantly better overall survival (median 23.5 versus 20 months), PFS (9.9 versus 8.4 months), and response rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/44\">",
"     44",
"    </a>",
"    ], and significantly more patients being candidates for a potentially curative (margin-negative) metastasectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56#H56\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Cetuximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based in large part on these data, FDA approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    for use in combination with FOLFIRI (",
"    <a class=\"graphic graphic_table graphicRef62726 \" href=\"mobipreview.htm?1/39/1663\">",
"     table 9",
"    </a>",
"    ) for first-line treatment of patients with K-ras mutation-negative EGFR-expressing mCRC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in conjunction with a first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    regimen is less certain; the data are mixed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H59#H59\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Plus oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The OPUS trial showed that among patients with K-ras wild type tumors, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      to FOLFOX4 significantly improved response rate (61 versus 37 percent) and median PFS although the magnitude of the difference was small (median 7.7 versus 7.2 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, the United Kingdom MRC COIN trial and a preliminary report of the NORDIC VII trial failed to show any benefit from the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      in patients with K-ras-WT tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/116,117\">",
"       116,117",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Panitumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    to first-line FOLFOX4 was shown in the PRIME trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/118\">",
"     118",
"    </a>",
"    ]. Among patients with wild type K-ras (n = 656), the addition of panitumumab to FOLFOX significantly improved both response rate (55 versus 48 percent) and median PFS (9.6 versus 8 months). Survival was impaired in patients with K-ras",
"    <strong>",
"     mutant",
"    </strong>",
"    mCRC who were treated with panitumumab plus combination chemotherapy, a finding that has been noted in other trials testing the addition of panitumumab (and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing chemotherapy. &nbsp;",
"   </p>",
"   <p>",
"    Nevertheless, these results, as well as other data indicating impaired survival and enhanced toxicity when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    was added to chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , led to a change in the FDA-approved manufacturer&rsquo;s product labeling in September 2012 that panitumumab was",
"    <strong>",
"     not",
"    </strong>",
"    <strong>",
"     indicated",
"    </strong>",
"    for use in combination with any form of chemotherapy. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Dual antibody therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We disagree with this viewpoint. The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in combination with FOLFOX is a reasonable alternative first-line regimen in patients with K-ras wild type tumors. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    (NCCN) and the European Society of Medical Oncology (ESMO) also support the use of panitumumab in combination with FOLFOX as an option for first-line therapy in patients with K-ras wild type disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/119\">",
"     119",
"    </a>",
"    ]. We avoid combining either cetuximab or panitumumab with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing regimen, a policy that is also supported by the NCCN guidelines. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H16555527#H16555527\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Panitumumab combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether these results serve to establish an EGFR targeted monoclonal antibody as a component of front-line therapy for K-ras wild type mCRC is unclear. The US Intergroup trial C80405 randomizes patients with K-ras wild type tumors to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    with either FOLFOX or FOLFIRI. The results of that trial should help to answer that issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following types of patients could conceivably be considered candidates for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    -based initial therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with symptomatic tumors and a contraindication to the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , the higher response rates associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      in combination with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based regimen, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      in combination with FOLFOX support the use of these first-line combinations for a patient with wild type K-ras tumors. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The consistently higher response rates with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      -containing chemotherapy could also play a role in the choice of conversion therapy in patients who have K-ras wild type tumors, and potentially resectable liver metastases. At least some data suggest that there is a minimal impact on response rates when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      is added to an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/102\">",
"       102",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients receiving either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    should undergo periodic monitoring of serum electrolytes, including magnesium and potassium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H35#H35\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'EGFR pathway inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Should a cetuximab or panitumumab-containing regimen be the default choice for second-line therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have explored the activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    as a component of second-line FOLFIRI after failure of initial FOLFOX; neither included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    as a component of the first-line regimen in all patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the large EPIC (Erbitux Plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       Irinotecan",
"      </a>",
"      in Colorectal cancer) trial, in which 1300 patients with EGFR-expressing, but not KRAS-selected, MCRC who had failed initial FOLFOX therapy were randomly assigned to single-agent irinotecan with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/120\">",
"       120",
"      </a>",
"      ]. The addition of cetuximab quadrupled the response rate (16 versus 4 percent), significantly prolonged PFS (4 versus 2.6 months), and, despite the higher frequency of side effects, was associated with better quality of life.",
"      <br/>",
"      <br/>",
"      Although there was no significant difference in overall survival, the primary endpoint, the high rate of crossover to cetuximab by those in the non-cetuximab-containing arm (50 percent), could have obscured the to ability detect a survival benefit. In fact, when patients who had crossed over were excluded as part of an exploratory analysis, an obvious survival difference emerged favoring combined therapy. Sequential use of cetuximab after irinotecan was not inferior to combining both agents as second-line treatment with regard to overall survival.",
"     </li>",
"     <li>",
"      Similarly, a randomized trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      plus FOLFIRI versus FOLFIRI alone after failure of initial 5-FU-containing chemotherapy (two-thirds prior",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , 20 percent prior",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ) showed that, in the K-ras WT group (n = 597), the addition of panitumumab was associated with a significant improvement in response rate (35 versus 10 percent) and median PFS (5.9 versus 3.9 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results confirm that the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    to an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based chemotherapy regimen after failure of initial 5-FU-containing chemotherapy is associated with greater treatment activity. These observations can be used to guide a decision for or against the use of cetuximab or panitumumab in combination with irinotecan in individual patients. As noted above, the FDA-approved labeling for panitumumab now specifically recommends against the use of panitumumab in combination with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/122\">",
"     122",
"    </a>",
"    ]. However, we disagree with this viewpoint, and consider that the addition of panitumumab to a non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing chemotherapy regimen in patients with K-ras wild type tumors is appropriate, an approach that is also allowed in",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Panitumumab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If rapid tumor growth is observed after first-line,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based therapy, one should consider adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based therapy to elicit higher antitumor activity, particularly because the biology of the disease in these patients might not allow for a step-wise, sequential therapeutic approach. By contrast, in a case of a rather indolent, slowly progressive tumor, sequential use of agents might be preferable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Are cetuximab and panitumumab interchangeable?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no trials directly comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . As noted above, in cross-trial comparisons, cetuximab and panitumumab appear to have comparable efficacy when used for single agents for salvage therapy in patients with chemotherapy-refractory mCRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/113,114\">",
"     113,114",
"    </a>",
"    ], and when used for first-line and second-line therapy of mCRC in conjunction with an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based chemotherapy regimen. For unclear reasons, completed trials to date indicate that panitumumab adds benefit to a first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen, while the data are mixed on the benefit of adding cetuximab to first-line oxaliplatin-based therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H62#H62\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Panitumumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H59#H59\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Plus oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both monoclonal antibodies (MoAbs) target the same antigen (the EGFR), and preclinical data suggest a similar mode of action (interference with ligand binding, downregulation of signaling activity, internalization of receptors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/123\">",
"     123",
"    </a>",
"    ]. From a pharmacologic standpoint, the main difference between both agents lies in their IgG backbones:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    is a chimeric",
"    <span class=\"nowrap\">",
"     mouse/human",
"    </span>",
"    MoAb, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    is a completely human MoAb. As a result, the incidence of hypersensitivity reactions with panitumumab is much lower, and this eliminates the need for routine premedication before therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The difference in on-label dosing schedules (every two weeks for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , weekly for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) are based more on how the respective trials leading to approval by the US Food and Drug Administration were designed than on true pharmacokinetic, pharmacodynamic, or pharmacogenomic differences. The two drugs have similar half-lives (approximately seven days), and pharmacokinetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/124\">",
"     124",
"    </a>",
"    ]. Results from a nonrandomized phase II trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/125\">",
"     125",
"    </a>",
"    ] and a multicenter retrospective analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/126\">",
"     126",
"    </a>",
"    ] suggest that cetuximab at a dose of 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two weeks results in similar plasma concentrations and single-agent activity as does weekly dosing. Results of randomized comparisons of weekly versus every two-week dosing are not yet available.",
"   </p>",
"   <p>",
"    In clinical practice, there is no therapeutic preference for using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    either as monotherapy, or in combination with chemotherapy. However, the lower rate of infusion reactions with panitumumab favors the use of this agent in regions with a high rate of cetuximab-related infusion reactions (eg, middle southeastern region of the United States, including North Carolina, Arkansas, Missouri, Virginia, and Tennessee). As noted above, the FDA-approved labeling for panitumumab now specifically recommends against the use of panitumumab in combination with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/122\">",
"     122",
"    </a>",
"    ]. However, we disagree with this viewpoint, and consider that the addition of panitumumab to a non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing chemotherapy regimen in patients with K-ras wild type tumors is appropriate, an approach that is also allowed in",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H34\">",
"     'Panitumumab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients receiving either drug should undergo periodic monitoring of serum electrolytes, including magnesium and potassium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H35#H35\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'EGFR pathway inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8976328\">",
"    <span class=\"h2\">",
"     Panitumumab after failure of cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    is active in patients who have failed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    therapy (and vice versa) is unclear. The similar mode of action would seem to support the existence of cross resistance, but there are few data that inform this issue.",
"   </p>",
"   <p>",
"    Two clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    in patients progressing on a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    -containing regimen have come to different conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first, presented in abstract form at the 2010 ASCO meeting, 32 patients with K-ras wild type metastatic CRC received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      after progressing on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/127\">",
"       127",
"      </a>",
"      ]. The objective response rate was 22 percent, and the disease control rate (objective response plus stable disease) among the 11 patients who had responded to prior cetuximab was 73 percent.",
"     </li>",
"     <li>",
"      A second trial, also reported in preliminary form only, included 20 patients with K-ras wild type metastatic CRC who had progressed on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/128\">",
"       128",
"      </a>",
"      ]. No patient responded, although 45 percent had stable disease (no progression for at least two cycles). The authors concluded that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      was of minimal benefit in cetuximab-refractory disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A possible explanation for these discrepant results was provided by a study in which investigators used a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    -sensitive human CRC cell line to develop a resistant version by prolonged in vitro exposure to cetuximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/129\">",
"     129",
"    </a>",
"    ]. The cetuximab-resistant cells contained a secondary EGFR mutation in the extracellular domain of the receptor that impaired binding of cetuximab but not other EGFR ligands, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    . This specific mutation was identified in 2 of 10 tumors from people with cetuximab resistance, one of whom received panitumumab and had an objective response.",
"   </p>",
"   <p>",
"    These data might support the view that a small subset of patients with K-ras WT tumors who are resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    will respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , but the best way to identify this subset is unclear. Testing for a specific mutation in the EGFR that might confer cetuximab resistance but panitumumab sensitivity is currently only available in research labs. It is also not known if this is the only mechanism that defines differential sensitivity. In addition, the duration of benefit that these patients might achieve is unknown. Given the evidence that the majority of patients who have been evaluated in a trial setting do not achieve durable benefit, the use of panitumumab in patients who progress on cetuximab should be done in the context of a clinical trial aimed at better defining this question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Dual antibody therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the phase II BOND-2 trial which compared a combination of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"      cetuximab",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"      bevacizumab",
"     </a>",
"    </span>",
"    with (CBI) or without (CB)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    as last-line therapy in patients with chemorefractory mCRC generated interest in dual-antibody combinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/130\">",
"     130",
"    </a>",
"    ]. BOND-2 reported unprecedented outcome results for patients previously treated with 5-FU, irinotecan, and (in 85 to 90 percent of cases)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    with regard to response rate (20 versus 37 for CB and CBI, respectively), time to tumor progression (TTP, 4.9 versus 7.3 months), and overall survival (11.4 versus 14.5 months). The toxicity profile was also tolerable.",
"   </p>",
"   <p>",
"    The following issues must be considered when interpreting these results and their implications for clinical practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BOND-2 was a small randomized phase II trial of 83 patients treated in a few highly specialized cancer centers, thus limiting the extrapolation of the findings to the unselected patient population treated by community oncologists.",
"     </li>",
"     <li>",
"      The unexpectedly long median overall survival in both treatment arms underscores the highly select nature of the patient population enrolled to the study.",
"     </li>",
"     <li>",
"      Patients who were considered candidates for the trial had already received (and apparently tolerated) several lines of therapy and still maintained a good enough performance status (0 to 1) (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 2",
"      </a>",
"      ) to be enrolled in the trial. This again underscores the fact that the patients enrolled on BOND-2 were highly selected and clearly not representative of the typical patient population with refractory mCRC.",
"      <br/>",
"      <br/>",
"      This issue might in part explain the unexpected results of both the PACCE and the CAIRO2 trials, both of which suggested a possible detrimental impact of concurrent use dual antibodies targeting VEGF and the EGFR in the setting of first-line therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/131,132\">",
"       131,132",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H64#H64\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Dual antibody therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients on BOND-2 were all",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      -naive so that the data cannot necessarily be used to justify therapy with dual antibodies in patients who have already received bevacizumab as part of their prior palliative medical therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data, a chemotherapy regimen containing both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and an anti-EGFR MoAb should not be considered a standard approach for first- or second-line therapy of mCRC outside of a clinical trial.",
"   </p>",
"   <p>",
"    This approach is being studied for second-line therapy in SWOG S0600 (second-line) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/133\">",
"     133",
"    </a>",
"    ]; eligible patients are encouraged to enroll. If trial enrollment is not feasible, or the patient is not eligible, we consider",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    (with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ) along the design of BOND-2 as a valid option for such patients. However, due to the limited data supporting this approach, it is not universally accepted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Management of skin toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;This subject, as well as the use of prophylactic systemic antibiotics in patients receiving EGFR-targeted therapy, is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=see_link\">",
"     \"Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with metastatic colorectal cancer (mCRC) cannot be cured and the intent of therapy is palliative. A subset of patients with liver, and in select cases, lung-limited disease can undergo resection of metastases with curative intent. Initial (\"conversion\") chemotherapy may increase the number of patients with metastases who are eligible for resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although long-term prognosis is poor for patients with unresectable mCRC, palliative chemotherapy can relieve symptoms, improve quality of life (QOL), and prolong survival. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Active drugs include the fluoropyrimidines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and the therapeutic monoclonal antibodies",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    . The optimal way to combine and sequence these agents is not yet established. In general, exposure to all active drugs is more important than the specific sequence of administration. Assay of tumor K-ras mutation status permits the selection of individuals who might benefit from strategies targeting the epidermal growth factor receptor (EGFR). Unfortunately, there are no accepted biologic or molecular markers of responsiveness to bevacizumab or to conventional cytotoxics, although these are active areas of research. (See",
"    <a class=\"local\" href=\"#H6686747\">",
"     'Predictive markers for response'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following represents our general approach for patients with nonoperable mCRC. Recommendations from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    are summarized in the tables (",
"    <a class=\"graphic graphic_table graphicRef80572 \" href=\"mobipreview.htm?3/8/3213\">",
"     table 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80554 \" href=\"mobipreview.htm?9/37/9819\">",
"     table 11",
"    </a>",
"    ). Specific recommendations for patients with isolated hepatic metastases are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     The chemotherapy backbone",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are able to tolerate it, we suggest a chemotherapy doublet (FOLFOX, XELOX, or FOLFIRI) (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ) rather than a single agent or a triplet regimen containing both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Initial doublet combinations versus sequential single agent chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      FOLFOX and FOLFIRI have similar first-line efficacy, and the decision to use one or the other should mainly be based on the expected toxicity profile of both regimens. Most American clinicians start with FOLFOX. Although less widely used, at least in the US, FOLFIRI may be preferred in patients with a preexisting neuropathy, or if the development of a severe sensory neuropathy might jeopardize their livelihood (eg, in a professional musician). Updated guidelines from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      suggest the use of FOLFIRI with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      (if K-ras WT) for patients who have unresectable disease, and who received adjuvant FOLFOX in the previous 12 months. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment-related toxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'FOLFOX versus FOLFIRI as first-line therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      While FOLFOX4 was the regimen used in the palliative and adjuvant registration trials, many American oncologists use a modification of FOLFOX6 (mFOLFOX6) because it does not require a day 2 bolus of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (LV) (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"       table 6",
"      </a>",
"      ). We prefer modified FOLFOX7 (mFOLFOX7), which eliminates bolus 5-FU completely, and causes significantly less myelosuppression (",
"      <a class=\"graphic graphic_table graphicRef55829 \" href=\"mobipreview.htm?10/19/10558\">",
"       table 12",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For patients who are capable of tolerating more intense chemotherapy, a three-drug initial regimen (eg, FOLFOXIRI (",
"      <a class=\"graphic graphic_table graphicRef70559 \" href=\"mobipreview.htm?3/32/3599\">",
"       table 3",
"      </a>",
"      )) could be considered in the setting of conversion therapy in patients with initially unresectable liver metastases who might become candidates for surgical resection if the response to chemotherapy is sufficient. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Choice of regimen'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial three-drug combinations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For patients receiving oxaliplatin, supplemental cal-mag infusions (1 g",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      plus 1 g",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      ) 30 minutes pre- and post-oxaliplatin may protect against some forms of neurotoxicity. Given the lack of definitive evidence that cal-mag interferes with antitumor efficacy (at least in metastatic disease) and the absence of other effective neuroprotectants, it is reasonable to do this in patients being treated in a palliative setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link&amp;anchor=H23#H23\">",
"       \"Neurologic complications of platinum-based chemotherapy\", section on 'Pharmacologic approaches'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The FOLFIRI equivalent of FOLFOX4 (bolus LV and 5-FU on days 1 and 2 and relatively low-dose 5-FU) was originally described by Douillard [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/74\">",
"       74",
"      </a>",
"      ]. More recent trials use a modification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/68\">",
"       68",
"      </a>",
"      ], which has a schedule similar to mFOLFOX6 (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ). We suggest the use of FOLFIRI rather than Douillard regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'FOLFOX versus FOLFIRI as first-line therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The substitution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      for short-term infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      (ie, the XELOX or CAPOX regimen) increases convenience and is probably as effective as FOLFOX. However, toxicity compared with modern regimens (mFOLFOX6 or mFOLFOX7) is not necessarily improved, and cost issues may need to be considered. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'XELOX'",
"      </a>",
"      above.). For American patients, we prefer capecitabine 850",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily plus oxaliplatin 130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef61781 \" href=\"mobipreview.htm?13/60/14286\">",
"       table 5",
"      </a>",
"      ). Oncologists in Europe and Asia more often use capecitabine 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily in conjunction with the same oxaliplatin dose. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Due to concerns over both efficacy and toxicity, we suggest not using capecitabine in combination with irinotecan in any clinical setting outside of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'XELIRI'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For unclear reasons, there is a potential for increased toxicity if patients on",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      are crossed over to capecitabine, and we suggest not doing this or at least starting with a lower capecitabine dose (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/134\">",
"       134",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Duration of FOLFOX/XELOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of initial FOLFOX therapy is controversial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In responding patients, we suggest discontinuing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      before the onset of severe neurotoxicity (after three to four months of therapy) and maintaining infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , with reintroduction of oxaliplatin at disease progression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Another acceptable alternative is to switch to an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based regimen. Continuation of treatment is another alternative in responding patients who have no clinically significant neuropathy.",
"     </li>",
"     <li>",
"      We suggest not pursuing a full break in therapy as the default strategy in patients who achieve a partial response or stable disease, because of the potential adverse impact on outcomes (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If a treatment break is negotiated because of toxicity or patient preference, patients should be informed as to the possibility that survival may be adversely impacted. In such cases, close follow-up with tumor assessment at two month intervals and early resumption of chemotherapy at the first sign of progression is recommended. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Biologics'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H9660072\">",
"       'Oxaliplatin-based regimens'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      On the other hand, if a clinical complete response is achieved, a complete break in therapy is reasonable since at least some data suggest that continued treatment beyond two cycles after confirmation of the complete response is not associated with better survival than watchful observation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Biologics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regardless of whether an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based or an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based chemotherapy regimen is selected, we suggest adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to the first-line regimen (",
"      <a class=\"graphic graphic_table graphicRef62939 \" href=\"mobipreview.htm?30/6/30830\">",
"       table 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65525 \" href=\"mobipreview.htm?36/17/37149\">",
"       table 13",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, there are two important caveats:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There are still only limited data on the benefit of adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen. In the first adequately powered randomized trial",
"      <span class=\"nowrap\">",
"       (XELOX-1/NO16966)",
"      </span>",
"      for first-line therapy, the addition of bevacizumab to FOLFOX was of little incremental benefit, but the study was criticized for early discontinuation of therapy before disease progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/80\">",
"       80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H46#H46\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Oxaliplatin regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The potential for improved outcomes from adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to first-line therapy must be balanced against the potential for serious treatment-related toxicity. In particular, the use of bevacizumab in elderly patients with a history of an arterial thromboembolic event within 6 to 12 months must be carefully considered. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Bevacizumab'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because of the risk of impaired wound healing, bowel perforation, and fistula formation, at least 28 days (and preferable six to eight weeks) should elapse between major surgery and administration of bevacizumab, except in emergency situations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227437#H1651227437\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For selected patients (eg, those with wild type K-ras tumors,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a contraindication to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ) adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      to a first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based therapy is a reasonable option. However, the benefit of adding cetuximab to a first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen is unclear, and we prefer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      in this setting, if FOLFOX is being used as a first line regimen. Revised FDA-approved labeling for panitumumab now specifically recommends against the use of panitumumab in combination with chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/122\">",
"       122",
"      </a>",
"      ]. However, we disagree with this viewpoint, and consider that the addition of panitumumab to FOLFOX in patients with K-ras wild type tumors is appropriate, an approach that is also allowed in",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      guidelines. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Panitumumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Cetuximab or panitumumab as a component of initial therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21096055\">",
"       'K-ras'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients receiving cetuximab or panitumumab should undergo periodic monitoring of serum electrolytes, including magnesium, calcium, and potassium. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H35#H35\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'EGFR pathway inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Patients who are not candidates for intensive therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are not candidates for an intensive first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based regimen, we suggest 5-FU plus LV (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H10#H10\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Leucovorin plus 5-FU'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We prefer short-term infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      rather than bolus administration, because of its favorable toxicity profile. However, rather than the original de Gramont regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/135\">",
"       135",
"      </a>",
"      ], we prefer a modified de Gramont regimen without the day 2 bolus doses of 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef65525 \" href=\"mobipreview.htm?36/17/37149\">",
"       table 13",
"      </a>",
"      ).In patients treated with first-line",
"      <span class=\"nowrap\">",
"       5-FU/LV,",
"      </span>",
"      we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). The survival benefit from adding bevacizumab must be balanced against the potential for serious treatment-related toxicity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H10#H10\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Leucovorin plus 5-FU'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An equally effective alternative first-line regimen, when fluoropyrimidines alone are indicated, is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      . The appropriate capecitabine dose is unclear. The on-label dose (1250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 days) is toxic in Americans, presumably due to higher nutritional folate intake, among other factors. Most American oncologists start with 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 days, and titrate the dose upward if tolerated.",
"      <br/>",
"      <br/>",
"      Capecitabine also requires dose reduction in those with renal function impairment, and in those being crossed over from",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/1/44058/abstract/134\">",
"       134",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H13#H13\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Orally active fluoropyrimidines'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'XELOX'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Treatment at progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of clinical trial data, we suggest the following approach after progression on initial therapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients initially treated with FOLFOX or XELOX, we switch to FOLFIRI or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      alone at the time of disease progression. For patients with K-ras wild type (ie, nonmutated) tumors,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      could then be added to irinotecan for third-line therapy, or",
"      <span class=\"nowrap\">",
"       cetuximab/panitumumab",
"      </span>",
"      alone considered for patients who are intolerant of irinotecan. For patients who show rapid progression on first-line therapy, we routinely add cetuximab or panitumumab to the second-line regimen to increase antitumor activity. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Are cetuximab and panitumumab interchangeable?'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We recommend that cetuximab and panitumumab not be used in patients with K-ras mutated tumors (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The use of other molecular predictors of response (including BRAF mutations) requires further validation before being incorporated into clinical practice. (See",
"      <a class=\"local\" href=\"#H6688281\">",
"       'Agents targeting the EGFR'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients receiving either drug should undergo periodic monitoring of serum electrolytes, including magnesium and potassium. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H35#H35\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'EGFR pathway inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients initially treated with FOLFIRI, one can either add",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      at the time of progression (if",
"      <span class=\"nowrap\">",
"       K-ras/BRAF",
"      </span>",
"      wild type) or switch to FOLFOX or XELOX. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients treated with a first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      -containing chemotherapy regimen, the continuation of bevacizumab in conjunction with a second-line fluoropyrimidine-based chemotherapy regimen can be considered a standard approach, particularly for those with a K-ras mutation, in whom EGFR-targeted therapy is not appropriate, as long as drug therapy is well tolerated. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Continuation of bevacizumab beyond progression'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Another option, for patients treated initially with FOLFOX, is FOLFIRI alone or FOLFIRI plus intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       aflibercept",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H56909840\">",
"       'Aflibercept'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If either bevacizumab or aflibercept is used as a component of the second-line chemotherapy regimen for patients with K-ras wild type disease, an EGFR-targeting monoclonal antibody should not be used concurrently. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Dual antibody therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based chemotherapy, an anti-VEGF agent, and (if K-ras wild type) an anti-EGFR therapy, and who require additional therapy, we suggest single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       regorafenib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4893926\">",
"       'Regorafenib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After failure of all conventional \"lines of therapy\", we suggest one of the following options if performance status is adequate and a tumor-directed therapeutic approach is still warranted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Enrollment in a phase I or II trial testing novel",
"      <span class=\"nowrap\">",
"       agents/combinations.",
"      </span>",
"     </li>",
"     <li>",
"      Reutilizing the regimen initially used in the treatment sequence (eg, FOLFOX). During the often lengthy phase of sequential therapy, tumors may regain sensitivity to previously used drugs. (See",
"      <a class=\"local\" href=\"#H4881383\">",
"       'Continuum of care model'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/1\">",
"      Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/2\">",
"      Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/3\">",
"      Schrag D. The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med 2004; 351:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/4\">",
"      Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/5\">",
"      Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/6\">",
"      Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/7\">",
"      Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/8\">",
"      Hecht JR, Mitchell E, Neubauer MA, et al. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 2010; 16:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/9\">",
"      Mitchell EP, Hecht JR, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients with low or negative tumor epidermal growth factor receptor levels: An updated analysis (abstract). J Clin Oncol 2007; 25:184s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/10\">",
"      Tsuchihashi Z, Khambata-Ford S, Hanna N, J&auml;nne PA. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 2005; 353:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/11\">",
"      de Reyni&egrave;s A, Boige V, Milano G, et al. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol 2008; 26:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/12\">",
"      Van Cutsem E, K&ouml;hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/13\">",
"      Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/14\">",
"      Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/15\">",
"      Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/16\">",
"      Li&egrave;vre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/17\">",
"      Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/18\">",
"      Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/19\">",
"      Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/20\">",
"      Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/21\">",
"      Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/22\">",
"      Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/23\">",
"      Han CB, Li F, Ma JT, Zou HW. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012; 30:741.",
"     </a>",
"    </li>",
"    <li>",
"     Information on the conditional approval of panitumumab (Vectibix) by the EMEA www.emea.europa.eu/pdfs/human/press/pr/32370307en.pdf (Accessed on April 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/25\">",
"      Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/26\">",
"      Behl AS, Goddard KA, Flottemesch TJ, et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 2012; 104:1785.",
"     </a>",
"    </li>",
"    <li>",
"     The full document from the College of American Pathologists available at www.cap.org/POET (Accessed on April 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/28\">",
"      Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009; 27:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/29\">",
"      De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/30\">",
"      Tejpar S, Celik I, Schlichting M, et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30:3570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/31\">",
"      Gajate P, Sastre J, Bando I, et al. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clin Colorectal Cancer 2012; 11:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/32\">",
"      Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/33\">",
"      Garm Spindler KL, Pallisgaard N, Rasmussen AA, et al. The importance of KRAS mutations and EGF61A&gt;G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009; 20:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/34\">",
"      Mao C, Yang ZY, Hu XF, et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012; 23:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/35\">",
"      Oden-Gangloff A, Di Fiore F, Bibeau F, et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer 2009; 100:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/36\">",
"      Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/37\">",
"      Winder T, Zhang W, Yang D, et al. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clin Cancer Res 2010; 16:5591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/38\">",
"      Huang F, Xu LA, Khambata-Ford S. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer. Clin Cancer Res 2012; 18:1156.",
"     </a>",
"    </li>",
"    <li>",
"     Adams RA, James MD, Smith CG, et al. Epidermal growth factor receptor (EGFR) as a predictive and prognostic marker in patients with advanced colorectal cancer (aCRC): The MRC COIN trial experience (Abstract 359). Data presented at the 2011 ASCO Gastrointestinal Cacners Symposium, San Francisco, CA, January 22, 2011. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=103&amp;abstractID=71291 (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/40\">",
"      &Aring;lgars A, Lintunen M, Carp&eacute;n O, et al. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J Cancer 2011; 105:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/41\">",
"      Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/42\">",
"      Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101:1308.",
"     </a>",
"    </li>",
"    <li>",
"     Bokemeyer C, Kohne C, Rougier P, et al. Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status (abstract #3506). J Clin Oncol 2010; 28:262s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/44\">",
"      Van Cutsem E, K&ouml;hne CH, L&aacute;ng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/45\">",
"      Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012; 18:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/46\">",
"      Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48:1466.",
"     </a>",
"    </li>",
"    <li>",
"     www.clarientinc.com/Default.aspx?tabid=398 (Accessed on April 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/48\">",
"      Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/49\">",
"      Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/50\">",
"      Italiano A, Follana P, Caroli FX, et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008; 15:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/51\">",
"      Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008; 14:5869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/52\">",
"      Lambrechts D, Lenz HJ, de Haas S, et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013; 31:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/53\">",
"      Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/54\">",
"      Dopeso H, Mateo-Lozano S, Elez E, et al. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin Cancer Res 2010; 16:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/55\">",
"      Boige V, Mendiboure J, Pignon JP, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010; 28:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/56\">",
"      Ebert MP, T&auml;nzer M, Balluff B, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med 2012; 366:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/57\">",
"      Lv H, Li Q, Qiu W, et al. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer. Cancer Invest 2013; 31:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/58\">",
"      Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/59\">",
"      Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 2011; 103:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/60\">",
"      de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25:3224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/61\">",
"      Yeoh C, Chau I, Cunningham D, et al. Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. Clin Colorectal Cancer 2003; 3:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/62\">",
"      Hejna M, Kornek GV, Raderer M, et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer 1998; 78:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/63\">",
"      Townsend AR, Bishnoi S, Broadbridge V, et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol 2013; 36:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/64\">",
"      Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/65\">",
"      Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/66\">",
"      Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 2006; 24:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/67\">",
"      Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/68\">",
"      Tournigand C, Andr&eacute; T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/69\">",
"      Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/70\">",
"      Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/71\">",
"      Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23:9441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/72\">",
"      Dy GK, Krook JE, Green EM, et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 2007; 25:3469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/73\">",
"      Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/74\">",
"      Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/75\">",
"      Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779.",
"     </a>",
"    </li>",
"    <li>",
"     Loupakis F, Cremolini C, Masi G, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC). Results of the phase III randomized TRIBE trial (abstract). Data presented at the 2013 ASCO Gastrointesitnal Cancers Symposium, San ?Francisco, CA, January 24-26, 2013. Abstract availabe online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=133&amp;abstractID=105744 (Accessed on February 14, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/77\">",
"      Saridaki Z, Androulakis N, Vardakis N, et al. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer 2012; 107:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/78\">",
"      Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/79\">",
"      Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/80\">",
"      Cassidy J, Clarke S, D&iacute;az-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/81\">",
"      Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25:4217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/82\">",
"      D&iacute;az-Rubio E, Tabernero J, G&oacute;mez-Espa&ntilde;a A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25:4224.",
"     </a>",
"    </li>",
"    <li>",
"     Ducreux M, Bennouna J, Hebbar M, et al. Efficacy and safety findings from a randomized phase III study of capecitabine and oxaliplatin vs infusion 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC) (abstract). J Clin Oncol 2007; 25:170s.",
"    </li>",
"    <li>",
"     Rothenberg ML, Navarro M, Butts C, et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd line treatment for patients with metastatoc colorectal cancer (MCRC) (Abstract). J Clin Oncol 2007; 25:171s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/85\">",
"      Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523.",
"     </a>",
"    </li>",
"    <li>",
"     Haller DG, Cassidy J, Clarke S, et al. Tolerability of fluoropyrimidines appears to differ by region (abstract). J Clin Oncol 2006; 24:149s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/87\">",
"      Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/88\">",
"      Chu E, Schulman KL, Zelt S, Song X. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer 2009; 115:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/89\">",
"      Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer 2009; 101:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/90\">",
"      Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 2008; 6 Suppl 3:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/91\">",
"      Mayer RJ. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2007; 25:4165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/92\">",
"      Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006; 24:3347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/93\">",
"      Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/94\">",
"      Meyerhardt JA, Kwok A, Ratain MJ, et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:1439.",
"     </a>",
"    </li>",
"    <li>",
"     Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin administration and time to treatment failure in metastatic colorectal cancer: Final results of the phase III CONcePT trial (abstract). J Clin Oncol 2008; 26s:abstr 4010. file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=55&amp;abstractID=34113 (Accessed on July 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/96\">",
"      Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27:5727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/97\">",
"      Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003; 21:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/98\">",
"      Doroshow JH, Synold TW, Gandara D, et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003; 30:14.",
"     </a>",
"    </li>",
"    <li>",
"     Green E, Sargent DJ, Goldberg RM, Grothey A. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741 (abstract). Data presented at the 2005 ASCO Gastrointestinal Cancers Symposium, Hollywood, Florida, January 28, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/100\">",
"      Schmoll HJ, B&uuml;chele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol 1999; 26:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/101\">",
"      Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/102\">",
"      Saltz LB, Clarke S, D&iacute;az-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/103\">",
"      Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/104\">",
"      Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008; 26:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/105\">",
"      Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539.",
"     </a>",
"    </li>",
"    <li>",
"     Grothey A, Hedrick EE, Mass RD, et al. Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): a comparative analyis of N9741 and AVF 2107) (abstract). J Clin Oncol 2006; 24:150s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/107\">",
"      Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/108\">",
"      Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/109\">",
"      Kabbinavar FF, Hurwitz HI, Yi J, et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27:199.",
"     </a>",
"    </li>",
"    <li>",
"     Arnold D, Andre T, Bennouna J, et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 30, 2012 (suppl; abstract CRA3503). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=97866 (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/111\">",
"      Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30:3499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/112\">",
"      Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/113\">",
"      Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/114\">",
"      Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.",
"     </a>",
"    </li>",
"    <li>",
"     Venook A, Niedzwicki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) &plusmn; cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preiminary results (abstract). J Clin Oncol 2006; 24:148s.",
"    </li>",
"    <li>",
"     Maughan TS, Adams R, Smith CG, et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial (abstract 3502). J Clin Oncol 2010; 28:261s.",
"    </li>",
"    <li>",
"     Tveit K, Guren T, Glimelius B, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group (abstract). Data pressented at the 2011 ASCO GI Cancer Symposium, San Francisco, CA, January 20-22, 2011. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=103&amp;abstractID=70979 (Accessed on March 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/118\">",
"      Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/119\">",
"      Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/120\">",
"      Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/121\">",
"      Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:4706.",
"     </a>",
"    </li>",
"    <li>",
"     FDA-approved manufacturer's label information available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2 (Accessed on October 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/123\">",
"      Snyder LC, Astsaturov I, Weiner LM. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer 2005; 5 Suppl 2:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/124\">",
"      Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 2008; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/125\">",
"      Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008; 19:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/126\">",
"      Bouchahda M, Macarulla T, Liedo G, et al. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011; 28 Suppl 1:S253.",
"     </a>",
"    </li>",
"    <li>",
"     Metges J, Raoul J, Achour N, et al. PANERB study: Panitumumab after cetuximab-based regimen failure (abstract e14000). J Clin Oncol 2010; 28:. Abstract available online at file://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=48675 (Accessed on March 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/128\">",
"      Wadlow RC, Hezel AF, Abrams TA, et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist 2012; 17:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/129\">",
"      Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/130\">",
"      Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/131\">",
"      Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/132\">",
"      Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563.",
"     </a>",
"    </li>",
"    <li>",
"     Enrollment information available online at www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=551934&amp;version=patient&amp;protocolsearchid=3680731 (Accessed on April 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/1/44058/abstract/134\">",
"      Hennig IM, Naik JD, Brown S, et al. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. J Clin Oncol 2008; 26:3411.",
"     </a>",
"    </li>",
"    <li>",
"     Siena S, Cassidy J, et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as first line treatment for metastatic colorectal cancer (mCRC): the PRIME trial (abstract). Data presented at the 2010 ASCO Gastrointestinal Cancers Symposium, January 22, 2010.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2503 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44058=[""].join("\n");
var outline_f43_1_44058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6686747\">",
"      PREDICTIVE MARKERS FOR RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6688281\">",
"      Agents targeting the EGFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21096055\">",
"      - K-ras",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6687366\">",
"      - BRAF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6687373\">",
"      - EGFR amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6688341\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4881461\">",
"      Cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4881480\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4881383\">",
"      CONTINUUM OF CARE MODEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL DOUBLET COMBINATIONS VERSUS SEQUENTIAL SINGLE AGENT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - FOCUS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - CAIRO trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial three-drug combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Capecitabine as substitute for infusional 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - XELOX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - XELIRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FOLFOX versus FOLFIRI as first-line therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Treatment-related toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      REDUCING DRUG TOXICITY WITH CHEMOTHERAPY HOLIDAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9660072\">",
"      Oxaliplatin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Irinotecan-based regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56910059\">",
"      AGENTS TARGETING VEGF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Should all patients receive first-line bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H29868651\">",
"      - Arterial thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H29868658\">",
"      - Wound healing",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H29868665\">",
"      - Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Drug discontinuation during treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Continuation of bevacizumab beyond progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56909840\">",
"      Aflibercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4893926\">",
"      Regorafenib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CETUXIMAB AND PANITUMUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Predictive markers for response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cetuximab or panitumumab as a component of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Cetuximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Panitumumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Should a cetuximab or panitumumab-containing regimen be the default choice for second-line therapy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Are cetuximab and panitumumab interchangeable?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8976328\">",
"      Panitumumab after failure of cetuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Dual antibody therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Management of skin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - The chemotherapy backbone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Duration of FOLFOX/XELOX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Biologics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Patients who are not candidates for intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Treatment at progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2503\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2503|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/20/5454\" title=\"table 1\">",
"      Chemo regimens met CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/32/3599\" title=\"table 3\">",
"      FOLFOXIRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/53/9053\" title=\"table 4\">",
"      TREE trials met colorectal ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/60/14286\" title=\"table 5\">",
"      XELOX regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 6\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/6/30830\" title=\"table 7\">",
"      Modified FOLFOX6 plus bevacizumab chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/48/42764\" title=\"table 8\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/39/1663\" title=\"table 9\">",
"      FOLFIRI plus cetuximab for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/8/3213\" title=\"table 10\">",
"      NCCN chemotherapy guidelines for metastatic colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/37/9819\" title=\"table 11\">",
"      NCCN rec mCRC nonintens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/19/10558\" title=\"table 12\">",
"      Modified FOLFOX7 regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/17/37149\" title=\"table 13\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=related_link\">",
"      Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=related_link\">",
"      Adjuvant chemotherapy for resected stage II colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41466?source=related_link\">",
"      Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=related_link\">",
"      Treatment protocols for colorectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_1_44059="Anaphylaxis key msgs";
var content_f43_1_44059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key messages in anaphylaxis education*: Anaphylaxis = Killer allergy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Who is at risk?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anyone, especially those allergic to foods such as peanut, tree nuts, shellfish, fish, milk, or egg, or to insect stings or bites, medications, or natural rubber latex.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        When can it happen?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Within minutes, anytime the allergic person comes in contact with his or her trigger.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        How do we know?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Several symptoms occur at the same time, such as sudden onset of itching, hives, flushing, hoarse voice, difficulty breathing, vomiting, diarrhea, dizziness, confusion, or shock.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Where can it happen?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anywhere, such as home, restaurant, school, child care or sports facility, summer camp, car, bus, airplane.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        What should we do?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inject epinephrine, call 911 or local emergency medical service number, and notify the individual's family (in that order)! Act quickly. Anaphylaxis can be mild, or it can be fatal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Why is follow-up needed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaphylaxis recurrences can occur. The trigger needs to be confirmed, and long-term preventative strategies need to be implemented.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For individuals at risk and their caregivers, and for the general public.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Simons FER. Anaphylaxis, killer allergy: Long-term management in the community. J Allergy Clin Immunol 2006; 117:367. Copyright &copy; 2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44059=[""].join("\n");
var outline_f43_1_44059=null;
var title_f43_1_44060="Drugs toxins causing ALF";
var content_f43_1_44060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some drugs, herbal products, and toxins associated with acute liver failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Abacavir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetaminophen (paracetamol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allopurinol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbon tetrachloride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comfrey",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dapsone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Didanosine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dideoxyinosine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disulfiram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Efavirenz",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gemtuzumab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Greater celandine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Halothane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        He Shon Wu",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herbalife&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxycut&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoflurane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoniazid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kava Kava",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketoconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Labetalol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LipoKinetix&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ma Huang",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MDMA (Ecstasy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methamphetamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monoamine oxidase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methyldopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicotinic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrofurantoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsteroidal anti-inflammatory drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenprocoumon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poison mushrooms (",
"        <em>",
"         Amanita phalloides",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propylthiouracil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyrazinamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Senecio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Statins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfonamides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Terbinafine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetracycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tolcapone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproic acid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44060=[""].join("\n");
var outline_f43_1_44060=null;
var title_f43_1_44061="Contents: Allergy and Immunology";
var content_f43_1_44061=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Allergy and Immunology",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Allergy and Immunology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"mobipreview.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?37/7/38013\">",
"         Allergen immunotherapy",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?0/23/382\">",
"         Anaphylaxis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?6/57/7071\">",
"         Asthma",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?24/28/25038\">",
"         Drug allergy",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?35/16/36109\">",
"         Eosinophil related disorders",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?19/50/20270\">",
"         Food allergy",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?5/51/5938\">",
"         HIV infection",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?15/22/15727\">",
"         Immunodeficiency states non HIV",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?22/52/23374\">",
"         Immunology basic science",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?2/37/2654\">",
"         Insect allergy",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?34/29/35293\">",
"         Mast cell disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?40/30/41454\">",
"         Other topics in allergy",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?6/35/6718\">",
"         Rhinitis and sinusitis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?1/52/1870\">",
"         Urticaria and angioedema",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?24/23/24949\">",
"         What's new in allergy and immunology",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-2C13784F98-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f43_1_44061=[""].join("\n");
var outline_f43_1_44061=null;
var title_f43_1_44062="Bronchial atresia CT III";
var content_f43_1_44062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left upper lobe bronchial atresia seen on a coronal CT image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal multiplanar reformat with mediastinal window settings shows the tubular hilar mass consistent with a mucoid impaction distal to the atretic bronchus. No evidence for an endobronchial tumor is seen, but tubular calcifications are seen in the mucoid impaction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44062=[""].join("\n");
var outline_f43_1_44062=null;
var title_f43_1_44063="Female ectopic ureter";
var content_f43_1_44063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ectopic ureter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ectopic ureter in a female patient. Probe indicates the location of an ectopic ureter in the vaginal vestibule between the urethra and vaginal opening.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Laurence Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_1_44063=[""].join("\n");
var outline_f43_1_44063=null;
